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Summary
Many complex properties of cancer cells are effectively under selection 
within the in vivo microenvironment or following therapeutic insult. This critical 
combination of instability and shifting selection drives the heterogeneity of 
tumour cell populations in terms of many critical features.
Small cell lung cancer (SCLC) is an aggressive, rapidly metastasizing 
neoplasm with an ability to develop resistance against chemotherapeutic 
agents. New SCLC therapeutic strategies are urgently needed that contain 
spreading d isease without further compromising tumour chemosensitivity.
Variants for attachment to tissue culture plastic of the NCI-H69 cell line, 
which grows in suspension but generates low frequency appearance of 
adhesion variants, were enriched, without prejudice for any specific extracellular 
matrix directed advantage, and then allowed for any proliferation/survival 
advantage in vitro to impact on the evolution of variation. Two sub-lines were 
generated representing two stages in variant enrichment.
The developed SCLC model, which encom passes elem ents of variation 
and heterogeneity, provides opportunities to link in vitro behaviour of SCLC with 
in vivo characteristics with particular reference to the challenges faced in the 
m anagem ent of SCLC such a s  the accrual of drug resistance.
The variant model was characterized using microscopy, flow cytometry 
and microarray analysis, revealing variation in adherence and morphology 
impacting on SCLC behaviour, proliferative rate and polysialylation of the neural 
cell adhesion molecule. The microarray analysis has also revealed new cancer 
biomarkers that can be explored in clinic studies.
This unique SCLC model w as used to gain insights into links with 
chem oresistance. The studies revealed that the variant selection did not result 
in expansion of a drug resistant clone. Moreover, evidence of clonal 
evolution/selection w as uncovered together with the finding of the absence of 
CSCs, even in enriched variants, a s  defined by the classical side population 
phenotype.
The defined PSA expression patterns of the variants allowed for 
screening of carbohydrates-based agents for polysialylation knock-down.
IV
Table of contents
Title .......................................................................................................... I
Declaration ..............................................................................................II
Acknowledgements ............................................................................. Ill
Summary ..............................................................................................IV
Table of contents ................................................................................. IV
List of figures ..........................................................................................IX
List of tables ...................................................................................... XII
Abbreviations .................................................................................... XIII
I. Introduction....................................................................................... -1  -
1.1. Cancer progression and origins of cellular heterogeneity.........- 2 -
1.2. Phenotypic plasticity...................................................................- 5 -
1.2.1. Definition and implications.....................................................- 5 -
1.2.2. EMT/MET: an example of cell plasticity............................................. - 6 -
1.2.3. The cancer stem cells plasticity and therapeutic challenges............... - 8 -
1.3. Metastasis..................................................................................- 11-
1.3.1. Metastasis: a multi-step cascade inviting early intervention............ - 1 1 -
1.3.2. Metastasis and phenotypic plasticity................................................. -14 -
1.4. Chemoresistance...................................................................... - 16 -
1.4.1. Apoptosis modulation.........................................................................-17 -
1.4.2. Cell cycle modulation: kinetic resistance.......................................... - 18 -
1.4.3. Multidrug resistance: innate and acquired......................................... - 19 -
1.5. Environment and cell adhesion................................................ - 23 -
1.5.1. Cell adhesion mechanisms.................................................................- 23 -
1.5.2. Cell adhesion and drug resistance......................................................- 26 -
1.6. Plasticity of the phenotype and genotype of SCLC............... - 28 -
1.6.1. Molecular characteristics....................................................................- 29 -
1.6.2. Chemoresistance and early invasion: therapeutic challenge............ - 31 -
1.7. NCAM biology..........................................................................- 32 -
1.7.1. Structure............................................................................................. - 32 -
1.7.2. Role in development and CNS...........................................................- 35 -
1.7.3. Polysialic acid and links with metastatic behaviour.......................... - 35 -
1.7.4. PSA-NCAM and the therapeutic challenge....................................... - 37 -
1.8. Aims of the thesis.....................................................................- 38 -
II. Materials and methods.................................................................- 40 -
11.1. Materials..................................................................................- 40 -
II. 1.1. Drug and molecular probes table................................................... - 40 -
II. 1.2. Antibodies and sources tables........................................................ - 41 -
11.2. Cell lines and culture conditions............................................ - 42 -
11.2.1. Cell lines.................................   - 4 2 -
11.2.2. Suspension and adherent cell culture................................................- 42 -
11.3. cDNA microarray....................................................................- 43 -
II.3.1. Drug treatment................................................................................ -43 -
V
11.3.2. RNA extraction.................................................................................- 43
11.3.3. RNA quality controls.........................................................................-44
11.3.4. Data acquisition.................................................................................. -44
11.3.5. Data analysis...................................................................................... -46
11.3.5.1. Arrays quality assessment.........................................................-47
11.3.5.2. Raw data processing and normalization..................................- 47
11.3.5.3. Quantification of differential expression................................. -48
11.3.5.4. Functional analysis and representation.................................... -49
11.4. Flow cytometry........................................................................- 50
11.4.1. Cytometers........................................................................................ - 50
11.4.2. Cell cycle analysis.............................................................................- 51
11.4.3. Immunofluorescence analysis............................................................-52
11.4.4. Cellular integrity assays....................................................................- 52
11.5. Imaging....................................................................................- 52
11.5.1. Microscopes...................................................................................... - 52
11.5.2. Transmission imaging.......................................................................- 53
11.5.3. Immunofluorescence labelling......................................................... - 53
11.5.4. Fluorescence imaging....................................................................... - 54
11.5.5. Timelapse imaging............................................................................- 54
11.6. SDS-PAGE/Immunoblotting.................................................. - 54
11.7. Statistical analyses....................................................................-55
III. Characterization of an in vitro SCLC model system.............. - 56
III. 1. Introduction..........................................................................- 56
111.2. Specific material and methods...............................................-60
111.2.1. Cell lines, cell culture and cell proliferation estimation................ - 60
111.2.2. Plastic substrate-adherent sub-population enrichment.................. -61
111.2.3. Attachment assay.............................................................................- 62
111.2.4. Cell size measurement.....................................................................- 62
111.2.5. DNA content measurement............................................................. - 63
111.2.6. Neuraminidase digestion of PSA.................................................... - 63
111.2.7. Cell adhesion assay: MSA.............................................................. - 63
111.2.8. Paraffin cell aggregates section preparation and staining.............. - 65
111.2.9. Invasion assay.................................................................................. - 66
111.3. Results.................................................................................... -67
111.3.1. SCLC cell lines in vitro phenotype and variants selection............. - 67
111.3.2. NCI-H69 model phenotype characteristic....................................... -72
111.3.2.1. Variants enrichment.................................................................- 72
111.3.2.2. Attachment properties..............................................................- 73
111.3.2.3. Cell size and DNA content......................................................- 75
111.3.2.4. PSA-NCAM............................................................................. - 77
111.3.3. NCI-H69 model: gene expression changes...................................... - 82
111.3.3.1. Arrays quality assessment........................................................- 82
111.3.3.2. Statistical analyses...................................................................- 82
111.3.3.3. Overview of the ontology analysis......................................... -86
111.3.4. NCI-H69 model: SCLC phenotype.................................................. - 88
111.3.5. NCI-H69 model: growth characteristics.......................................... - 92
111.3.6. NCI-H69 model: cell adhesion........................................................ - 94
111.3.6.1. Cell-ECM adhesion: MSA...................................................... - 96
111.3.6.2. Cell-cell adhesion....................................................................-99
III.3.7. NCI-H69 model: cell motility and invasiveness........................... - 104 -
III-4. D iscu ssio n ........................................................................................ - 106 -
IV. C hem osensitivity  and heterogeneity o f  the N C I-H 69 variants... - 1 1 4 -
IV. 1. Introduction and a im s ..................................................................- 1 1 4 -
IV.2. Specific M aterial and M ethods.................................................. - 121 -
IV.2.1. Drugs and inhibitor................................................................ -121 -
IV.2.2. Cell lines................................................................................ -121 -
IV.2.3. ABCG2 immunodetection.................................................... -121 -
IV.2.4. Hoechst side population assay.............................................. -121 -
IV.2.5. TPT uptakes.................................................................................... -122-
IV.2.6. alamarBlue assay...................................................................-123 -
IV.2.6.1. Method design: continuous exposure vs. end-point assay...-123 -
IV.2.6.2. Chemosensitivity testing.............................................. -124 -
IV.2.6.3. % reduction calculation............................................... -124 -
IV .3. R esu lts ................................................................................................- 125 -
IV.3.1. ABC transporters expression........................................................ -125 -
IV.3.2. ABCG2 profiling and function..................................................... - 126 -
IV.3.3. Identification and analysis of the side population phenotype.-129 -
IV.3.4. TPT Pharmacokinetics...........................................................-136 -
IV.3.5. TPT pharmacodynamics -  the overall response to topotecan..... - 139 -
IV.3.5.1. Topoisomerase expression........................................... -139 -
IV.3.5.2. alamarBlue method implementation and optimisation - 140 -
IV.3.5.3. Chemosensitivity to TPT..................................................... - 144 -
IV.3.5.4. Effect of the variant phenotype on TPT chemosensitivity..- 144 -
IV .4. D iscussion  - 148 -
V. Focus on PSA-NCAM - 153 -
V . l .  Introduction and aim s - 153 -
V.2. Specific m aterials and m e th o d s  - 156 -
V.2.1. Inhibitors and treatment.................................................................. -156-
V.2.2. Cell lines......................................................................................... - 156 -
V.2.3. RT-PCR........................................................................................... - 156 -
V.2.4. Time lapse imaging................................................................. -158 -
V.3. R esu lts  - 160 -
V.3.1. Surface glycocalyx modulation.............................................. -160 -
V.3.1.1. Major glycosylation pathways.............................................. - 160 -
V.3.1.2. Sialic acid pathway in the variants........................................ - 161 -
V.3.2. Chemical-biology approach to intervention on PSA synthesis - 164 -
V.3.2.1. First generation compound: R1108....................................... - 165 -
V.3.2.2. Other compounds................................................................... - 166 -
V.3.3. Effect onNCAM decoration...........................................................- 166 -
V.3.3.1. R1108..................................................................................... - 166 -
V.3.3.2. ICT compounds......................................................................- 167 -
V.3.4. Cytotoxicity..................................................................................... - 168 -
V.3.4.1. R1108: dose-dependant cytotoxicity..................................... - 168 -
V.3.4.2. A role for R1108 metabolic products in cytotoxicity?......... - 172 -
V.3.4.3. A role for purification regimen of R1108 compound?........ - 173 -
V.3.4.4. ICT compounds......................................................................- 174 -
V.3.5. R1108 toxicity: microarray study.................................................. - 176 -
VII
V.3.5.1. Induction of stress-related genes............................................ -178 -
V.3.5.2. MT induction validation........................................................ -180 -
V.3.5.2.1. MT induction upon R1108/2006 treatment................. - 180 -
V.3.5.2.2. ICT compounds............................................................ -180 -
V.3.6. Metallothionein................................................................................ -181 -
V.3.6.1. Inhibition of CHO growth by R1108....................................- 182 -
V.3.6.2. Effect on mitosis....................................................................-184 -
V.4. Discussion..............................................................................- 188 -
VI. Discussion.................................................................................. -195 -
Appendix I: Reagents and suppliers...............................................- 207 -
Appendix II: Western blotting solutions -208 -
Appendix III: RT-PCR solutions...................................................- 210 -
Appendix IV: SCLC cell lines panel PSA-NCAM expression... - 211 -
Appendix V: 2008 arrays quality assessment............................... - 212 -
Appendix VI: SCLC characteristics..............................................- 214 -
Appendix VII: Cell cycle and growth - 216 -
Appendix VIII: Cell adhesion.........................................................- 219 -
Appendix IX: MSA.......................................................................... - 227 -
Appendix X: Cell motility - 232 -
Appendix XI: Glycosylation............................................................- 234 -
Appendix XII: 2005 arrays quality assessment - 235 -
References  - 238 -
VIII
List of figures
I. Introduction
Figure 1.1: Cellular plasticity: the EMT / MET transition  - 7 -
Figure 1.2: The tumour metastatic process...............................................................- 12 -
Figure 1.3: Chemoresistance mechanisms overview .............................................  - 17 -
Figure 1.4: ABC transporters protein arrangements................................................  - 20 -
Figure 1.5: Major classes of cell adhesion molecules.............................................  - 25 -
Figure 1.6: Proposed mechanisms for integrin-mediated protection from genotoxic
therapy......................................................................................................................  - 27 -
Figure 1.7: NCAM isoforms structure and polysialylation pattern...........................-33 -
II. Materials and methods
Figure II. 1: DNA microarray processing................................................................. - 45 -
Figure II.2: DNA microarray analysis process.......................................................- 46 -
III. Characterization of an in vitro SCLC model system
Figure III.l: Summary of the SCLC model system characterization objectives ... - 59 -
Figure III.2: MSA slides layout................................................................................  - 65 -
Figure III.3: In vitro characteristics of the panel of SCLC cell lines  - 68 -
Figure III.4: SCLC cell lines and adherent variants  - 70 -
Figure III.5: SCLC cell lines and variants NCAM and PSA-NCAM expression ..- 71 - 
Figure III.6: In vitro appearance of the NCI-H69 variants over increasing
Passage...................................................................................................................... - 72 -
Figure III.7: Attachment properties of the different adhesion variants of the NCI-H69
cell line...................................................................................................................... - 74 -
Figure III.8: NCI-H69 variants cell and nuclei diameters.......................................  - 76 -
III.9: Flow cytometry determination of NCI-H69 variants DNA content..............  - 77 -
Figure III. 10: PSA and NCAM expression in the NCI-H69 variants..................... - 78 -
Figure III.l 1: PSA-NCAM and NCAM expression in the NCI-H69 variants  - 79 -
Figure III. 12: Immunoblotting detection of NCAM and PSA-NCAM.................. - 80 -
Figure III. 13: Fluorescence detection of NCAM and PSA-NCAM in NCI-H69 SP
cells...........................................................................................................................  -8 1 -
Figure III. 14: Microarray statistical analysis .......................................................... - 85 -
Figure III. 15: SCLC and NSCLC markers (Kraus et al., 2002) expression in the NCI-
1169 variants............................................................................................................. - 89 -
Figure III. 16: SCLC m arkers..................................................................................  - 91 -
Figure III. 17: Growth properties of the different variants of the NCI-H69 cell
Line............................................................................................................................  - 92 -
Figure 111.18: Cell cycle and growth-related gene expression...............................  - 94 -
Figure III. 19: Cell adhesion and cytoskeleton.......................................................  - 95 -
Figure 111.20: Adhesion profile of the NCI-H69 variants on ECM proteins  - 97 -
Figure 111.21: Cell morphology on MSA ECM proteins spot.................................  - 98 -
Figure 111.22: Reversibility of the attached phenotype........................................  - 100 -
Figure 111.23: Growth properties of the NCI-H69 model cultured on hydrophobic
substrate.................................................................................................................... -102-
Figure 111.24: Expression and localization of NCAM and PSA-NCAM in the NCI-H69
variants grown on hydrophobic surfaces...............................................................  -103 -
Figure III.25: Determination of the invasion potential of the NCI-H69 variants......-105 -
IV. Chemosensitivity and heterogeneity of the NCI-H69 variants
Figure IV. 1: Topotecan — a camptothecin derivative.........................................  -117-
Figure IV.2: ABC transporters expression in NCI-H69 variants.........................  - 125 -
IX
Figure IV.3: ABCG2 immunofluorescence detection..........................................  - 126 -
Figure IV.4: Hoechst 33342 uptake profiles in the A549 and each of the NCI-H69
variants...................................................................................................................  - 128 -
Figure IV.5: A549 Hoechst 33342 uptake profiles..............................................  - 130 -
Figure IV.6: NCI-H69 SP Hoechst 33342 uptake profiles...................................  - 133 -
Figure IV.7: NCI-H69 AP3 Hoechst uptake profiles...........................................  - 134 -
Figure IV.8: NCI-H69 AP78 Hoechst uptake profiles.........................................  - 135 -
Figure IV.9: Modulation of TPT uptake with the ABCG2 inhibitor FT C   - 136 -
Figure IV. 10: Differences of TPT uptake for the NCI-H69 variants................... - 137 -
Figure IV. 11: Profiles of TPT uptake for variant NCI-H69 cells........................  - 138 -
Figure IV. 12: FL4 signal of TPT uptakes with or without FTC ..........................  - 139 -
Figure IV. 13: Topoisomerase expression across all NCI-H69 variants............... - 140 -
Figure IV. 14: Continuous alamarBlue exposure is toxic for all NCI-H69
variants................................................................................................................... - 141 -
Figure IV. 15: AlamarBlue method optimization.................................................  - 143 -
Figure IV. 16: Dose response to continuous TPT treatment  - 144 -
Figure IV. 17: TPT treatment of all NCI-H69 variants as single cell suspension ...- 146 -
Figure IV. 18: TPT treatment of all NCI-H69 variants pre-seeded into w ells  - 147 -
Figure IV. 19: Solid tumours cancer stem cell markers  - 152 -
V. Focus on PSA-NCAM
Figure V.l: Time-lapse imaging analysis............................................................  -159 -
Figure V.2: Venn-diagram representation of glycosylation-related genes expression
modulation in the NCI-H69 variants....................................................................  - 161 -
Figure V.3: Sialic acid biosynthesis pathway and sialylation of glyconjugates .. - 163 -
Figure V.4: ST8SIA4 and ST8SIA2 expression..................................................  - 164 -
Figure V.5: Effect of R1108 treatment on PSA levels.........................................  - 167 -
Figure V.6: Effect of 24h ICT compounds treatment on NCAM decoration  -168 -
Figure V.7: Effect of a 48h R1108 treatment on NCI-H69 variants cell lines  - 169 -
Figure V.8: R1108 toxicity.....................................................................................  - 171 -
Figure V.9: Benzyl alcohol effect on cells............................................................. - 173 -
Figure V.10: R1108 purification batches............................................................. - 174 -
Figure V. 11: Induction of cell death by candidate PST inhibitors.......................  - 175 -
Figure V.l2 Transcriptional responses to R1108 ................................................  - 177 -
Figure V.l3: Immunoblotting detection of metallothionein induction................ -180 -
Figure V.l4: Immunoblotting detection of metallothionein induction after 24 h
treatment.................................................................................................................  -181-
Figure V .l5: mouse Metallothionein-1 overexpressing CHO.............................  - 182 -
Figure V .l6: Effect of a range of R1108/2006 concentrations on the growth of the
population of CHO-K1 and mMT-CHO-Kl......................................................... -183 -
Figure V.l 7: Effect of various concentrations of R1108 on cell growth  - 184 -
Figure V.l8: Effect of increasing concentrations of R1108 on the mitotic outcome of
the CHO cell lines over three generation............................................................  -186 -
Figure V.l9: Effect of various concentrations of R1108 on the mitotic duration and the 
intermitotic time (IM T).........................................................................................  - 187 -
VI. Discussion
Figure VI. 1: Overview of the thesis highlights addressing the stated aims of the
Study.......................................................................................................................  - 196 -
Figure VI.2: NCI-H69 variant m odel.................................................................... -198 -
Figure VI.3: SCLC................................................................................................  - 206 -
X
Appendix IV: SCLC cell lines panel PSA-NCAM expression.
Figure 1: SCLC cell lines panel PSA-NCAM expression...................................  -211 -
Appendix V: 2008 arrays quality assessment.
Figure 1: 2008 arrays — MAS5 computed quality control report....................... - 212 -
Figure 2: 2008 arrays — AffyPLM package for Bioconductor quality assessment
— RLE and NUSE p lots.......................................................................................  -213-
Appendix IX: MSA.
Figure 1: MSA adhesion profile after PSA digestion..........................................  - 227 -
Figure 2: Cell morphology on MSA ECM proteins spot after endoN digestion .. - 228 -
Figure 3: Reassembled full MSA array — NCI-H69 S P .....................................  - 229 -
Figure 4: Reassembled full MSA array — NCI-H69 AP3 ..................................  - 230 -
Figure 5: Reassembled full MSA array — NCI-H69 AP78 ................................  - 231 -
Appendix XII: 2005 arrays quality assessment.
Figure 1: 2005 arrays — MAS5 computed quality control report....................... - 235 -
Figure 2: 2008 arrays. AffyPLM package for Bioconductor quality assessment — RLE
and NUSE plots  - 236 -
Figure 3: Microarray analysis accounting for failed quality control array  - 237 -
XI
List of tables
I. Introduction
Table 1.1: Metastasis-related genes........................................................................  -14 -
Table 1.2: ABC transporters known to be involved in M DR.................................  - 21 -
Table 1.3: SCLC molecular characteristics............................................................. - 29 -
II. Materials and methods
Table II. 1 drug and molecular probes used ............................................................  - 40 -
Table II.2 primary antibodies used  -41 -
Table II.3 secondary antibodies used  -41 -
Table II.4 Cell lines routine culture description....................................................  - 42 -
Table II.5: Flow cytometry fluorescence optics....................................................  -51 -
Table II.6: CBS camera fluorescence filters..........................................................  - 54 -
III. Characterization of an in vitro SCLC model system
Table III.l: SCLC cell lines description................................................................. - 60 -
Table III.2: Distribution and enrichment amongst the GO SLIM categories of the 1004
probes....................................................................................................................... - 87 -
VI. Focus on PSA-NCAM
Table V.l: RT-PCR primers..................................................................................  - 157 -
Table V.2: R1108 batches..................................................................................... -166 -
Table V.3: ICT compounds....................................................................................  -166 -
Table V.4: Effect of R1108 different batches on PSA decoration of NCAM .... - 167 -
Table V.5: R1108 batches — toxicity profile......................................................  - 172 -
Table V.6: Transcriptional responses to R1108...................................................  - 179 -
Appendix VI: SCLC characteristics.
Table 1: SCLC and NSCLC markers expression in the NCI-H69 variants  - 214 -
Table 2: SCLC markers expression in the NCI-H69 variants..............................  - 215 -
Appendix VII: Cell cycle and growth.
Table 1: Overlap between 1189 gene list and GO: 7049 cell cycle..................... - 216 -
Table 2: Cell growth. Overlap between 1189 gene list and GO: 40007 growth.. - 218 -
Appendix VIII: Cell adhesion.
Table 1: Overlap between 1189 gene list and GO: 7155: cell adhesion.............  - 219 -
Table 2: Overlap between 1189 gene list and GO: 5856: cytoskeleton and GO: 7010:
cytoskeleton organisation and biogenesis............................................................  - 222 -
Table 3: Overlap between 1189 gene list and GO: 30054: cell junction  - 225 -
Table 4: Integrins expression................................................................................  - 226 -
Appendix X: Cell motility.
Table 1: Overlap between GO 6928 cell motility and 1189 gene lis t .................. - 232 -
Appendix XI: Glycosylation.
Table 1: Glycans structure and biosynthesis (KEGG 1.7)...................................  - 234 -
Appendix XII: 2005 arrays quality assessment.
Table 1: Microarray analysis accounting for failed quality control array  - 237 -
XII
Abbreviations
A absorbance
AB alamarBlue
ANOVA Analysis of variance
AP Adherent phenotype
ATP adenosine triphosphate
BSA Bovine Serum Albumin
CAM Cell Adhesion Molecule
CAM-DR Cell Adhesion-Mediated Drug resistance
CDS Cell Dissociation Solution
CHO Chinese Hamster Ovary cells
CSC Cancer stem cell
DMEM Dulbecco's Modified Eagle Medium
DMSO Dimethyl sulfoxide
DTT Dithiotreitol
ECM Extracellular Matrix
EDTA ethylene diaminetetraacetic acid
EGTA ethylene glycol tetraacetic acid
EMEM Eagle’s Minimum Essential Medium
EMT epithelial to mesenchymal transition
FCS Fetal Calf Serum
FDR False discovery rate
Fn Fibronectin
FTC Fumitremorgin C
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GO Gene ontology
h hours
HOP hydrophobic bacteriological Petri dishes
HPLC high performance liquid chromatography
HRP HorseRadish Peroxidase
HSPG heparan sulfate proteoglycan
ICC Immunocytochemistry
ig Immunoglobulin
igSf Immunoglobin SuperFamily
kDa kiloDalton
L Litre
m milli
m meter
M micro
M Molar concentration
XIII
MET mesenchymal to epithelial transition
min minutes
MSA Multiple Substrate Array
MT Metallothionein
n nano
NaCI Sodium Chloride
NCAM Neural Cell Adhesion Molecule
NE Neuroendocrine
Neu5Ac Sialic acid
PBS Phosphate Buffered Saline
PCR Polymerase chain reaction
PI Propidium Iodide
PI3K phosphatidylinositol 3- kinase
PMSF PhenylMethylSulphonyl fluoride
PSA Polysialic acid
PVDF PolyVinyliDene Fluoride
QC Quality controls
RMA Robust multiarray average
RNA Ribonucleic acid
rpm rotation per minute
RPMI Roswell Park Memorial Institute
RT room temperature
RT reverse transcription
Sec seconds
SCLC Small Cell Lung Cancer
SD Standard Deviation
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis
Sia Sialic acid
SP suspension phenotype
TCP tissue culture plastic
TPT Topotecan
U Units
W Watt
w r wild type
XIV
Chapter I — Introduction
I. Introduction
The loss of genomic stability and resulting gene alterations are key 
molecular pathogenic steps that occur early in tumourigenesis. However, many 
complex properties of cancer cells are effectively under selection within the in 
vivo microenvironment or following therapeutic insult. This critical combination 
of instability and varying selection drives the heterogeneity of tumour cell 
populations in terms of many critical features including: cell growth 
characteristics, invasion behaviour, metastatic potential and the forms of innate 
or acquired resistance to therapy. The current study addresses the 
development of a small-cell lung cancer (SCLC) model, which encom passes 
elements of variation and heterogeneity, to provide opportunities to link in vitro 
behaviour of SCLC with in vivo characteristics with particular reference to the 
challenges faced in the m anagem ent of SCLC such a s  the accrual of drug 
resistance. SCLC is an aggressive, rapidly metastasizing neoplasm with a high 
propensity for bone marrow involvement. The striking ability of SCLC to develop 
resistance against chemotherapeutic agents has led to the proposal that 
changes in cytokine receptor expression and cell adhesion properties within the 
tumour microenvironment contribute both to metastatic potential and to the 
laying of the foundations of chemoresistance. Difficulty arises when attempting 
to link the steady-state phenotype of SCLC cells in vitro with opportunities for 
therapeutic design and validation. In vitro cultures may present a coherent 
model, accessible to analysis but these and their linked signalling pathways are 
not challenged by the in vivo environment. However; in vitro models that 
disassemble the components of variation within a tumour cell population provide 
a starting position to understand the plasticity or heterogeneity of phenotypes 
within a dynamic tumour system. Here the aim was to use such a SCLC model 
to address the specific origins of resistance to a relevant cytotoxic agent or 
indeed to novel therapies based on the targeting of cellular processes that 
control cellular interactions and are relevant to behaviour within 
microenvironments.
Chapter I — Introduction
1.1. Cancer progression and origins of cellular heterogeneity
The importance of genetic changes in neoplastic progression is well 
recognized, with the alteration of three general groups of genes — oncogenes, 
tumour-suppressor genes and genome stability genes — all contributing in 
complex combinations to tumourigenesis. Mutations in oncogenes and tumour 
suppressor genes (TSGs) enhance the net reproductive rates of a cell, while 
mutations in genetic stability genes increase the rate of mutational processes 
such a s  point mutations, insertions, deletions, gene amplification, chromosome 
rearrangem ents and gain or loss of whole chromosomes (Vogelstein and 
Kinzler, 2004). According to Vogelstein (Vogelstein and Kinzler, 2004), there 
are three major challenges in understanding origins and progression in cancer: 
the discovery of new genes that have a causal role in neoplasia; the delineation 
of the pathways through which these genes act and the basis for the varying 
actions in specific cell types; the exploitation of this knowledge for the target 
validation and drug discovery to improve treatment in the clinic.
Cancer progression is recognized as involving significantly more 
complexity and multi-functionality than mutation driven clonal expansion. 
Indeed, recent advances have showed that cancer is a s  much an epigenetic 
d isease a s  it is a genetic disease, and epigenetic alterations in cancer often 
serve a s  potent surrogates for genetic mutations (Jones and Baylin, 2007). 
Epigenetics is defined as modifications of DNA or associated factors that have 
information content and are hereditable (aside from the DNA sequence itself). 
Normal epigenetic modifications of DNA encom pass three types of changes, all 
of which are interrelated: chromatin modifications, DNA methylation, and 
genomic imprinting (see for review Bernstein et aL, 2007). A common them e to 
d isease epigenetics is the disruption of phenotypic plasticity (Feinberg, 2007). 
Epigenetic or ‘transcriptional’ targeted therapies can involve attem pts to modify 
DNA methylation-linked epigenetic mechanisms used by the cancer cells for 
long-term silencing of gene expression. However, the problem remains that it 
cannot be assum ed that molecular targets are equally and optimally present by 
all neoplastic cells. Pragmatically, our understanding of the consequences of 
molecular defects and identification of therapeutic opportunities must address
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the added complexity of intra-tumour variation when viewed at specific point in 
time during diagnostic or therapeutic processes.
A readily observable form of genetic instability is chromosomal instability 
(CIN) leading to abnormally structured chromosomes and changes in 
chromosome numbers (Rajagopalan et al., 2003; Sieber et al., 2003) putatively 
arising from abnormalities in chromatin dynamics and a reduced fidelity of the 
surveillance of cell cycle events. One end result of chromosomal instability is 
aneuploidy. Aneuploidy is observed in most cancers and is in its own right a 
driver of chromosomal instability (Duesberg and Li, 2003). It is still unclear 
whether genetic instability is an early event and therefore a driving force of 
cancer progression or a late stage consequence of the somatic evolution that 
leads to cancer (Rajagopalan et al., 2003; Sieber et al., 2003) but can have the 
impact of driving clonal elements in a progressing tumour. Although it is 
accepted that most cancers are clonal in origin (Nowell, 1976), tumour cells 
may have different karyotypes and phenotypes. Indeed, individual cells of a 
given cancer often differ widely from each other in phenotypic properties such 
a s  metastatic capacity, drug sensitivity, growth rates, metabolism, and 
morphology (Fialkow, 1979; Konemann et al., 2000). Co-existing with such 
variation in tumour cell system s is the operation, in som e cancers at least, of a 
process by which cancer stem cells (CSCs) may sustain tumourigenesis, 
generating cellular hierarchies and heterogeneity through the ‘stem-like’ 
properties of self-renewal and differentiation (Visvader and Lindeman, 2008). 
CSCs may also contribute to chemoresistant subfractions or sub-populations 
with extended recovery potential in a variety of malignancies, including brain 
tumours, leukemias, and breast carcinomas (Hart and El-Deiry, 2008; Reya et 
al., 2001) leading to a search for targets for the specific elimination of CSCs 
(Beier eta!., 2008).
Thus, tumour cell heterogeneity arising by different routes, not least 
through the innate plasticity or stochastic nature of cellular processes, provides 
a wide range of cellular repertoires. Within this state there can be bias 
associated with the selective pressure of the local environment from which 
different repertoires can provide selective advantage. Indeed, cancer 
development is recognized to be an evolutionary process and tumour 
progression has been compared to Darwinian evolution (Nowell, 1976;
- 3 -
Chapter I — Introduction
Tomlinson and Bodmer, 1999). Cancer genes (used in the broadest sense  to 
include oncogenes and tumour suppressor genes) mediate the evolution of 
cancer cells, so cancer genes can be envisaged to function by increasing 
“cellular fitness.” The term “cellular fitness” is useful because it appeals to a 
comm on-sense understanding of Darwinian evolution, and it correctly implies a 
broad range of mechanisms. Increased “cellular fitness” m eans that a heritable 
event has allowed clonal expansion under selection. The comment by Prof. Mel 
Greaves (Institute of Cancer Research, UK) that, “The only fitness test of 
natural selectability in evolution is survival and reproductive success” (Greaves,
2007) could apply equally to the in vitro and in vivo situations.
Clearly, tumour growth is a complex process ultimately dependent on 
proliferation and cell dynamics and the potential for nurture in the spread to new 
microniches. A common view of tumour growth kinetics is based on the general 
assumption that tumour cells grow exponentially (Bru et al., 2003). Such 
kinetics agrees with the unlimited proliferative activity of tumour cells recorded 
in early, mainly in vitro, studies. However, a  number of poorly explained issues 
remain in disagreem ent with a simple exponential regime of cell proliferation 
even when modified for apoptotic / cell death events. For example, there is a 
clear discrepancy between the exponential tumour growth theory and 
experimental data obtained from tumour cells growing in vivo: tumour doubling 
times have been found to greatly exceed cell cycle times. Lower-than-expected 
activity of tumour cells and greater-than-expected aneuploidy has also 
consistently been found. These issues are of importance since conventional 
chemotherapy is largely limited by tissue kinetics (Bru et al., 2003), while failure 
and relapse can arise from phenotypic plasticity that impacts on selectability -  
in the context of this thesis, the undesirable potential to maximise Darwinian 
fitness for the selection of metastatic and drug-resistant variants that can drive 
new phases of tumour growth.
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1.2. Phenotypic plasticity
1.2.1. Definition and implications
In ecological terms, phenotypic plasticity “is the ability of an organism to 
express different phenotypes depending on the biotic or abiotic environment" 
(Agrawal, 2001). The term “plasticity” has been used in a variety of biological 
contexts from epigenetics to stem cell biology (Wagers and W eissman, 2004). 
In the case  of the latter, the classical definition of stem cell plasticity implies the 
ability of stem cells to provide progenitors that differentiate into various cell 
lineages, although the possibility that stem cells may be capable of 
differentiation across tissue lineage boundaries has recently emerged (Wagers 
and Weissman, 2004). This apparent greater potency of adult stem cells has 
been termed stem cell plasticity, with true stem cell plasticity being defined as 
dedifferentiation and redifferentiation or even transdifferentiation (Lakshmipathy 
and Verfaillie, 2005). The situation is even less certain in the case  of putative 
solid tumour CSC sub-populations in which phenotypic heterogeneity is likely to 
operate (Visvader and Lindeman, 2008) and co-exist with clonal expansion 
processes. It appears likely that CSCs are distinct from the cell of origin that 
receives the ‘first oncogenic hit(s)’ and that they do not necessarily originate 
from the transformation of normal stem cells. The term of plasticity has also 
been applied to epigenetics. Indeed, Feinberg (2006) defined genetic and 
epigenetic plasticity as “an enhanced ability to stably evolve its phenotype, with 
both a genetic and epigenetic basis”.
Although normal and tumour cell plasticity, have been widely used to 
describe differentiation and particularly epithelial-mesenchymal transitions 
(Prindull and Zipori, 2004), recently, phenotypic plasticity has taken on another 
dimension in cancer biology with the notion that cancer is indeed not only a 
genetic d isease but an epigenomic d isease (Jones and Baylin, 2007), 
presumably with the implication that if parts of the disease process demonstrate 
plasticity, then they may be reversible by therapeutic targeting. The acceptance 
of the importance of heterogeneity at the tumour cell level (Konemann et al., 
2000) combined with increasing consideration given to the integration of cancer 
stem cell theory into clonal expansion models (Visvader and Lindeman, 2008),
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the description of oncogene-induced plasticity (Rapp et al., 2008) and the 
epigenetics influences in cancer biology (Feinberg, 2007), all raise attention to 
the notion of disassembling tumour cell heterogeneity, within experimentally 
accessible system s, before investigating phenotypic plasticity per se.
A stringent definition of phenotypic plasticity of a  tumour cell would 
describe the ability to reciprocally dedifferentiate, redifferentiate, and/or 
transdifferentiate in response to specific stimulation (Yaccoby, 2005). Feinberg 
(2007) has provided a refinement of his definition of phenotypic plasticity as uthe 
ability of cells to change their behaviour in response to internal or external 
environmental c u e s This is a pragmatic view of plasticity and it is this latter 
operational definition of phenotypic plasticity that has been adopted in the 
current study.
1.2.2. EMT/MET: an example of cell plasticity
Behavioral transformations of cells, reflecting phenotypic plasticity, 
characterize embryogenesis, wound healing, physiological adaptation and 
neoplasia (Eyden, 2004; Grunert et al., 2003; Jechlinger et al., 2003). The 
plasticity of solid tumour cells has been extensively studied for epithelial-to- 
mesenchymal transition (EMT) and mesenchymal-to-epithelial reverse transition 
(MET). Plasticity is indisputable for both EMT and MET, a s  they have been 
observed at a single cell level and moreover they both appear to be reversible 
phenomenon. Both transitions entail drastic phenotypic and functional changes. 
Indeed, an immobile epithelial cell tightly bound to adjacent cells loses its cell­
cell contact (i.e. tight- and adherens-junctions) and becom es a mobile 
fibroblast-like mesenchymal cell (Prindull and Zipori, 2004). EMT occurs widely 
under both normal and pathologic conditions. EMT occurs at diverse steps 
during embryo development. While MET occurs during somitogenesis, kidney 
development and coelomic-cavity formation (Thiery and Sleeman, 2006).
Figure 1.1 shows the different stages occurring during EMT and MET. 
EMT induces the loss of polarized phenotype accompanied by transcriptional 
loss of epithelial markers, such E-cadherin an important caretaker of the 
epithelial polarised phenotype, and upregulation of mesenchymal markers, such 
as  fibronectin and vimentin. While MET is the reverse process (Prindull and
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Zipori, 2004; Thiery and Sleeman, 2006). The term EMT has been applied to a 
variety of epithelial plasticity scenarios where epithelial cells become 
fibroblastoid in shape and lose their epithelial phenotype but never fully 
transition to mesenchymal cells (Grunert et al., 2003).
EMT
Tight-junction
dissociation
Adherens-j unction and 
desmosome dissociation
EMT effectors
Growth factors 
Cytokines 
ECM_______
Epithelial cells
Epithelial m arkers M esenchym al m arkers
E-cadherin Fibronectin
Claudins Vitronectin
Occludins FSP1
Desmoplakin Vimentin
Cytokeratin-8, -9  and -18 Sm ooth-m uscle actin
Mucin-1 FGFR2 Illb and IIIc splice variants
Tight-junction 
formation. ^ ^
completion o f  cell- 
polarity programme
MET effectors
Adhesion 
Cortical actin MFs
Mesenchymal cells
MET
Desmosome
association
Rho-GTPase activation, 
cortical-actin-cytoskeleton 
reorganization, 
adherens-j unction assembly
Initial E-cadherin 
adhesive contact
Figure 1.1: Cellular plasticity: the EMT /  MET transition (from Thiery and Sleeman, 
2006).
EMT is a developmental program that is often activated during cancer 
invasion and metastasis. Due to its importance in development and pathology, 
EMT has been extensively studied, helped by the development of in vitro 3-D 
cultures (O'Brien et al., 2002). EMT is also a process highly responsive to the
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environment and is guided by a functional interplay of multiple signal 
transduction pathways (e.g. TGF-p, Notch and Wnt) coordinating the action of 
transcription factors (such as Snail), triggering gene responses such as the 
transcriptional repression of E-cadherin - essential for the maintenance of the 
epithelial phenotype (Derynck and Akhurst, 2007; Moustakas and Heldin, 2007).
Recently, EMT induction was shown to increase resistance to UV- 
induced apoptosis in a mouse mammary epithelial cell line, alongside increased 
migratory ability, indicating the relevance of EMT in cancer biology and the 
genomic stress responses of tumour cells (Robson et al., 2006). Moreover, 
Mani et al. (2008) have uncovered a direct link between two plasticity- 
associated phenomena, EMT and the gain of epithelial stem cell properties. 
Indeed, induction of EMT in non-tumourigenic immortalized human mammary 
epithelial cells resulted in the acquisition of a CD44high/CD24l0W phenotype 
associated with both human breast cancer stem cells and normal mammary 
epithelial stem cells. Furthermore, transient induction of EMT creates a 
heritable, self-renewing state as shown by the ability of the cells to grow as 
m am m ospheres once the EMT-inducing factors are inactivated. The potential 
for such transitions with links to stem cell biology are unexplored in SCLC.
1.2.3. The cancer stem cells plasticity and therapeutic challenges
The recognition of a sub-populations of ‘cancer stem cells’ (CSCs) in 
solid cancers has reinvigorated the field including the concept of cancer cell 
plasticity (Prindull and Zipori, 2004). The description reflects the functional 
capacity of cancer stem cells to sustain tumourigenesis and population 
heterogeneity through the ‘stem-like’ properties of self-renewal and 
differentiation capacity (Visvader and Lindeman, 2008). CSCs cells have the 
potential to give rise to more differentiated cell forms (Reya et al., 2001). The 
existence of CSCs implicates a pluripotent stem cell a s  the cell of origin for 
cancer, although this is not certain. A current line of investigation in cancer 
biology is to link tumourigenesis and stem cell biology. Despite being different 
entities normal tissue stem cells and CSCs share similar properties: drug 
resistance, differentiation and increased mitotic capacity (Hirschmann-Jax et al., 
2004). Furthermore, there is a continuing drive to identify functional markers of
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neoplastic cells with stem-like properties (Visvader and Lindeman, 2008). 
Searching for such markers in SCLC is problematic given the inherent 
heterogeneity observed.
CSCs may contribute to tumourigenic and chem oresistant sub-fractions 
in a variety of malignancies, including brain tumours, leukaemias, and breast 
carcinomas (Hart and El-Deiry, 2008; Reya et al., 2001) leading to a search for 
targets for the specific elimination of CSCs (Beier et al., 2008) or the 
mechanisms by which CSCs evade cytotoxic therapies (Visvader and 
Lindeman, 2008). Enhanced drug efflux mediated by ATP-binding cassette 
transporters is one of several mechanisms of multi-drug resistance potentially 
linked with the chem oresponse failure of human cancers. For example the 
ABCB5 novel drug transporter (Huang et al., 2004) is a chem oresistance 
mediator in human malignant melanoma (Frank et al., 2005). ABCB5 has been 
recognized as  a CSC marker (Visvader and Lindeman, 2008) given that 
ABCB5+ tumour cells detected in human melanoma patients show a primitive 
molecular phenotype and in vivo genetic lineage tracking can demonstrate a 
specific capacity of ABCB5+ sub-populations for self-renewal and differentiation 
(Schatton etal., 2008).
Som e DNA interactive drugs are preferably subject to adenosine 
triphosphate (ATP)-dependent efflux by the breast cancer resistance protein 
(BCRP) - a 655 amino-acid polypeptide designated as ABCG2 
(MXR/BCRP/ABCP1 / Doyle and Ross, 2003; Ee et al., 2004). ABCG2 also 
shows an intriguing linkage with the CSC phenotype (Visvader and Lindeman,
2008), given that enhanced ABCG2 transporter expression contributes to the 
defining ability of pluri-potential "side population" of cells to exclude the DNA 
minor groove-binding dye Hoechst 33342 (Goodell, 2002; Goodell et al., 2005; 
Hirschmann-Jax et al., 2005; Hirschmann-Jax et al., 2004; Storms et al., 2000) 
and enforced expression of the ABCG2 cDNA directly confers the side 
population phenotype to bone-marrow cells (Zhou et al., 2001). It is likely that 
the physiological function of ABCG2/Bcrp1 expression in hematopoietic stem 
cells is to provide protection from cytotoxic xenobiotics (Zhou et al., 2002). 
Interestingly, the ABCG2 transporter is functional for TPT and the related 
agents 9-aminocamptothecin, Irinotecan and SN-38 (Polgar et al., 2008; Robey 
et al., 2007). The ABCG2 half-transporter is sensitive to inhibitors (eg
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Fumitremorgin C / FTC), such inhibition resulting in resistance reversal 
(Rabindran et al., 2000) and has therefore been of therapeutic interest. 
However, ABCG2 is yet to have a fully defined role in drug resistance in human 
cancers due to complex substrate specificity patterns, co-expression of other 
ATP-binding cassette transporters, the effects of mutation on the spectrum of 
molecules transported and uncertainty over the impact of only moderate 
increases in transporter function (Doyle and Ross, 2003; Nakanishi etal., 2003; 
Rabindran etal., 2000; Ross and Doyle, 2004).
Considering the in vitro potential for clonal evolution (Visvader and 
Lindeman, 2008), it is remarkable that CSCs can be identified in sub-fractions of 
established cell lines (Blazek et al., 2007; Fan et al., 2006; Fukuda etal., 2004; 
Kondo et al., 2004; Setoguchi et al., 2004) although the link between stem  cell 
marker expression and clonogenicity may be weak (Srivastava and 
Nalbantoglu, 2008). According to the CSC theory, significant ABCG2 function 
may be restricted to cell sub-populations that may vary considerably in 
frequency in human tumours and may have uncertain representation in 
established cell lines from solid tumours. The existence of side population 
phenotypes in SCLC biopsies or in vitro cell lines remains to be investigated.
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1.3. Metastasis
Metastasis is considered to be a critical and often defining phase in solid 
tumour progression and its outcome a leading cause for cancer-related death 
rather than the local impact of the primary tumour. Due to difficulties in study, 
with until recently only end-point m etastasis information being accessible much 
remains to be discovered about the basic metastatic process. However, in vivo 
video imaging has opened new ways to study the metastatic cascade (Wyckoff 
et al., 2000). Mathematical models of the early phases of m etastasis dynamics, 
using modified Gompertzian models, have previously been used to inform a 
rationale for screening and treatment (Clare et al., 2000). Despite obvious 
limitations for prediction it appears that metastatic initiation could occur at a 
tumour volume of a primary lesion that is only slightly smaller than that at the 
time of tumour diagnosis (Koscielny eta l., 1985).
1.3.1. Metastasis: a multi-step cascade inviting early intervention
The metastatic process is a multi-step cascade (figure 1.2), and all these 
steps are essential (reviewed in Steeg, 2006) but may differ considerably in 
their kinetics and probability. The first step in the metastatic process is invasion, 
the penetration of the basem ent membrane and stroma surrounding the primary 
tumour, this requiring changes in cell adhesion to the extracellular matrix (ECM) 
and proteolytic degradation of surroundings (Friedl and Wolf, 2003). For the cell 
to disseminate into the body, they need to enter the circulation — a blood 
vessel or the lymphatic system — phenomenon called intravasation (Wong and 
Hynes, 2006). Time spent in circulation for disseminated tumour cells is 
believed to be short. However the bloodstream is a difficult environment to 
survive in due to shear pressure, presence of immune cells and lack of 
attachment, indeed anoikis — death upon detachm ent — is thought to 
contribute to m etastasis inefficiency (Steeg, 2006). Capture in the bloodstream 
is generally thought to be due to size restriction of capillary structures or binding 
to coagulation factors (Steeg, 2006). Tumour cells must then escape  from the 
vasculature (extravasation) in order to form a m etastasis — although growth at
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the secondary site without crossing the vascular wall has been observed 
(Weidner, 2002).
4) Intravasation
Proliferation
5) Survival in circulation
6) Arrest in new organ 
7) Extravasation
Death
A
‘Dormant’
Death
A
‘Dormant’
1) Tumour cell growth
2) Angiogenesis
3) Invasion
 Single cell____________Micrometastasis J
Clinically undetectable Clinically detectable
metastasis metastasis
Figure 1.2: The tumour metastatic process (from McGee et a l ,  2006).
With only very few cells in the circulation forming metastasis, growth at 
metastatic sites is considered to be the limiting factor of the metastatic cascade. 
The host molecular influence is believed to play a major role in colonization 
efficiency — the theory of “seed” and “soil” compatibility (Steeg, 2006). Cells at 
the new site can undergo proliferation, apoptosis or dormancy. Indeed, it is 
thought that within 24h of intravasation most cells undergo apoptosis (Wong 
and Hynes, 2006). Dormancy can also occur at the later stage of
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micrometastasis and is thought to be the result of apoptosis balancing
proliferation (Townson and Chambers, 2006). It is a frequent occurrence for 
certain types of cancer to m etastasize to specific organs and it is said that 
“homing” could not be explained by blood flow patterns, rather cancer cells 
appear to be drawn to tissues. An alternative to this theory is that the
microenvironment of those organs could offer better growth potential
(Chambers et al., 2002).
Despite the diversity of invasion and migration, the multi-step nature of 
m etastasis is currently becoming clearer through the identification of
m etastasis-related genes. Moreover microarray analysis shows great promises 
in identifying a molecular signature of m etastasis in primary tumours 
(Ramaswamy et al., 2003; va n ' t  Veer et al., 2002). Table 1.1 presents a non- 
exhaustive list of metastasis-related genes but represents those that may be 
pertinent to models for plasticity of metastasis-related cell behaviour.
Multiple environmental factors (motility-inducing chemokines and growth 
factors) alongside ECM remodelling proteins (i.e. matrix metalloproteinases) 
can regulate tumour cell motility (Friedl and Wolf, 2003). Recently, a nuclear 
protein referred to a s  ‘genome organizer’ SATB1 (SATB homeobox 1) was 
found to alter gene expression in breast cancer, inducing an aggressive 
phenotype promoting tumour growth and m etastasis (Han et al., 2008). Also, a 
direct link between m etastasis and hypoxia was recently uncovered. Indeed the 
hypoxia-inducible factor-1 a (HIF-1a) was found to regulate the expression of 
TWIST an essential mediator of cancer m etastasis (Yang et al., 2008). 
Comparison of tumourigenic non-metastatic cells with metastatic tumour cells 
has identified genes potentially involved in m etastasis repression (loss of 
function in m etastasis) named m etastasis suppressor genes (MSG). Those 
genes represent attractive potential biomarkers candidates as well as 
therapeutics targets (Shevde and Welch, 2003; Steeg, 2003).
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Table LI: Metastasis-related genes.
pro-migratory factors (Friedl and Wolf 2003)
Phosphoglucose isomerase (GPI / AMF)
Stromal-cell-derived factor-1/CX-chemokine receptor-4 (SDF1 / CXCR4) 
Epithelial growth factor (EGF) 
lysophosphatidic acid (LPA)
Insulin-like growth factor-1 (IGF1)
Matrix metalloproteinase 1,2 and 13 (MMP1,2 and 13) 
membrane-type 1 matrix metalloproteinase (MT1-MMP)
Metastasis suppressor genes (Shevde and Welch, 2003; Steeg, 2003)
non-metastatic cells 1, protein (NM23A) expressed in (NME1 /NM 23) 
mitogen-activated protein kinase kinase 4 (MAP2K4 / MKK4)
CD82 molecule (CD82 / KAI1)
breast cancer metastasis suppressor 1 (BRMS1)
KiSS-1 metastasis-suppressor (KISS 1)
Rho GDP dissociation inhibitor (GDI) beta (ARHGDIB / RHOGDI2) 
mediator complex subunit 23 (MED23 / CRSP3) 
thioredoxin interacting protein (TXNIP / VDUP1)
TIMP metallopeptidase inhibitors (TIMPs) 
cadherins
Src-suppressed C kinase substrate (SSeCKS)
N-myc downstream regulated 1 (NDRG1 / Drg-1 / CAP43 / RTP)
1.3.2. Metastasis and phenotypic plasticity
Traditional models for m etastasis propose that secondary tumours result 
from rare cells with migratory potential, appearing at later stages of tumour 
progression. Those models have been challenged, especially with insights 
provided by microarray analysis. Indeed, using microarray analysis 
Ramaswamy et al. (2003) have suggested that metastatic potential of human 
tumours could be encoded in the primary tumour and that gene expression 
signature could be common for many tumour types. Moreover, van’t Veer et al. 
(2002) have been able to predict tumour dissemination, with a 90% accuracy 
using gene expression profile of primary tumours. This has led to the 
suggestion that genetic alterations responsible for carcinogenesis were also
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responsible for m etastasis (Bernards and Weinberg, 2002), and that tumour 
progression and m etastasis may be underpinned by the behaviour of migrating 
and phenotypically plastic cancer stem cells (Brabletz et al., 2005).
It has been suggested that reversible transitions may not only enable the 
development of embryonic stem cells to adult stem but also, through the 
fundamental property of plasticity, facilitate metastatic spread and the 
progression of micrometastases. As suggested by the loss of epithelial 
differentiation and acquisition of migratory phenotype, reflecting EMT / MET 
transitions, are thought to play an important role in m etastasis (Friedl and Wolf, 
2003). In the present study there is therefore a rationale for an expectation of 
overlap of plasticity-related genes with those potentially permissive for 
m etastasis and those recruited in the expression of stem-like properties -  an 
unexplored area for SCLC heterogeneity.
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1.4. Chemoresistance
The concept of drug resistance has been partly based on the work of 
Luria and Delbruck (1943) on spontaneous mutations in bacteria producing 
variants resistant to bacteriophages. Applying that concept to tumour cells, the 
Goldie-Coldman model (Goldie and Coldman, 1979) proposed that the 
probability for a tumour to contain resistant cells is a function of the mutation 
rate and that even with a low mutation rate of 1 in 106 mitoses, resistant cells 
would be found in a clinically detectable tumour (1 cm3 / 109 tumour cells). This 
has informed the attempts of chemotherapeutic approaches to combination 
therapy and the development of several model for drugs administration to 
prevent the appearance of clonal resistance (DeVita et al., 1975; Norton, 1997; 
Panetta, 1998). Disappointingly, it is the general experience that tumours that 
respond rapidly to cytotoxic drugs also relapse. It is likely that optimal adjuvant 
drug therapy must include both induction (‘cytotoxic’) and maintenance 
components e.g. m etastasis-suppressive maintenance drugs (Epstein, 2005).
Cancer cells can develop several mechanisms of resistance impeding 
the activity of agents (figure 1.3). The following overview will focus on the 3 drug 
resistance mechanisms relevant for the thesis aims.
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Figure 1.3: Chemoresistance mechanisms overview (adapted from Wilson et al., 2006).
1.4.1. Apoptosis modulation
For tissue homeostasis to be maintained there is a need for a balance 
between proliferation and programmed cell death, or apoptosis. Apoptosis is an 
active multi-step multi pathway cell death program regulated by a complex 
balance between numerous anti-apoptotic and pro-apoptotic molecules. 
Apoptosis can be initiated via two pathways: the intrinsic pathway —  regulated 
by the mitochondria —  or the extrinsic pathway —  involving death receptors 
(Letai, 2008). Proliferation alone is not sufficient for tumour progression, indeed 
oncogene activation and genetic instability ought to induce apoptosis, therefore 
resistance to apoptosis is essential to tumour growth. As irradiation treatments 
and conventional agents often act (e.g. cytotoxicity) through apoptosis 
induction, deficiency in this pathway can induce resistance to therapy (Igney 
and Krammer, 2002). Apoptosis is a multi-pathway program and resistance can
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occur at different levels. A central role is often attributed to the protein p53, a 
key element in genomic stress-induced apoptosis, which is frequently disrupted 
in cancer influencing tumour cells response to chemotherapy (Kastan, 2007; 
Lowe et al., 1994). Other mechanisms of resistance include overexpression of 
anti-apoptotic proteins such as BCL2 (Zhang et al., 1999), BCL-XL (Minn et al., 
1995), FLIP (Krueger et al., 2001) or survivin (Grossman et al., 2001) and 
inactivation — downregulation or mutation — of pro-apoptotic proteins like BAX 
(Yin et al., 1997), APAF1 (Soengas et al., 2001) or CD95 (Fas) (Peli et al., 
1999) as well as  downregulation of death receptors TRAIL-R1 and TRAIL-R2 
(Shin et al., 2001). Resistance can also occur through excessive survival 
pathway activation such as the PI3K/AKT (Vivanco and Sawyers, 2002).
1.4.2. Cell cycle modulation: kinetic resistance
Progression through the cell cycle is a highly regulated process with 
many checkpoints, regulating transitions from phases of the cycle in order to 
prevent replication of DNA dam ages driving genomic instability (Nurse, 2000). 
Major cell cycle transitions are driven by cyclin-dependent kinase (CDK) 
regulated by cyclins and cyclin-dependent kinase inhibitors (CDKI). Those 
regulators function to permit the cell to maintain the timing of both the onset and 
the fidelity of DNA replication and mitosis (Georgi et al., 2002). The em ergence 
of neoplasia with the loss of spatial control of growth and temporal control of 
proliferation invariably reflects a dysregulation of the cell cycle. It is clear that 
many cell cycle regulatory proteins can act as oncogenes or tumour suppressor 
genes, or are closely associated with the transformation process (Smith et al., 
2006). Cell cycle-derived resistance has been attributed to the cause of drug 
resistance to agents, essentially arising from the position of the cell in the cell 
cycle (Shah and Schwartz, 2001), hence highlighting the importance of 
combination chemotherapy.
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1.4.3. Multidrug resistance: innate and acquired
Multidrug resistance (MDR) describes resistance (innate or acquired) to 
a combination of agents structurally and functionally unrelated. MDR was first 
described when cell lines selected for resistance to a drug demonstrated cross­
resistance to chemically unrelated drugs (Biedler and Riehm, 1970). This was 
soon interpreted a s  a reduced plasma membrane permeability due to the 
expression of a cell surface glycoprotein (Juliano and Ling, 1976; Ling and 
Thompson, 1974). One of the most studied MDR mechanisms is drug efflux and 
is frequently due to enhanced expression of members of the ATP binding 
cassette  (ABC) family of transporters. ABC transporters are ATP (adenosine 
triphosphate) binders involved in mostly unidirectional energy-dependent 
transport across all cell membranes. They transport a wide variety of substrates 
across extra- and intracellular membranes, including metabolic products, lipids 
and sterols, in addition to xenobiotics. The ABC genes code for a large family, 
49 members, of transmembrane proteins constituted of 7 c lasses according to 
sequence homologies, A to G (see for review Dean et al., 2001; Huang and 
Sadee, 2006; Scotto, 2003).
ABC transporters share 30 to 50% sequence homologies. Typically, ABC 
transporters are composed of 2 transmembrane domains (composed of 6 a 
helices) and 2 nucleotides (ATP) binding domains (figure I.4a). However som e 
members of the ABCC (MRP) family (MRP1, 2, 3, 6 and 7) have five extra 
transmembrane regions forming a third transmembrane domain (figure I.4b). 
The ABCE and ABCF families contain genes with an ATB-binding domain but 
no transmembrane domain and are not known to be involved in any membrane 
transport function. Finally, som e ABC family members, such as  ABCG2 (figure 
I.4c), are half-transporters containing only one transmembrane domain and one 
ATP binding domain (Couture et al., 2006) and must combine with another half 
transporter to gain functionality.
The nucleotide binding domain (NBD) is more conserved across ABC 
transporters than the transmembrane domains (TMD), suggesting that in 
transporters of different functions and substrates, the NBDs are powering the 
transports, while the TMDs are thought to contain the substrate binding site 
(Hollenstein et al., 2007; Kerr, 2002). ABC transporters are active transporters
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and can pump substrate against a concentration gradient requiring energy i.e. 
binding and hydrolysis of ATP (Higgins and Linton, 2004).
a. ABCB1
TMD2 TMD3r r 'n
Extracellular
Intracellular
NBD1 NBD2
COOH
b. ABCC1
TMD1 TMD2 TMD3
n h 2-
Extracellular
Intracellular
NBDl NBD2
COOH
c. ABCG2
TMD
(  >1
Extracellular
Intracellular
COOHNBDl
N H 2
Figure 1.4: ABC transporters protein arrangements (adapted from Couture et a l 2006). 
Representative structures o f the three different ABC proteins arrangements, a. full 
transporters, b. Transporters containing an extra transmembrane domain, c. half 
transporters containing only one transmembrane domain and one nucleotide binding 
domain.
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ABC transporters are responsible for uptake and efflux of a multitude of 
substances involved in diverse physiological process. Furthermore, ABC 
function is one of the major causes of drug resistance and chemotherapeutic 
failure in cancer. Several notorious ABC transporters are involved in MDR (table 
1.2), thus targeting ABC transporters for the reversal of drug resistance is of 
clinical relevance (Ponte-Sucre, 2007).
Table 1.2: ABC transporters known to be involved in MDR.
Gene symbol Common name Known resistance factor for
ABCB1 Pgp / MDR1 anthracyclines, etoposide, Vinca alkaloids1
ABCC1 MRP1 anthracyclines, camptothecins2
ABCC2 MRP2 cisplatin, camptothecins2
ABCC3 MRP3 etoposide2
ABCC4 MRP4 nucleotide analogues2
ABCC5 MRP5 nucleotide analogues2
ABCG2 BCRP / MXR topotecan, flavopiridol, mitoxantrone3
ABCG5 / doxorubicin4
‘Ambudkar et al. (2003), 2Kruh and Belinsky (2003), 3Hardwick et al. (2007), 
4Visvader and Lindeman (2008)
The first discovered ABC transporter involved in MDR is the widely 
studied P-glycoprotein (Pgp / ABCB1 also known as multidrug resistance 
protein 1 / MDR1) (Juliano and Ling, 1976). ABCB1 normally functions in 
kidney, intestine, liver and blood-brain barrier and is overexpressed in a variety 
of cancers (e.g. lymphomas, leukemias, neuroblastoma, kidney, liver and colon 
cancer) contributing to resistance to various agents including actinomycin D, 
paclitaxel, anthracyclines and etoposide (Ambudkar et al., 2003). The second 
frequently studied ABC transporters is the breast cancer resistant protein 
(BCRP / ABCG2 also known as mitoxantrone resistant protein / MXR). ABCG2 
was first discovered in the breast cell line MCF7, selected for resistance to 
mitoxantrone (Nakagawa et al., 1992) or doxorubicin (Chen et al., 1990). 
ABCG2 is endogenously expressed at apical m embranes of polarised cells
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such as  hepatocytes, enterocytes and endothelial cells suggesting a role in 
protection against environmental substances. Its expression in numerous 
cancers (e.g. leukemias, SCLC, and melanoma) confers resistance to drugs 
such a s  topotecan, mitoxantrone and flavopiridol (Hardwick et al., 2007; Mao 
and Unadkat, 2005). Recently, a role of ABC transporters as phenotypic 
markers of stem cells has been uncovered (Alison, 2003; Bunting, 2002). 
Furthermore, the stem cells marker ABCG2 has been shown to be a molecular 
determinant for the Hoechst 33342 side population phenotype (Zhou et al.,
2001). These intriguing roles of ABCG2 in stem cell biology have been 
discussed in previous sections.
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1.5. Environment and cell adhesion
The microenvironments of tumours introduce level of inherent complexity 
in defining cellular phenotypes with implications for tumour suppression and 
progression (Bissell and Radisky, 2001). Many resistance models (particularly 
in vitro) lack relevance for host-tumour interactions and hence the unknown 
impact and role of tumour cell adhesion properties (Joyce, 2005). For instance, 
integrin-associated signalling can render tumour cells more resistant to anti­
cancer agents, a phenomenon termed cell-adhesion-mediated drug resistance 
(CAM-DR) in SCLC (Buttery et al., 2004). However, the search for anti­
adhesion molecules offers promising and possibly low-toxicity strategies that 
may be broadly applicable cancer treatment (Schmidmaier and Baumann, 
2008).
The following brief overview of the major cell adhesion mechanisms 
encom passes the role of the glycocalyx and the implications for cancer biology 
and drug resistance. In the case  of mammalian cell systems, the term 
glycocalyx w as initially applied to the polysaccharide matrix excreted by 
epithelial cells forming a coating on the surface of epithelial tissue -  imparting 
passive protection. Here the term is used to refer conveniently to the specific 
decoration of cell surface molecules -  a feature that can impact on cancer cell 
behaviour. Accordingly, malignant transformation is associated with changes in 
glycosylation, resulting in ‘abnormal’ glycosylations patterns in tumour cells. 
Indeed, it is recognized that carbohydrate-mediated adhesion in cancer plays a 
role in m etastasis and angiogenesis (Kannagi et al., 2004).
1.5.1. Cell adhesion mechanisms
Cell adhesion to other cells or the surrounding substrate (extracellular 
matrix) mediated by cell adhesion molecules (CAM), is an important component 
of tissue architecture enabling the association of cells into a  3D structure 
providing additional multi-level spatial, mechanical and gradient properties. In 
addition to cell-cell and cell-matrix interactions, CAMs have recognized roles in 
influencing cell shape and polarity, cytoskeletal organization, cell motility, 
proliferation, survival and differentiation (Hynes, 1999). A crucial role has been
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attributed to the cytoskeleton — a network of actin filaments, microtubules and 
intermediate filaments — in mediating cell organization and cell motility (Hynes, 
1999). Cell junctions can be divided in 2 types, cell-cell adhesion — principally 
mediated by desm osom es, tight junctions, gap junctions and adherens junctions 
(Cavallaro and Christofori, 2004) — and cell-matrix adhesion — mainly focal 
adhesions and hemi-desmosomes. There are 4 major superfamilies of CAMs 
(figure 1.5):
Cadherins — are the principal components of desm osom es and 
adherens junction. The cadherin superfamily consists in classical cadherins 
involved in Ca2+ dependent homophilic binding and non-classical cadherins 
including protocadherins. Cadherin superfamily includes cadherins,
protocadherins, desmogleins, and desmocollins, and more (Cavallaro and 
Christofori, 2004). Nearly all cadherins have a single transm em brane domain 
(figure I.5a), the extracellular domain is composed of repeated blocks (cadherin 
repeats) variable in number (Stemmier, 2008).
The immunoglobulin superfamily cell adhesion molecule (IG-CAM) — 
members are expressed in many different cell types and involved in many 
biological processes. They are characterized by the presence of 1 or more 
immunoglobulin-like (Ig-like) domain and various number of fibronectin type III 
(Fn III) domain (figure I.5b). Ig-CAM is a very diverse group of proteins, typically 
they have a large extracellular domain, a single transmembrane domain and a 
cytoplasmic tail (Juliano, 2002). They are involved in both homophilic and 
heterophilic interactions (Cavallaro and Christofori, 2004).
Selectins — are a family of 3 glycoproteins (E-, L- and P-selectin) with an 
extracellular domain highly conserved among them and between species. 
Selectins are membrane proteins (figure I.5c) containing a N-terminal sugar 
binding lectin domain followed by a epidermal growth factor (EGF)-like motif, a 
series of short consensus repeat, a transmembrane domain and a cytoplasmic 
tail (Ley, 2003). Selectins bind heavily glycosylated proteoglycans such as 
selectin P ligand (SELPLG / P-selectin glycoprotein ligand 1 precursor / PSGL-
1), or the carbohydrates sialyl Lewis a and sialyl Lewis x (Witz, 2008).
Integrins — are heterodimeric transmembrane proteins composed of 2 
subunits a  and p non-covalently linked. In mammals there are 18 a  and 8 p 
subunits forming 24 distinct integrins. Integrins act primarily a s  extracellular
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matrix receptor and are the principal receptors for cell-matrix interactions 
(Berrier and Yamada, 2007). Integrins function as dimers (figure I.5d), with the 
ligand-binding site formed by the a- and (3-subunits extracellular domains. 
Cytoplasmic tails are usually short (van der Flier and Sonnenberg, 2001). 
Integrins are capable of transmitting information in either direction across the 
membrane, cytoplasmic interactions trigger conformational changes of the 
extracellular domain while matrix interactions trigger changes in cytoplasmic 
regions and further downstream signalling (Wegener and Campbell, 2008).
Other CAMs — includes syndecans, disintegrin family.
a. Cadherins
b. Immunoglobulin 
superfamily
c. Selectins
d. Integrins
Plasma Plasma
membrane membrane
Cytoplasm Intercellular space Cytoplasm
Figure 1.5: Major classes o f  cell adhesion molecules (adapted from Hynes, 1999). The 
figure show: a. a classic cadherin engaged in homophilic binding, b. a member of the 
immunoglobulin superfamily, NCAM engage in homophilic binding, c. a selectin, P- 
selectin (left) bound to a heavily glycosylated proteoglycan (PSGL-1) and d. an integrin 
bound to a member of the Ig-SF (ICAM-1).
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1.5.2. Cell adhesion and drug resistance
A role for cell-cell contact in drug resistance was first suggested when 
CHO cells grown in spheroid system s were found to be more resistant to 
radiation dam age than individual cells (Durand and Sutherland, 1972). Since 
then, cell adhesion-mediated drug resistance (CAM-DR) mechanisms have 
been uncovered in a number a tumours, such as breast cancer (Aoudjit and 
Vuori, 2001), colon cancer (Kouniavsky et al., 2002), glioma (Uhm et al., 1999) 
and myeloma (Hazlehurst etal., 2000). Recent studies have proposed CAM-DR 
as a de novo drug resistance process, allowing the cells to evade cytotoxic 
effects and favour the accrual of multi-drug resistance (Hodkinson et al., 2007), 
implying mechanisms for adaptation.
SCLC is surrounded by an extensive stroma matrix — the extracellular 
matrix (ECM) — containing fibronectin, laminin and tenascin (Sethi etal., 1999). 
Adhesion to the ECM profoundly affects the behaviour of SCLC in vivo and in 
vitro. The importance and influence of the extracellular matrix in SCLC is well 
recognized including the findings that selective adherence of SCLC cells to 
ECM confers resistance to apoptosis (see for review Buttery et al., 2004; 
Hodkinson et al., 2007). Indeed, Sethi et al. have showed that in vitro adhesion 
to fibronectin provides SCLC cell protection from the action of cytotoxic agents 
mediated through p1 integrin-dependent activation of the phosphatidyl inositol 
3-kinase (PI3-kinase / PI3K) pathway. Further studies provide similar evidence 
for drug resistance conferred by adhesion to laminin, also shown to act through 
the PI3Ksignalling pathway (Tsurutani etal., 2005).
PI3K has a well recognized role in cell survival through the direct 
regulation of the apoptosis machinery (Downward, 2004). Moreover, PI3K has 
been found to be constitutively active in SCLC cells, promoting anchorage- 
independent growth (Moore et al., 1998) and to be an essential survival signal 
in SCLC as well as a key regulator of cell cycle progression (Krystal et al.,
2002). Moreover, p i integrin expression has been linked with a poor prognosis 
for patients with SCLC (Oshita et al., 2002). Recently, a role was also 
suggested for the chemokine receptor CXCR4 (C-X-C chemokine receptor type 
4) in mediating the p1 integrin-dependent adhesion of SCLC cells to 
surrounding ECM (Hartmann et al., 2005) -  relevant to a role in SCLC ‘homing’
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in tumour spread. The pi-integrin-dependent resistance pathway has been 
further elucidated (figure 1.6). In SCLC cells p i integrin-mediated activation of 
PI3K activation, via phosphorylation of downstream targets Akt (AKT1 / v-akt 
murine thymoma viral oncogene homolog 1 / Protein kinase B / PKB) and 
GSK3P (glycogen synthase kinase 3 beta), was found to lead to an override of 
G2/M checkpoint mechanisms and arrest, induced by etoposide and ionizing 
radiation treatment, hence promoting progression through the cell cycle and 
progression to mitosis (Hodkinson et al., 2006). SCLC cells also differentially 
activate Akt post-adhesion to ECM substrates. For instance, SCLC adhesion to 
laminin, fibronectin, collagen I and collagen IV leads to activation of the Akt 
pathway, however, it is clear that Akt activation appears to be dependent on the 
cell line derivation as well as the ECM component (Tsurutani et al., 2005). 
Therefore it is clear that cell-ECM interactions impact on the underlying 
properties of tumour heterogeneity.
ECM
EtoposideExtracellular space integrins
Cytoplasm
FAK
DNA damage
P13GSK30Cell cycle 
arrest
Cell
death
Akt
Figure 1.6: Proposed mechanisms for integrin-mediated protection from genotoxic 
therapy (adaptedfrom Hodkinson et al., 2007).
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1.6. Plasticity of the phenotype and genotype of SCLC
Lung cancer is the most common form of cancer usually diagnosed when 
patients present symptoms. There are 4 major histologic types of lung cancer: 
SCLC and three NSCLC, undifferentiated (large cell carcinoma), 
adenocarcinoma and squam ous cell carcinoma (Minna etal., 2002). SCLC is an 
aggressive d isease with a poor prognosis accounting for approximately 20% of 
all lung cancer. SCLC is a particularly fast growing cancer characterized by 
frequent and early m etastasis and the development of chem oresistance 
(Beadsmoore and Screaton, 2003). Chemotherapy is the main form of 
treatment but despite an initial good response to therapy, the patient almost 
always relapses with recurring disease (Hoffman etal., 2000).
As for other solid tumours, many genetic changes are suspected of 
involvement in the full pathogenesis of SCLC (reviewed in Balsara and Testa,
2002). SCLC dem onstrates genetic instability -  ranging from gene mutation to 
chromosomal deletion, aberrations and changes in ploidy -  SCLC tumours 
show a high incidence of chromosomal instability and loss of heterozygosity 
(Ninomiya et al., 2006). Deletion of the short arm (p) of chromosome 3, occurs 
in more than 90% of SCLC and is the most reported of the genetic anomalies. 
This recurrent loss suggests than one or several tumour suppressor genes 
(TSG) are located on this chromosomal region (Balsara and Testa, 2002; 
Whang-Peng etal., 1982).
Little is known about the molecular alterations that occur during SCLC 
development. SCLCs are classified as neuroendocrine (NE) tumours and 
display both epithelial and neuroendocrine markers. The origin of the SCLC 
precursor cell is subject to wide debate but is relevant for the use of 
neuroendocrine markers for early detection (Warren and Hammar, 2006). 
Because SCLCs express several neuroendocrine markers, it has been 
proposed that it could arise from the neoplastic transformation of neurocrest- 
derived neuroendocrine lung cells. An alternative hypothesis suggests that 
neoplasm would arise from pluripotent cells of endodermal origin and undergo 
early neuroendocrine differentiation, although the cell type receiving the first 
oncogenic hit remains unclear (Gudermann and Roelle, 2006).
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1.6.1. Molecular characteristics
Several molecular alterations are characteristics to SCLC tumours and 
frequently displayed by SCLC derived cell lines (Table 1.3). These molecular 
characteristics are frequently used as markers and can be related to SCLC 
profiling, including neuroendocrine phenotype, m etastasis and chem oresistance 
(reviewed in Iyengar and Tsao, 2002; reviewed in Sattler and Salgia, 2003; 
Taneja and Sharma, 2004; Wistuba et a/., 2001).
Table 1.3: SCLC molecular characteristics.
‘Classical markers’
MYC family 
BCL2 
SCF/c-kit 
c-Met 
CXCR4 
p53
Retinoblastoma (Rb)
‘Neuroendocrine markers’
Gastrin-releasing peptide (GRP)
Neural cell adhesion molecule (NOAM)
Achaete scute homologous protein (ASCL1)
Chromogranin A (CgA)
L-dopa decarboxylase
Neuron-restricted silencer factor (NRSF/REST)
Neuron-specific enolase (NSE)
The neuroendocrine phenotype: Ectopic expression of NE genes is 
essential to SCLC pathogenesis. The transcription factor Achaete-scute 
homologue-1 (ASCL1) known to be involved in neuronal commitment in 
vertebrates is expressed by ‘classic’ SCLC cell lines. Its depletion leads to 
downregulation of som e neuroendocrine features in SCLC cell line underlying 
its role in maintenance of NE phenotype (Borges et al., 1997). In addition, 
deficient activity of the neuron restrictive silencer factor (NRSF) has been 
observed in SCLC. NRSF is expressed in non-neuronal tissue and has role in 
repression of neuronal genes (Gurrola-Diaz et al., 2003). Additionally, several
growth factor
cell adhesion and migration
transcription factor in neuronal differentiation
neuroendocrine secretory protein
transcription repression o f neuronal genes
oncogene 
antiapoptotic 
growth factor 
growth factor
tumour suppressor 
tumour suppressor
- 29-
Chapter I — Introduction
neuronal proteins including chromogranin A (CgA), neuronal cell adhesion 
molecule (NCAM) and neuron-specific enolase (NSE) are expressed by SCLC 
tumour and are widely used as NE differentiation markers.
Tumour suppressor; oncogenes and apoptosis: Although SCLC tumour 
development remains to be elucidated, som e insight w as provided by the 
development of a mouse model of SCLC. Somatic inactivation of p53 and 
Retinoblastoma 1 (Rb1) was necessary and sufficient to generate SCLC-like 
tumours with histopathologic characteristics and metastasizing capacity 
strikingly similar to SCLC (Meuwissen et al., 2003). Alteration in p53 and Rb 
alteration occurs in over 90% of cases of SCLC (Wistuba et al., 2001). 
Abnormal expression of MYC family of oncogenes is common in SCLC tumour 
and cell lines (Kim et al., 2006; Takahashi et al., 1989). MYC oncogenes are 
DNA binding proteins known to be involved in transcription regulation, cellular 
proliferation and apoptosis (Sattler and Salgia, 2003). Aberrant expression of 
the negative regulator of cell death BCL2 has been observed in most SCLC and 
inhibition induces cytotoxicity in SCLC xenografts (Oltersdorf etal., 2005)
Autocrine growth stimulation: Autocrine growth stimulation has long been 
recognized in SCLC and is well documented. SCLC tumours and cell lines 
express several receptors tyrosine kinase (RTK). Among them is c-kit receptor 
to the Stem Cell Factor (SCF). SCF and c-kit are coexpressed in a majority of 
SCLC cell lines resulting in autocrine growth stimulation (Krystal et al., 1996). 
Functional c-Met/Hepatocyte Growth Factor (HGF) pathway can also be found 
in SCLC influencing cell proliferation and motility (Jagadeesw aran et al., 2007; 
Maulik et al., 2002). Moreover, an extensive array of neuropeptides and their 
receptor expression has been implicated in driving the growth of SCLC tumour 
in autocrine and paracrine fashions (for a review, see  Heasley, 2001).
Metastasis and homing: SCLC often m etastasise to the bone marrow 
and bone marrow m etastases are an important negative prognostic in SCLC 
(Beadsmoore and Screaton, 2003). It is thought to be due to the SDF1 / CXCR4 
axis (CX-chemokine receptor-4 and ligand CXCL12 / CXC chemokines ligand 
12, also known as stromal derived factor 1 / SDF-1) known to be involved in 
bone marrow homing (Hartmann etal., 2004). Indeed, high amount of SDF1 are 
constitutively secreted by marrow stromal cells and SCLC cells express
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functional CXCR4 mediating migration, integrin activation and adhesion to 
stromal cells (Burger etal., 2003).
1.6.2. Chemoresistance and early invasion: therapeutic challenge
Due to its propensity for m etastasis, the SCLC tumour is often metastatic 
at the time of diagnosis. Thus SCLC is rarely treated by surgical resection. 
Staging — limited or extensive disease — alongside the extent of m etastasis 
both dictate the treatment regiment. Chemotherapy is the standard care, 
radiotherapy is only used in limited d isease (Beadsmoore and Screaton, 2003). 
Combination chemotherapy regimens include a platinum agent (cisplatin or 
carboplatin) combined with etoposide, are the standard of care for most SCLCs. 
Currently, new drugs and combinations are undergoing clinical trials, including 
topotecan, iritonecan, paclitaxel and amrubicin (Ferraldeschi et al., 2007; 
Murray and Turrisi, 2006; Rosti et al., 2006). Novel approaches employing 
targeted therapies are currently undergoing investigation, including BCL2 and 
receptors tyrosine kinase targeting (Fischer et al., 2007). After the completion of 
first line therapy, 80% of patients with limited disease and almost all patients 
with extensive d isease relapse, underlying the need for second line therapy. 
The main second treatments include a combination of cyclophosphamide, 
doxorubicin and vincristine or the use of topotecan as single agent treatment 
(Tiseo and Ardizzoni, 2007).
Despite initial advances in treatment, the development of 
chem oresistance remains a problem. Chemotherapy improves the survival of 
patients with limited-stage or extensive-stage SCLC, but it is curative in only a 
minority of patients. Trials have demonstrated som e survival advantage for 
patients, with a call for a better understanding of the underlying SCLC biology to 
progress further. As discussed previously, there is a need to understand the 
classical SCLC chemoresistance mechanisms and their co-existence for cell 
adhesion mediated resistance processes and active roles for the neuronal 
protein marker PSA-NCAM in SCLC m etastasis (Lantuejoul etal., 1998).
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1.7. NCAM biology
The neural cell adhesion molecule (NCAM, also denominated NCAM1 or 
CD56) belongs to the immunoglobin superfamily of cell adhesion molecule 
(IgCAM). NCAM was first detected in the chick brain and retina (Rutishauser et 
al., 1976; Thiery et al., 1977) and is present on neural cells and various 
neuroendocrine tumours, almost all SCLC tumour cells show NCAM expression 
detected at the plasma membrane (Lantuejoul etal., 1998).
1.7.1. Structure
NCAM is a group of glycoproteins emanating from a single gene located 
on band q23 of chromosome 11 (Nguyen et al., 1986). NCAM is composed of 5 
immunoglobin (Ig) domains and 2 fibronectin (Fn) domains and 4 isoforms exist 
(figure I.7a). Of these isoforms, 3 are produced by alternative splicing and a 
secreted form can be generated by either expression of the SEC exon or 
proteolytic cleavage (Walmod et al., 2004). The two large isoforms, 140 and 
180 kDa, contain intracellular domains of different length, while the 120 kDa 
form is attached to the membrane via a GPI-anchor. In addition to these forms, 
further heterogeneity can occur; the first is the presence of a differentially 
expressed 10 amino acid extra sequence —called VASE — situated in the IglV 
domain (Small and Akeson, 1990). Although the role and expression pattern of 
the different NCAM isoforms is not yet clear, a shift from NCAM 120 in normal 
to NCAM 140 and 180 expression has been observed in pancreatic tumour 
progression in mice (Perl et al., 1999) and isoforms expression seem s to 
correlate with neuroblastoma differentiation status (Winter et al., 2008).
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Figure 1.7: NCAM isoforms structure and polysialylation pattern, a. NCAM isoforms 
(adapted from Walmod et al., 2004). b. Scheme representing a polysialyltransferase 
(ST8SIA4) transferring sialic acid to NCAM (Angata and Fukuda, 2003). c. Diagram 
representing PSA found on bi- or tri-antennary N-glycan chains attached to the fifth Ig- 
like domain of all isoforms of NCAM (Kleene and Schachner, 2004).
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NCAM can be highly glycosylated shifting its molecular weight -  and as 
such provides a relevant exemplar molecule for understanding the 
consequences of carbohydrate decoration and roles of specific aspects of the 
glycocalyx in SCLC. There are 6 potential sites for A/-glycosylation present on 
NCAM and glycosylation occurs at all of these sites. Furthermore, NCAM can 
present an additional developmentally-regulated decoration pattern, 
polysialylation (figure I.7b and c): linear polymers of up to 200 residues of a2-8 
linked sialic acid (polysialic acid, PSA, PolySia). Two Golgi-associated a2-8 
polysialyltransferases — ST8SIA2 (STX) and ST8SIA4 (PST) — facilitate the 
transfer of sialic acid via an a-2,3-linked sialic acid residue to A/-linked glycans 
of the IgV domain of NCAM (Walmod et al., 2004). ST8SIA2 and ST8SIA4 are 
separately regulated at the transcriptional level and have different overlapping 
pattern of expression. Both enzymes are capable of independent NCAM 
polysialylation although cooperation is likely to happen (Angata and Fukuda, 
2003). Thus far only a few mammal proteins decorated with PSA have been 
described: the voltage-dependent sodium channel a-subunit in rat brain (Zuber 
et al., 1992), the human and mice milk CD36 expressing O-linked PSA (Yabe et 
al., 2003) and both transferases capable of autopolysialylation (Close and 
Colley, 1998).
NCAM is involved in both homophilic and heterophilic interactions and a 
complex network of intracellular signalling is activated upon homophilic and 
heterophilic binding (Ditlevsen et al., 2008). Several models have been 
proposed for NCAM homophilic trans-interaction between opposite cells: anti­
parallel binding between the 2 N-terminal domains (Igl and Igll) or interactions 
involving all 5 Ig domains (Kasper et al., 2000). NCAM heterophilic ligands 
includes the glial cell line-derived neurotrophic factor (GDNF) (Paratcha et al.,
2003), another neural CAM (L1) (Ditlevsen et al., 2003), brain-derived 
neurotrophic facto (BDNF), platelet-derived growth factor (PGDF) (Ditlevsen et 
al., 2008). NCAM is also known to interact with several ECM components, 
including the glycosaminoglycan heparin, collagen I to IV and a number of 
chondroitin sulfate proteoglycans (CSPG) and heparan sulfate proteoglycans 
(HSPG) (Walmod et al., 2004). NCAM does not possess catalytic activities and 
signalling is mediated by intracellular and extracellular partners, one central
- 34-
Chapter I — Introduction
partner is the fibroblast growth factor receptor (FGFR) activated upon NCAM 
homophilic binding (Kiselyov et a/., 2005). Recently, a role was suggested for 
the PI3K/Akt pathway in NCAM-mediated neuronal cell survival (Ditlevsen et a/.,
2003)
1.7.2. Role in development and CNS
NCAM is highly expressed during development and expression is 
subsequently isolated to parts of the central nervous system in the adult. While 
the amount of PSA decoration decreases with development and VASE 
expression correspondingly increases and therefore the level of PSA 
decoration, in simple terms, could be seen to be correlated with the need to a 
switch from a dynamic phase requiring tissue plasticity into a  stable or 
differentiated state. Indeed, PSA decoration of NCAM regulation and NCAM 
regulation seem  to be independent and in the adult PSA-NCAM is only 
expressed in areas showing high degree of plasticity, such as  the lateral 
ventricule and hippocampus where PSA plays a role in regulating several steps 
of adult neurogenesis (Kiss et a/., 2001; Walmod et al., 2004). In the central 
nervous system, PSA-NCAM plays a pivotal role in neuronal development and 
synaptic plasticity linked to memory and learning as well as in axon guidance 
and neurite outgrowth (Rutishauser, 2008). NCAM knock-out mice show a 
smaller olfactory bulb and reduced body weight and display an impairment of 
their learning faculties (Cremer et al., 1994). However, dramatic effects can be 
shown as a result of PSA knock-out mice, indeed the absence of PSA by 
deletion of the two polysialyltransferases leads to a lethal phenotype rescued by 
a simultaneous NCAM deletion (Weinhold etal., 2005).
1.7.3. Polysialic acid and links with metastatic behaviour
NCAM has been described as  having tumour suppressor function. 
Indeed, reduced NCAM expression is associated with poor prognosis in a 
number of cancers, for instance, loss of NCAM expression has been linked to 
m etastasis dissemination in pancreatic tumours (Crnic et al., 2004; Perl et al., 
1999). However, in neuroblastoma and neuroendocrine tumours NCAM
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expression concomitant with high polysialylation is associated with a poor 
prognosis (Lantuejoul et al., 1998). The carbohydrate PSA provides a 
polyanionic cell surface decoration of NCAM affecting function and membrane- 
membrane apposition. Indeed, PSA has been shown to increase the amount of 
intercellular space affecting membrane-membrane closeness (Yang et al., 
1992). And recently, Johnson et al. (2005) have provided direct evidence that 
NCAM polysialylation increases inter-membrane repulsion and abrogates 
NCAM homophilic adhesion and C-cadherin-mediated inter-membrane 
adhesion. Numerous studies show increase in adhesion after PSA removal by 
endoneuraminidase — an enzyme specific to the a2,8 linkage of sialic acid — 
however adhesion to specific member of the ECM seem s to be dependant on 
the cell type. Indeed PSA removal w as shown to increase cell-cell aggregation 
(Rutishauser et al., 1985), cell adhesion to laminin (Acheson et al., 1991), 
cadherin and fibronectin (Fujimoto et al., 2001), fibronectin and collagen IV but 
not laminin (Dennis et al., 1982). PSA is therefore considered an anti-adhesive 
molecule reducing cell interactions with implications for cell motility and 
metastasis. PSA has been shown to be a requirement for 0-2A brain progenitor 
migration (Wang et al., 1994) and aberrant expression of PSA-NCAM is 
associated with tumour malignancy and metastasis. Indeed generation of SCLC 
cell line variant sublines with high levels of PSA expression correlate with 
reduced cell-cell adherence, greater clonogenic ability in semisolid media, and a 
significantly higher incidence of intracutaneous m etastases in nude mice 
(Scheidegger et al., 1994). Suzuki et al. (2005) showed that mice inoculated 
with glioma cells transfected with ST8SIA2 harboured extensive tumour 
spreading properties compared to the controls expressing only NCAM. In vivo 
injection of endoneuraminidase reduced lung m etastases in animals inoculated 
with rhabdomyosarcoma cell line expressing PSA (Daniel et al., 2001). PSA 
decoration has also been linked to tumour proliferation with PSA removal 
inducing tumour growth inhibition by affecting NCAM signalling (Seidenfaden et 
al., 2003).
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1.7.4. PSA-NCAM and the therapeutic challenge
Over the past few years, glycoscience has become a growing field of 
research with recognition that glycans play an important role in essential cell 
biology processes (Merry and Merry, 2005). Interest has been increased with 
the availability of analytical tools and the discovery that aberrant glycosylations 
occurs in all types of cancer (Hakomori, 2002). Such insights provide for new 
therapeutics opportunities (Shriver et at., 2004). An important component of the 
glycocalyx in som e tumour cells is the decoration of NCAM known to assist the 
metastatic spread. The control of changes in NCAM decoration is therefore an 
attractive proposition. An early model (Acheson et al., 1991) of glycocalyx 
dynamics makes the striking prediction that PSA could affect not only NCAM 
function, but also other ligands not directly involved in NCAM-mediated 
adhesion -  widening the possible functional impact of PSA targeted agents -  
suggesting that PSA modulation in cancer may be necessary at specific stages 
but not sufficient. Importantly, in normal adult cells PSA-NCAM is virtually non­
existent, only occurring at limited defined sites in the brain, increasing the 
attractiveness for selective targeting. A recent attempt to capitalise on this 
selective PSA expression has involved vaccination of SCLC patients with 
polysialic acid or A/-propionylated polysialic acid conjugated to keyhole limpet 
hemocyanin in an attempt to eradicate chemoresistant micrometastatic disease 
(Krug et a/., 2004).
A therapeutic concept — relevant to SCLC and forming a backdrop to the 
direct of the present study — would be to limit PSA decoration of NCAM, by 
post-translational small molecule targeting prior to or during cell-shedding by a 
tumour, to increase the adhesive properties of cells and therefore reduce or 
prevent their detachment. Clearly, this simple concept uncovers issues of the 
recruitment of aberrant cell behaviour and concomitant resistance, underlining 
the need for new SCLC experimental system s to test concepts and to provide 
possible validation/screening opportunities for candidate agents.
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1.8. Aims of the thesis
The overall aim of the thesis was to disassem ble the complexity of the 
cellular in vitro phenotypes associated with SCLC and to understand how 
phenotypic variation might impact on aspects of SCLC biology. The 
conservation of gene expression patterns and biomarkers from tumour to cell 
line (noted above) provide som e confidence that in vitro studies can progress a 
fundamental of SCLC biology. The classification of SCLC cell lines (reviewed in 
the subsequent sections) suggests a clear potential for variation and plasticity 
with implications for clinical and therapeutic challenges. Furthermore, any 
disassembly of complexity should proved cellular system s that can be 
progressed into more complex analytical situations -  not least 
microenvironment manipulation and in vivo assessm ent.
Thus a study was undertaken to enrich cultures for SCLC ‘adhesion’ 
variants, without prejudice for any specific ECM directed advantage, and then to 
allow for any proliferation/survival advantage in vitro to impact on the evolution 
of variation. The aim was to establish and characterize the new SCLC sub-lines 
that represent the nature and consequence of variant enrichment and to 
undertake an assessm ent of this defined in vitro SCLC for heterogeneity and 
plasticity. The working hypothesis is that phenotypic plasticity of a tumour m ass 
acts as  a driver for m etastasis and the accrual of chem oresistance through an 
enhancem ent of Darwinian fitness. Therefore in order to understand the 
implications of phenotypic heterogeneity in vitro, the aim was to use such a 
unique SCLC model to gain insights into:
1) How changes in cell-cell and cell-substrate interactions might 
impact on the molecular signatures of SCLC and cellular phenotypic behaviours 
such as in vitro growth, cell survival, cell motility and cell adhesion. In particular 
to understand the down stream implications on the proliferative advantage 
within SCLC heterogeneity and clonal selection.
2) How phenotypic or variant heterogeneity can affect critical 
pathways for drug resistance to an exemplar cytotoxic anticancer agent with a 
known mechanism of action that offers opportunities to a sse ss  different modes 
of resistance using both gene expression and functional assays.
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3) The use the SCLC model to explore the possible impact of 
variation and plasticity on an as yet undetermined role for cancer stem cell 
origins in SCLC drug resistance.
4) How differences in polysialylation of NCAM map to the 
heterogeneity of SCLC populations, with reference to expression patterns of 
glycosylation pathways, and therefore offer the ability for cells to express PSA- 
NCAM plasticity or offers opportunities for therapeutic target of the glycocalyx.
The subsequent thesis chapters encom pass these general aims, provide 
pertinent overviews to frame the context of more detailed experimental aims 
and provide details of the specific methodologies employed. The overall 
synthesis is contained within the Main Discussion chapter with directions for 
future research and exploitation of the study’s  findings.
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II. Materials and methods
All reagents were stored, handled and disposed of according to Cardiff 
University Health and Safety regulations, informed by the Material Safety Data 
Sheets, provided by the suppliers. Information about specific methodologies 
and reagents, linked with a focus area of investigation, are provided within the 
results chapters.
II.l. Materials
All chemical reagents used are listed in Appendix I, together with their 
sources.
II.l.l. Drug and molecular probes table
Drugs and fluorescent dyes were prepared, stored and disposed of 
according to the supplier instructions.
Table II.l: Drug and molecular probes used.
Name Carrier Source Storage Concentrationused
Topotecan h 2o GlaxoSmithKline (Brentford, 
UK)
-80°C 10 pM
Fumitremorgin C DMSO Sigma (St Louis, MO, USA) 4°C 10 pM
R1108/2 methanol Institute o f cancer therapeutics 
(Bradford, UK)
- 20°C 0.03 to 0.3 pM
DRAQ5 / Biostatus (Shepshed, UK) 4°C 20 pM
Propidium Iodide / Invitrogen Molecular Probes 
(Carlsbad, CA, USA)
4°C 3 pM
Hoechst 33342 / Invitrogen Molecular Probes 4°C 5 pM
(Carlsbad, CA, USA)
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II. 1.2. Antibodies and sources tables
Table 11.2: Primary antibodies used. WB/westem blot, IF/immunofluorescence and 
FC/flow cytometry.
antigen isotype clonename source
concentration used 
(pg/mL) or dilution
FC IF WB
PSA-NCAM rat IgM 12F8 BD Bioscience Pharmingen (San
Diego, CA, USA)
PSA mouse IgM 2-2B AbCys (Paris, France)
—  1.25 0.5
1:400 1:400 1:4000
NCAM mouse IgGi B159 BD Bioscience Pharmingen (San
Diego, CA, USA)
MT mouse IgGi E9 DakoCytomation (Ely, UK)
1.25 1.25 0.16
—  0.46
ABCG2
GAPDH
mouse IgG2 5D3 Chemicon international (Millipore, 
Temecula, CA, USA)
mouse
IgG2b
Abeam (Cambridge, UK)
—  5
1:1000
Table II.3: Secondary antibodies used. WB/westem blot, IF/immunofluorescence and 
FC/flow cytometry.
antigen host conjugate source
concentration used 
(pg/mL)
FC IF WB
Mouse Igs 
Rabbit Igs
rabbit
swine
Rat IgG+IgM goat
Rat IgM goat
Mouse IgG goat
HRP DakoCytomation (Ely, UK)
HRP DakoCytomation (Ely, UK)
HRP Jackson ImmunoResearch (West
Baltimore Pike, PA, USA)
Alexa 488 Invitrogen Molecular Probes
(Carlsbad, CA, USA)
Alexa 568 Invitrogen Molecular Probes
(Carlsbad, CA, USA)
—  —  0.1
—  —  0.1
—  —  0.33
—  2 —
2 2 —
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II.2. Cell lines and culture conditions
II.2.1. Cell lines
Table II.4: Cell lines routine culture description.
name description medium splitratio growth type source
NCI-H691 Homo sapiens, SCLC RPMI-1640* 1:6 suspension American Type 
Culture Collection1
COR-L472 Homo sapiens, SCLC RPMI-1640 1:6 suspension Dr P. Twenty man"
COR-L882 Homo sapiens, SCLC RPMI-1640 1:2 suspension Dr P. Twentyman"
COR-L2793 Homo sapiens, SCLC RPMI-1640 1:6 suspension Dr P. Twentyman"
SHP-774 Homo sapiens, SCLC RPMI-1640 1:6 suspension American Type 
Culture Collection1
COR-L512 Homo sapiens, SCLC RPMI-1640 1:3 suspension Dr P. Twentyman"
COR-L232 Homo sapiens, lung large 
cell carcinoma
RPMI-1640 1:10 adherent Dr P. Twentyman"
A5495 Homo sapiens, lung alveolar DMEM* 
cell carcinoma
1:20 adherent American Type 
Culture Collection1
SU-DHL-46 Homo sapiens, B cells 
lymphoma
RPMI-1640 1:30 suspension Prof. F. E. Cotter1"
CHO-K17 Cricetulus griseus, ovary EMEM** 1:20 adherent Dr J. H. Beattie‘v
mMTCHO-Kl8 Cricetulus griseus, ovary EMEM** 1:20 adherent Dr J. H. Beattie‘v
‘Gazdar et a l  (1980), 2Baillie-Johnson et al. (1985), 3Twentyman et al. (1992), 4Fisher and Paulson 
(1978), 5Lieber et al. (1976), Epstein et al. (1976), 7Kao and Puck (1968), 8Beattie et al. (2005), *Gibco 
(Invitrogen, Carlsbad, CA, USA), **Sigma (St Louis, MO, USA), ‘Manassas, VA, USA, nMRC Clinical 
Oncology & Radiotherapeutics Unit, MRC Centre, Cambridge, UK, "‘institute o f Child Health, London, 
UK, IVRowett Research Institute, Aberdeen, UK.
II.2.2. Suspension and adherent cell culture
Cell lines (see table II.4) were routinely cultured twice a week. All media 
were supplemented with 10% fetal calf serum (FCS) (Autogen Bioclear, Caine, 
UK), 0.5 mM glutamine (Sigma, St Louis, MO, USA), 10 U/mL penicillin (Sigma, 
St Louis, MO, USA) and 0.1 mg/mL streptomycin (Sigma, St Louis, MO, USA). 
Cultures were maintained at 37°C under standard culture conditions in a 
humidified incubator with 5% C 0 2. All adherent SCLC cell lines were detached 
using cell dissociation solution (CDS / Sigma, St Louis, MO, USA), a non- 
enzymatic solution prepared in PBS and containing ethylene diaminetetraacetic
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acid (EDTA). Other adherent cell lines were detached using trypsin / EDTA 
(Gibco Invitrogen Carlsbad, CA, USA).
II.3. High-density oligonucleotide microarray
Two sets of microarray analyses were performed during the study. The 
first, termed ‘2005 arrays’, was done early in the thesis and tested the effect of 
a potential ST8SIA4 inhibitor (R1108) on the NCI-H69 parental cell line and a 
variant (NCI-H69 AP55). The second, termed ‘2008 arrays’, w as performed to 
characterize the established three-line NCI-H69 model: NCI-H69 SP vs. NCI- 
H69 AP3 vs. NCI-H69 AP78.
11.3.1. Drug treatment
For the 2005 arrays, NCI-H69 SP and NCI-H69 AP55 were seeded in 
triplicate at a concentration of 3 x 106 cells per T75 flasks and allowed to 
establish for 48h under normal culture conditions. Cells were then treated with 
R1108 (0.3 mM) for 6 h and then cells were washed with phosphate buffered 
saline (PBS) prior to RNA extraction.
For the 2008 arrays NCI-H69 cultures were seeded at 3 x 106 cells in a 
standard culture dish in triplicate. After 72h, adherent cells were washed once 
with PBS before adding 1.5 mL of TRIZOL to the flask prior to RNA extraction
11.3.2. RNA extraction
Total RNA were isolated using TRIZOL (Invitrogen, Carlsbad, CA, USA) 
— a modified protocol to the single-step RNA isolation developed by 
Chomczynski and Sacchi (1987) — according to the manufacturer’s instruction. 
PBS washed adherent cell cultures received 1.5 mL of TRIZOL, while 
suspension cell cultures were spun down (10 min, 100 g) washed once with 
PBS and then resuspended in 1.5 mL of TRIZOL. Homogenised sam ples were 
let to stand for 10 min at room temperature (RT). After addition of 300 pL of 
chloroform, each sample was thoroughly shaken and the mixture was added to 
Phase lock gel Heavy (Eppendorf, Hamburg, Germany) and spin down for 2 min
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at 12000 x g (Murphy and Hellwig, 1996). RNA from the upper aqueous phase 
was then precipitated by adding 500 pL of isopropanol. After 10 min at RT, 
sam ples were centrifuged at 12000 x g and 4°C for 10 min. After pellets were 
washed with 75% ethanol, centrifuged at 7500 x g / 4°C for 5min and dried at 
RT for 10 min, RNAs were dissolved in 200 pL of H2 O. Sam ples were 
precipitated overnight at -20°C with 0.1 volume of 3M sodium acetate and 2.5 
volume of 100% ethanol and centrifuged at 12000 x g / 4°C for 30 min. Finally, 
pellets were washed with 80% ethanol and centrifuged at 12000 x g/4°C for 10 
min and RNAs were resuspended in H2O. RNA sam ples were kept at -80°C 
until further use.
11.3.3. RNA quality controls
RNA quantities and quality controls (QC) were a ssessed  by measuring 
the absorbance (A) of the RNA solution at 260 nm and 280 nm on a 
spectrophotometer (DU® 800 UV/visible Spectrophotometer; Beckman Coulter, 
Fullerton, CA, USA). RNAs were then given to the Affymetrix GeneChip 
expression profiling service (CBS, School of medicine, Cardiff) for further quality 
assessm ent on Agilent RNA Chip (Agilent, Santa Clara, CA).
11.3.4. Data acquisition
The microarray processing steps were performed by Affymetrix 
GeneChip expression profiling service (CBS Cardiff) and are described in figure
II.l. The Human genome U133A array (HGJJ133A) w as chosen for 
hybridization of the 2005 arrays, while the 2008 arrays were hybridized onto the 
Human genome U133A_2.0 array (HG_U133A_2.0). All probes sets 
represented on the genechip HGJJ133A are identically replicated on 
HG_U133A_2.0; however the HG_U133A_2.0 has a reduced size compared to 
HGJJ133A allowing smaller sample volumes. Both arrays represent 14500 
well-characterized human genes.
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1) Primer hybridization
Total RNA  
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2) Reverse transcription
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labeling of antisense cRNA
-U  Biotinylated 
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7) Fragmentation JL
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Figure II.l: DNA microarray processing. Diagram representing the steps involved in 
microarray RNA processing (from Affymetrix Expression Analysis Technical Manual).
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II.3.5. Data analysis
Unless stated otherwise all bioinformatics analyses were performed 
using GeneSpring® 7.3 (Agilent Technologies, Stockport, UK). Figure II.2 shows 
the step-wise process used for the microarray analysis.
RNA
GeneSpring
Affymetrix GeneChip expression profiling service 
CBS Cardiff
Human Genome
U 133A 2.0 Array
CEL
files
Identification of 
molecular mechanisms
^ BioConductor N
Quality assessment
\
V y
RMA normalization
Filtering
Statistical analyses
Fold change
Clustering
Significant representation 
in gene ontology
Identification of 
candidate genes
Figure II.2: DNA microarray analysis process. Flow diagram representing the steps 
involved in microarray analysis of the 2008 arrays.
- 4 6 -
Chapter I I — Materials and methods
11.3.5.1. Arrays quality assessment
Quality assessm ent for the arrays hybridization were performed using the 
open source software framework BioConductor (Gentleman et al., 2004) run in 
R (http://cran.r-proiect.org/). Two packages from the BioConductor project were 
used to control the quality of the raw data (CEL files): AffyPLM and simpleaffy. 
Those packages identify problems that could arise at different steps of the 
microarray experiment.
The simpleaffy package (Wilson and Miller, 2005) uses values computed 
for/from MAS5 algorithm and reports on 5 metrics commonly used to a sse ss  
array hybridization quality, namely: background, percent present, scale factor, 
GAPDH 573’ ratio and Actin 573’ ratio. Those QC metrics are described in 
details in the documentation accompanying the package as well as  in the 
Affymetrix manual (http://www.affymetrix.com/index.affx). Results are visualised 
in a  plot that e a se s  the identification of outliers. Metrics that do not follow the 
standard recommendations from Affymetrix are coloured red.
The AffyPLM application (Bolstad, B; http://bmbolstad.com) has proven 
to be useful quality assessm ent tool (Hershey et al., 2008; Robinson and 
Speed, 2007). The package was used to produce relative log expression (RLE) 
and normalised unsealed standard error plots (NUSE) plots. RLE values are 
computed by comparing each gene against the median across arrays for that 
particular gene. Assuming most genes will have similar value across arrays 
RLE value should be around 0. Thus, RLE boxplots provide a quality 
assessm ent tool. NUSE plots the standardized standard error estim ates from 
the Probe Level Models fit so that the median standard error for that gene is 1 
across all arrays. This process accounts for differences in variability between 
genes. For both plots, any microarray that stands out from the group could be 
the result of poor RNA quality or failed hybridization to the microarray.
11.3.5.2. Raw data processing and normalization
Microarray raw data needs processing in order to calculate gene 
expression and normalization, to remove chip-to-chip variations, in order to 
optimize the signal-to-noise ratio. The identification of up- or down-regulated
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genes depend on the normalization method used (Millenaar et a/., 2006), 
underlying the need to choose the right normalization method depending on the 
biology.
Processing and per-chip normalisation — The robust multiarray average 
(RMA) preprocessing and normalisation method (Irizarry et al., 2003) was 
chosen because it yields the most reproducible results and performs well with 
low confounding noise projects (Seo et al., 2004), such a s  the microarray 
analysis of established cell lines. RMA normalisation w as performed in 
GeneSpring 7.3 (Agilent Technologies, Stockport, UK). RMA corrects arrays for 
background using a quantile normalization, based on the complete data set, 
with a fitted model to detect abnormally behaving probes and exclude them for 
calculating gene expression, such that the intensities across each chip are 
adjusted to produce identical distributions (Irizarry et al., 2003). RMA 
normalization is a per-Chip normalization applied on a single sample,
Per-gene normalisation — “The normalised to median” per-gene 
normalization was performed in GeneSpring 7.3 (Agilent Technologies, 
Stockport, UK) as advised by Agilent (http://www.chem.aailent.com/). Each 
gene was normalised to the median measurement for that gene across all the 
arrays in the data set. Per gene normalization centres normalised expression 
values around 1 (“normal” expression around 1, downregulation from 0 to 0.9 
and upregulation from 1.1).
II.3.5.3. Quantification of differential expression
Detection call — Normalised data were first filtered based on Affymetrix 
detection call information (http://www.Affvmetrix.com) determined with the MAS 
5 algorithm (microarray suite version 5 software, Affymetrix). MAS5 assigns a p- 
value based on detection level, this p-value is subsequently used to generate a 
‘detection call’ indicating whether a transcript is reliably expressed. This 
detection call flags transcripts as Absent, Marginal or Present (Pepper et al., 
2007). Data were filtered so that genes not flagged Present in at least 1 in 9 
arrays were excluded from further analysis.
T-Test — Pair-wise comparison of conditions w as performed in 
GeneSpring 7.3 (Agilent Technologies, Stockport, UK) using T-test statistical
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analysis, followed by the Benjamini and Hochberg correction for multiple testing 
(Benjamini and Hochberg, 1995) with a p-value cut-off of 0.05.
Analysis of variance (ANOVA) — Analysis of Variance followed by the 
Benjamini and Hochberg correction for multiple testing (Benjamini and 
Hochberg, 1995) with a p-value cut-off of 0.05, was performed in GeneSpring 
7.3 (Agilent Technologies, Stockport, UK).
Significance analysis of microarrays (SAM) — SAM (Tusher et al., 2001) 
was performed using the Microsoft Excel addin v3.0. The analysis was 
performed using a SAM-FDR (false discovery rate) cut-off of 0.
Filter on fold change — Finally, only genes with their expression altered 
by more than two fold were selected for further analysis.
II.3.5.4. Functional analysis and representation
Functional analyses were performed in GeneSpring 7.3 (Agilent 
Technologies, Stockport, UK) using resources from IHOP (information protein 
hyperlinked / http://www.ihop-net.org/UniPub/iHOP / Hoffmann and Valencia, 
2004), KEGG pathways (Kyoto encyclopedia of genes and genom es / 
http://www.genome.ad.jp/kegg/pathway.html / Kanehisa et al., 2004) and gene 
ontology (GO / http://www.geneontology.org / Ashburner et al., 2000). When 
possible, gene nomenclature were chosen according to the human genome 
organization (HUGO / http://www.hugo-international.org / Eyre et al., 2006).
Ontologies used — Gene ontologies (http://www.aeneontoloav.org/) are 
vocabularies that describe the attributes of genes (for example, their biological 
functions). Each term in the vocabularies is called a GO term which represents 
a possible attribute value possessed by one or more genes. Gene ontologies 
are relational in the sense  that GO terms are related and form a directed acyclic 
graph. The Gene Ontology Consortium (Ashburner et al., 2000) is creating three 
standard gene ontologies that describe the associated biological processes, 
cellular components and molecular functions for genes and their products (RNA 
or protein products encoded by genes). GO annotations are m ade to associate 
each gene or gene product with its related GO terms. Those GO terms reflect 
the normal function, process, and localization (component) of the gene or gene 
product. KEGG pathways (http://www.aenome.ad.ip/keaa/pathwav.html) are a
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collection of manually drawn pathway m aps representing knowledge on the 
molecular interaction and reaction networks for biological processes (Kanehisa 
et al. ,2004).
Gene ontology enrichment analysis — Gene ontology enrichment 
analysis was performed in GeneSpring 7.3 using the Gene Ontology Browser 
feature (Agilent Technologies, Stockport, UK). A p-value, using a 
hypergeometric test without multiple testing correction, is assigned based on 
whether the number of selected genes within each category is greater than 
expected by random sampling given the subset of the total number of genes 
within that GO annotation.
Clustering — Hierarchical clusterings were performed in GeneSpring 7.3 
(Agilent Technologies, Stockport, UK). Similarity m easures were calculated 
using Pearson correlation and average linkage as the clustering algorithm. The 
resulting gene trees group together the genes with similar expression pattern 
(see for review D'Haeseleer, 2005).
Results representation — Microarray results were represented using 
GeneSpring 7.3 (Agilent Technologies, Stockport, UK) as  gene trees or bar 
graph. Bar graphs represent partially normalised data without per-gene 
normalisation. Indeed, although ratios, given by per-gene normalisation, help to 
reveal pattern of expression they remove information about gene expression 
level. In bar graph representation probes are sorted according to the control 
value for each probe (median value across all chips). All microarray 
representations show the average value of the three triplicates.
All microarray data (except bar graph) are coloured according to the 
expression value of the first condition (NCI-H69 SP), yellow indicates 
overexpression, black average expression and blue underexpression.
II.4. Flow cytometry
II.4.1. Cytometers
Analyses were carried out on one of two different cytometers:
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1) FACScan system (Becton-Dickinson Immunocytometry Systems, 
San Jose, CA, USA) incorporating an argon ion laser (15 mW output) used to 
the 488-nm line.
2) FACS Vantage flow cytometer (Becton-Dickinson 
Immunocytometry Systems, San Jose, CA, USA) equipped with a  Coherent 
Enterprise II laser (Coherent, Inc., Santa Clara, CA, USA) simultaneously 
emitting at multiline UV (351-355 nm range) and 488-nm wavelengths with the 
beam s made noncolinear using dichroic separators. The laser power was 
regulated at 30 mW (monitored on the multiline UV output).
All parameters were collected using CellQuest software (Beckton- 
Dickinson Immunocytometry Systems, San Jose, CA, USA). Forward and 90° 
light scatter were analyzed to exclude any cell debris. Unless stated otherwise 
data were collected for 1 x 104 cells using the FSC param eter a s  the m aster 
signal. Optics used for both system s are listed in Table II.5.
Data analyses were performed using CellQuest software (Beckton- 
Dickinson Immunocytometry Systems, San Jose, CA, USA) or FlowJo (Tree 
Star, San Carlos, CA, USA).
Table II.5: Flow cytometry fluorescence optics.
FACScan
alexa 448 
DRAQ5 
PI 
TPT
Hoechst 33342
FACS Vantage
n . , . .. .. , x Parameter & . . Parameter &Probe / drug excitation (nm) . . . excitation (nm)emission filter (nm) v 7 emission filter (nm)
488
488
FL1 530 /30  
FL3 650 LP
488
488
488
488
UV
UV
UV
FL1 530 /3 0  
FL3 695 LP 
FL2 585 /42 
FL1 5 3 0 /3 0  
FL4 5 3 0 /3 0  
FL5 4 2 4 /4 4  
FL4 620 LP
II.4.2. Cell cycle analysis
DNA measurements were made using the preparation described 
previously (Njoh et al., 2006; Smith et al., 2000). Cells were removed from the
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substrate spun down (100 x g), washed once with PBS and fixed with 100% 
methanol for 20 min at -20°C. After centrifugation (200 x g /1 0  min), cells were 
resuspended in 200 pL of PBS and 20 pM DRAQ5 was added and held at room 
temperature 5 min before acquisition.
11.4.3. Immunofluorescence analysis
The general flow cytometric method has been previously described 
(Smith et al.t 2007). Attached cells and suspension cells were harvested spun 
down at 100 x g for 10 min, washed once with PBS and fixed with 100% 
methanol at -20°C for 20 min. After one wash with PBS and spin (200 x g / 5 
min), cells were incubated overnight with 10% goat serum in PBS. Following 
centrifugation (200 x g / 5 min), the cell pellet was resuspended with the 
suitable primary antibody in 200 pL of 1% goat serum in PBS and incubated at 
room temperature for 1 h. Cell suspensions were washed with PBS, spun down 
(200 x g / 5 min) and the pellet was resuspended with the suitable secondary 
antibody in 200pL of 1 % goat serum in PBS and incubated for 45 min at room 
temperature. Finally, cells were washed with PBS and resuspended with 200 pL 
of PBS
11.4.4. Cellular integrity assays
Cells were harvested and resuspended in full RPMI medium to a 
concentration of 2 x 105 cells / mL. Viability was assessed  by adding propidium 
iodide (PI), as  a non-permanent dye for cells with intact membranes, to a  final 
concentration of 3 pM to the cells and incubating for 10 min at 37°C prior to 
acquisition on the FACS Vantage.
II.5. Imaging
II.5.1. Microscopes
All camera, shutter and stage were initially controlled by AQM 2000 
software (Kinetic Imaging Ltd, Wirral, UK) before all system s were moved to
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MetaMorph version 7.5 (Molecular Devices, Downingtown, PA, USA). All image 
analyses were conducted using MetaMorph Offline starting at version 6.3 to 
version 7.5 (Molecular Devices, Downingtown, PA, USA). Several microscopy 
system s have been used:
1) Fluorescence microscope CBS cam era system (CBS Cardiff) 
consisting of an inverted Axiovert S100 TV microscope (Carl Zeiss, Inc., 
Welwyn Garden City, UK) with Hamamatsu camera (model C4742-95-12, 
Hamamatsu Photonics, Welwyn Garden City, UK), fluorescent lamp (model 
ebx75 isolated, Carl Zeiss, Inc., Welwyn Garden City, UK) and shutter lambda 
10-2 (Kinetic Imaging Ltd, Wirral, UK).
2) Timelaose microscope system (CBS Cardiff) composed of a 
HAL100 microscope (Zeiss, Welwyn Garden City, UK) fitted with temperature 
(37°C) regulating incubator system and CO2  (5%) supply (Solent Scientific, 
Segensworth, UK). Illumination was controlled by a shutter (Prior Scientific, 
Cambridge, UK) placed in front of the transmission lamp and a motorized xyz 
stage (Prior Scientific, Cambridge, UK) permitted multi-field acquisition. Phase 
transmission images (x10 objective lens) were acquired with a cooled CCD 
cam era (model 4920 COHU, San Diego, CA, USA).
11.5.2. Transmission imaging
Bright field images from live cells in full culture media were captured on 
the CBS cam era system.
11.5.3. Immunofluorescence labelling
Cells were harvested and cell suspensions (100 pL of approximately 
1x105 cells per mL) were cytospun (Cytospin 2, Shandon Scientific, Runcorn, 
UK) onto microscope slides for 5 min at 30 x g. Cells were washed once in 
PBS, before fixation with 100% cold methanol for 20 min at RT. Cells were 
washed once with PBS, then blocked by 200 pi of 1% bovine serum albumin 
(BSA) in PBS for 30 minutes, at RT. Blocking solution was then replaced with 
200 pL of the suitable primary antibody in 1 % BSA / PBS and incubated 2h at 
RT. After 3 w ashes with PBS, 200 pL of the suitable secondary antibody and
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Hoechst in 1% BSA / PBS was added to the slides followed by incubation at RT 
for 2h. Finally after 3 washes with PBS, slides were mounted with coverslips 
using Hydromount (National Diagnostics, Atlanta, QA, USA) mounting media.
II.5.4. Fluorescence imaging
Images from fluorescently-stained slides were captured on the CBS 
cam era system using the suitable filters block (see Table II.6).
Table II.6: CBS camera fluorescence filters.
excitation (nm) DCLP(nm) emission (nm)
alexa 488 4 8 0 /30 505 5 3 5 /4 0
alexa 568 560 /40 595 630 / 60
Hoechst 33342 340 455 4 8 0 /4 0
II.5.5. Tim elapse imaging
For live cell imaging of different cell types or treatments over short or 
long period of time, time-lapse imaging was used. A standard multi-well culture 
dish containing the cells was incubated on a stage of a time-lapse instrument as 
previously described (Errington et al.t 2005; Marquez et al., 2003). Conditions 
(drug treatment, cell type, field numbers, time delay...) are described in each 
chapter specific material and methods.
II.6. SDS-PAGE/Immunoblotting
Adherent cells were detached using CDS for 2 min. Suspension cells 
were centrifuged and treated with CDS for 2 min. Cells were then washed twice 
with cold PBS and incubated with 100 pL of lysis buffer per 106 cells (see 
Appendix II) for 30 min on ice. After centrifugation at 15000 x g and 4°C for 15 
min, sam ples were quantified using Bio-Rad DC  Protein Assay (Bio-Rad, Hemel 
Hempstead, UK) according to the manufacturer instructions with BSA as 
standard. Briefly, dilution of cell extracts were incubated 15 min with Bio-Rad
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DC Protein Assay solution (Bio-Rad, Hemel Hempstead, UK) and absorbance 
at 750 nm was measured with a plate reader POLARStar OPTIMA (BMG 
Labtech, Offenburg, Germany) using a 750-12 nm emission filter.
Sample aliquots containing the sam e amount of protein were heated (15 
min at 70°C) in 0.5 volume of sample loading buffer and separated by 7.5 or 
12% SDS-PAGE (Bio-Rad, Hemel Hempstead, UK). Sam ples were run 
alongside molecular weight marker (Rainbow marker RPN800 / GE Healthcare, 
Little Chalfont, UK). Proteins were transferred onto Hybond-P PVDF membrane 
(GE Healthcare, Little Chalfont, UK) for 15 min or 1 h at 15 Volts using a Semi­
dry blotter (GE Healthcare, Little Chalfont, UK). After blocking with blocking 
solution (see Appendix II) for 1 h at RT, membranes were incubated with anti- 
PSA-NCAM or anti-MT (0.5 pg / mL or 0.46 pg / mL, respectively, in blocking 
solution) for 2 h at RT. Membranes were then washed 3 times with wash 
solution and incubated for 1 hour at room temperature with secondary 
antibodies-HRP conjugated: rabbit anti-mouse (0.1 pg / mL) or Goat anti-rat 
(0.33 pg / mL). After 3 w ashes proteins were detected using enhanced 
chemiluminescent (ECL) Advance Detection Kit (GE Healthcare, Little Chalfont, 
UK). Images were captured with AutoChemi System (UVP, Upland, CA, USA).
II.7. Statistical analyses.
All additional statistical analyses were carried out using GraphPad Prism 
software version 3.00 for windows (GraphPad Software, San Diego, CA, USA).
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III. Characterisation of an in vitro SCLC model system
III.l. Introduction
The events leading to drug resistance acquisition and m etastasis in 
SCLC remain unclear. Several in vitro SCLC cell lines have been derived from 
patients over the past two decades in order to elucidate the sequence and 
nature of the steps involved. These in vitro models of SCLC display a range of 
phenotypic characteristics while frequently retaining the NE properties of the 
tumours. An early study by Carney et al. (1985) described 4 major categories of 
morphology for SCLC in vitro culture: type 1- tight floating aggregates with 
frequent central necrosis, type 2- irregular, dense aggregates without central 
necrosis, type 3- very loose aggregates and type 4- attached growth with non- 
SCLC appearance. Most SCLC cell lines grow in vitro a s  floating aggregates 
type 1 and 2 (Carney et al., 1985). Alongside this classification regarding their 
cell-cell interactions and adhesion properties in vitro, SCLC cell lines can also 
be divided into 2 classes: ‘classic’ and ‘variant’ (Carney et al., 1985). SCLC 
variants (v-SCLC), with resemblance to NSCLC and a loss of the NE 
phenotype, can be more aggressive (Shtivelman and Namikawa, 1995). SCLC 
cultures can differentiate spontaneously to variant forms with enhanced 
m etastasis (v-SCLC) generating sublines with diminished sensitivity to 
etoposide, cyclophosphamide and gamma radiation (Kraus et al., 2002) 
attributed to a reversible Akt suppression of cell death.
A central difficulty has been the in vitro growth patterns of SCLC cell 
lines -  involving slow growth rates, propensity for cell aggregation in 
suspension and variable expression of adherent growth. Thus assays for growth 
inhibition often lack dynamic range or readouts that can be readily compared 
with those of other tumour cell lines. Such difficulties have resulted in the 
exclusion or withdrawal of SCLC cell lines from wider screens for 
chemosensitivity such as those carried out by the Developmental Therapeutics 
Program of the US NCI. However this complexity associated with the SCLC 
phenotype is likely to be intrinsic to the inherent plasticity expressed by SCLC 
biology. Despite the difficulties, several in vitro SCLC plasticity models based on 
variant selection or enrichment have been developed: drug resistant variant
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(Mirski et al., 1987), chemical induction of differentiation (Gilchrist et al., 2002; 
Khan et al., 1993), v-ras / c-myc induction of NSCLC phenotype (Falco et al., 
1990; Risse-Hackl et al., 1998), changes of morphology upon alteration of 
culture conditions (Terasaki et al., 1986), selection on the basis of biochemical 
markers (PSA expression) (Scheidegger et al., 1994) or standard tissue culture 
plastic substrate (Doyle etal., 1990; Salge eta!., 2001; Seddon etal., 1998).
A frequently used SCLC cell line is the NCI-H69 cell line — an 
established, clonable cell line with a classic phenotype and the potential to form 
proliferating tumours as xenografts. Under standard suspension culture 
conditions, the NCI-H69 cell line grows as floating aggregates (type 2 
morphology). Previous studies have demonstrated the ability to derive plastic- 
adherent variants from the NCI-H69 cell line possibly associated with a putative 
stem cell-like sub-population generating small cell and non-small cell-like 
populations. The transition from suspension to adherent growth was 
accompanied by tissue factor and metalloproteinase expression, biochemical 
characteristics more compatible with aggressive growth and high metastatic 
potential observed in SCLC patient (Salge et al., 2001). Bromodeoxyuridine 
(BrdU) induction of differentiation also led to NCI-H69 morphological 
transformation to an epithelial phenotype (Gilchrist et al., 2002) with a decrease 
in NCAM expression, integrin expression upregulation and loss of 
tumourigenicity in mice. The capacity for ‘transformation’ suggests that NCI-H69 
might provide a suitable system for the stated objectives of the current study. It 
was therefore decided that there was a need to a sse ss  the suitability of NCI- 
H69 against a range of SCLC cell lines. The strategy was to first affirm the 
suitability of NCI-H69 by undertaking a review of the characteristics of a 
reference SCLC cell line panel (Baillie-Johnson etal., 1985; Carney etal., 1985; 
Koros et al., 1985). The aim was to permit a reference classification of the 
SCLC characteristics with respect to the culture conditions employed.
Direct observation of classical suspension cultures of SCLC cell lines 
reveals the presence of sub-populations attempting to attach to a standard cell / 
tissue culture plastic (TCP) substrate, but never becoming dominant under 
normal culture passaging due to constant dilution of the cultures. This property 
exemplifies the problem with maintaining SCLC cell lines in culture without
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effectively applying a degree of selection for a given phenotype with proliferative 
advantage. Here, this propensity to attempt substrate attachment was used to 
develop a phenotypically reversible cell system based on the suspension 
phenotype of NCI-H69, in which cultures were progressively enriched over a 
period of >50 passages for sub-populations growing with an attached 
phenotype (AP) on a standard plastic cell culture substrate. This was achieved 
by the gentle mechanical removal of suspension or loosely attached cells from 
the culture at each passage, and the EDTA harvesting of attached cells for 
further culture.
The overall aim of the thesis was to disassemble the complexity of the 
cellular phenotypes associated with SCLC and to understand how phenotypic 
variation might impact on aspects of SCLC biology. Thus this chapter describes: 
the scoping of the NCI-H69 characteristics with respect to a wider SCLC panel; 
the selection / enrichment procedure for adhesion variants; the establishment 
and characterisation of new SCLC sublines and an assessment of the defined 
in vitro system to study SCLC plasticity. The major characterisations carried out 
are summarised in figure III. 1 using both whole population and single cell 
analysis approaches, the latter to address the important issue of heterogeneity.
Figure III.l: Summary o f the SCLC model system characterization objectives.
Phenotypic variations
Enrichment
Cell
adhesion
Growth
properties
Gene
expression
SCLC marker: 
PSA-NCAM
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In summary, the experimental objectives of this chapter are to first review 
the overall morphological properties and PSA-NCAM expression profile of a 
small cell lung cancer panel. Then to develop a SCLC model system to 
investigate and address phenotypic variation; to isolate adherent variants and 
thus investigate:
> Growth properties and DNA content of each variant
> Cell-cell and cell-substrate properties of each variant
> Microarray expression profiling for direct comparisons and to determine 
unique biomarkers.
> PSA-NCAM expression, turnover and impact on variants and patterns 
during substrate reversal.
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III.2. Specific material and methods
III.2.1. Cell lines, cell culture and cell proliferation estimation
Cell lines: a panel of 6 SCLC cell lines and 1 reference NSCLC was used 
in this study. All lines were maintained as previously described (see Material and 
methods). Table III.l describes the sources of the cell lines. This panel includes 4 
cell lines described as classic SCLC cell lines: NCI-H69, COR-L47, COR-L51 
and COR-L88 (Baillie-Johnson et al., 1985; Carney et al., 1985). The 
morphological characteristics of the SCLC cell line COR-L279 were never 
described. The SHP-77 cell line has the morphology of a  variant but the 
biochemical properties of classical SCLC cell lines (Koros et al., 1985). The 
NSCLC cell line COR-L23 was used as a control.
Table III.l: SCLC cell lines description.
.. . previoussource patient , ..chemotherapy
NCI-H691 pleural effusion male yes
SHP-772’5 primary tumour male no
COR-L473,4 lymph node male no
COR-L513’4 pleural effusion male yes
COR-L883’4 pleural effusion male yes
COR-L2794 lymph node male no
COR-L233 (large cells) pleural effusion male unknown
‘Gazdar et al. (1980), 2Fisher and Paulson (1978), 3Baillie-Johnson et al.
(1985), twentyman et al. (1992), 5Campling et al. (1997).
Cell culture: all SCLC and NSCLC cell lines were cultured as previously 
described (see Materials and methods) in RPMI (Gibco, Invitrogen, Carlsbad, CA, 
USA). Unless stated otherwise, cells were grown on tissue culture treated 
substrate.
In vitro cell proliferation estimation: 1 x 105 cells in 3 mL were set up in 
triplicate in a standard 6 well-dish and incubated under standard culture
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conditions. Cells were counted using Z1 Coulter particle counter (Beckman 
Coulter, Fulton, California) at 24, 48, 96 and 144 h. Mean values and standard 
deviations were calculated from triplicate wells.
Growth on hydrophobic or tissue culture substrates: cells were grown on 
hydrophobic (HOP) bacteriological Petri dishes (Fisher Scientific, 
Loughborough, UK) or tissue culture (TCP) tissue culture treated Petri dishes 
(Corning, Fisher Scientific, Loughborough, UK). Cells in TCP were cultured as 
normal while cells in HOP were refed without disturbing the cell aggregates. To 
estimate the in vitro cell proliferation on hydrophobic substrates: 5 x 106 cells in 
10 mL were seeded in 9 cm diameter dishes in triplicate. Cells were detached, 
dissociated and counted at 24h intervals and cell numbers of triplicates were 
averaged, standard deviations were calculated and results were plotted with 
GraphPad Prism (GraphPad Software, San Diego, CA, USA).
III.2.2. Plastic substrate-adherent sub-population enrichment
Routine culture enrichment work was primarily carried out through the 
acknowledged technical support of Ms Marie Wiltshire, providing a consistent 
methodology and schedule for culture maintenance.
Initial enrichment: to obtain the plastic substrate-adherent populations of 
COR-L88, COR-L279, SHP-77 and NCI-H69, biweekly, flasks were lightly 
tapped to remove any loosely adherent cells. Floating cells were, then, removed 
from the culture flasks and plastic-adherent cells were fed with fresh medium. 
This process was repeated until sufficient number of plastic adherent cells 
(detachable from the substrate only by application of an EDTA solution) was 
obtained.
NCI-H69 model development: the enrichment approach w as extended in 
the case  of NCI-H69 SP to establish independent variant cell lines, termed NCI- 
H69 AP3 and NCI-H69 AP78 (attached phenotype enriched at passage 3 and 
passage 78). The variant cell lines were subsequently subcultured as two 
separate cell lines. NCI-H69 AP3 was cultured under constant enrichment
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process, while NCI-H69 AP78 was subcultured as an attached cell line under 
standard culture conditions.
111.2.3. Attachment assay
Cells were detached, dissociated and counted as previously described 
(see Materials and methods). Cells were set up in triplicate at 4 x 106 cells per 
T25 flasks and cultured under standard cell culture conditions. At 6, 24 and 48 h 
post seeding, cells in suspension and attached cells (after removal with cell 
dissociation fluid, Sigma, St Louis, MO, USA) in each flask were counted 
separately using Z1 Coulter particle counter (Beckman Coulter, Fulton, 
California). Mean values and standard deviations were calculated from 
triplicate. Statistical differences were calculated with GraphPad Prism 
(GraphPad Software, San Diego, CA, USA) using one-way ANOVA followed by 
Bonferroni's Multiple Comparison Test to compare pairs.
111.2.4. Cell size measurement
Attached cells were detached and left to dissociate in CDS for 2 min in 
the incubator. Suspension cells were spun down, resuspended in CDS and left 
to dissociate for 2 min in incubator. After centrifugation, cells were resuspended 
in full medium and seeded onto glass dishes (Lab-Tek II chambered coverglass, 
Nalge Nunc International, Rochester, NY, USA). The DNA dye DRAQ5 was 
added to the medium to a final concentration of 20 pM. Bright field and DRAQ5 
pictures of 10 random fields on the dishes were taken on the CBS cam era (X20 
magnification). Analysis was carried out in Metamorph (Molecular Devices, 
Downingtown, PA, USA) on 101 single cells randomly selected. The diameter of 
the entire cell (bright field image) and the nucleus of the sam e cell (DRAQ5 
image) were determined by drawing a line across the cell and the nucleus. 
Statistical analyses were performed in GraphPad Prism (GraphPad Software, 
San Diego, CA, USA), using a non-parametric test comparing 3 groups 
(Kruskal-Wallis test) followed by Dunn’s multiple comparison test for each pair.
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111.2.5. DNA content measurement
Cells were detached, dissociated, spun down, washed in cold PBS and 
resuspended in 100% methanol. After 20 min incubation at -20°C, cells were 
spun down, resuspended in PBS supplemented with DRAQ5 to a final 
concentration of 20 pM. Stained cells were then analyzed by flow cytometry 
(see Materials and methods) using a FACS scan (Becton-Dickinson 
Immunocytometry Systems, San Jose, CA, USA) with cell quest software 
(Becton-Dickinson Immunocytometry Systems, San Jose, CA, USA) and the 
results were analyzed using FlowJo software (Tree Star, San Carlos, CA, USA) 
as previously described (Smith etal., 2000).
111.2.6. Neuraminidase digestion of PSA
Endoneuraminidase (endoN) was purchased from AbCys S.A. (Paris, 
France). This non-toxic bacteriophage enzyme specifically cleaves PSA and is 
active in culture medium (Rutishauser et a/., 1985; Wang et at., 1994). PSA 
cleavage was performed on live cells by adding the enzyme directly to the 
culture medium. Cells (2 x 106) were seeded in T25 flasks with 5 mL of 
complete culture medium and allowed to settle down for 24h. Then, 0.7 units of 
endoN or heat-inactivated endoN (80°C for 15 min) were added to the flasks 
and cells were incubated overnight (12h-15h). To ensure complete removal of 
PSA, western blot detection of NCAM and PSA was performed on an aliquot of 
cells after each digestion.
111.2.7. Cell adhesion assay: MSA
The adhesion potential of the variants with or without PSA removal (see
III.2.7) to ECM components was measured using MSA technology (Kuschel et 
al., 2006) according to manufacturer’s instruction. Briefly, MSA slides (figure
III.2) were adjusted to room temperature (1 h), mounted in a ProPlate multi­
array slide module (Grace BIO-LABS, Bend, Oregon) which provides individual 
chambers for each array and the wells were rinsed twice with PBS. Single cell 
suspensions were prepared in serum-free medium as follows, adherent cells
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were detached with CDS and suspension cells were centrifuged at 1000rpm for 
5 min and resuspended in CDS. All cells were then centrifuged and 
resuspended in serum-free medium at the desired density. Cells were passed 
gently three times through a 19 gauge needle to dissociate aggregates and 5 x 
105 cells were put aside for western blot analyses of PSA expression. Cells 
(3x104 in 200 pL) were then added to the wells and incubated at 37°C under 
standard culture condition. During the incubation time, slides were rigorously 
agitated by hand for 4 sec every 10 min. After 2h, the slides were dismounted, 
washed with PBS++ (PBS supplemented with Ca2+ 0.1 mM and Mg2+ 1mM), 
incubated for 10 min with the fixation and staining solution (50% methanol, 10% 
acetic acid, 40% H2 O and 0.05% (w/v) Coomassie blue), rinsed in PBS, stained 
with 5pM Hoechst 33342 in PBS for 10 min. Finally, the slides were left to dry at 
room temperature and mounted using Hydromount (National Diagnostics, 
Atlanta, GA, USA). Arrays were imaged using fluorescence and bright field 
microscopy (CBS camera objective x10 see  Materials and methods). Images were 
analyzed using MetaMorph Offline version 6.3 (Molecular Devices, 
Downingtown, Pennsylvania).
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1 Poly-L-Lysine1
2 Serum Albumin Bovine2
3 Fibronectin3
4 Fibronectin cellular4
5 Vitronectin3
6 Heparan sulfate proteoglycan5
7 Laminin6
8 Laminin5
9 Type I collagen6
10 Type I collagen7
11 Type II collagen8
12 Type III collagen6
13 Type IV collagen6
14 Type IV collagen5
15 Type V collagen6
16 Type VI collagen6
Figure III.2: MSA slides layout. Overview of the MSA array (adapted from the MSA 
protocol) indicating the arrangement of the 14 ECM proteins along with their sources, 
synthetic, 2serum, 3human plasma, 4human fibroblast, 5basement membrane of
f \  7 8Engelbreth-Holm-Swarm murine sarcoma, human placenta, rat tail, chicken cartilage.
III.2.8. Paraffin cell aggregates section preparation and staining
Paraffin embedding, sectioning, haematoxylin-eosin and dewaxing were 
performed in collaboration with Dr J.M. Morgan (Clinical scientist, Department of 
Histopathology, University Hospital of Wales). Cells were grown on hydrophobic 
surfaces for 7 days, then centrifuged, washed with cold PBS once and fixed 
overnight in 10% formalin in isotonic PBS at pH 7.0 to 7.2. After fixation at room 
temperature for 12 - 16 h the cells were allowed to settle out from suspension 
and the cell pellet was transferred to a 1.5 ml microcentrifuge tube. The pellet 
was then washed twice in PBS, before adding 50pL of 4% agar at 60°C. When 
set, the agar containing the cells was then processed for paraffin embedding by 
sequential dehydration, of 1 hour in each, in ethanol series, 10% to 100%, 
followed by immersion in xylene, 4 washes of 1 h each. The agar / cell pellet
Arra;
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was then processed to a paraffin block and 4 pm sections were cut. Sections 
were then dewaxed, washed and either processed for standard haematoxylin 
and eosin (H&E) staining or for immunofluorescent staining with anti-PSA 
antibody, clone 2-2B (Abcys, Paris, France) as previously described (see 
Material and methods).
III.2.9. Invasion assay
Matrix invasiveness potential of the variants was tested using the in vitro 
Cell Invasion Assay (Calbiochem, San Diego, CA, USA) comprising a cell 
culture insert containing an 8 pm pore size polycarbonate membrane coated 
with an uniform layer of dried basem ent membrane matrix. Cells in log phase 
were detached, washed and resuspended in serum free medium. The prepared 
cell solution (3 x 105 cells per well in triplicates) was added to the upper 
chamber of the well while medium supplemented with 10% FCS was added to 
the lower chamber. Chambers were then incubated for 48 hours under standard 
culture conditions. Dissociation and labelling of invaded cells are performed in 
one step using the cell detachment solution containing calcein-AM (dilution 
1:300). After transfer in duplicate of the solution containing the cells to a 96-well 
plate (Greiner Bio-One Ltd, Stonehouse, UK), calcein-AM fluorescence was 
measured using a Fluostar Optima multi-well plate reader (BMG 
Labtechnologies, Durham, NC, USA) along with a 485/10 excitation filter and a 
520/10 emission filter.
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III.3. Results
III.3.1. SCLC cell lines in vitro phenotype and variants selection
The panel of SCLC cell lines used in this study displays a range of 
phenotype. Figure III.3 shows bright field images of the SCLC cell lines as 
grown under local laboratory conditions. The large cell lung carcinoma, COR- 
L23 cells grow as tightly substrate-adherent culture with an epithelioid 
morphology. The morphologies of the SCLC cell lines (apart from COR-L279) 
have been previously described in the literature and, with the exception of the 
COR-L47, no significant changes in morphology were apparent when culturing 
the cells in our laboratory. The panel of SCLC cell lines offers a selection of 
almost all types of SCLC in vitro morphology. The COR-L51 cell line grows as 
tightly packed cell aggregates as previously described. Three of the cell lines, 
COR-L47, SHP-77 and NCI-H69, grow as type 2 morphology (irregular 
relatively dense aggregates). However, COR-L47 was previously classified as a 
type 1 morphology (tight floating aggregates with frequent central necrosis), 
while the SHP-77 cell line has been previously described as a difficult cell line to 
classify and has been designated as mixed type 2 and 4 SCLC cell line (Fisher 
and Paulson, 1978; Koros e ta !., 1985). Moreover, NCI-H69 and SHP-77 display 
very few cells lightly attached to the substrate and not displaying an epithelial 
phenotype. The last two cell lines, COR-L88 and COR-L279, displayed loose 
aggregates with a large proportion of cells attached to the substrate.
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NSCLC COR-L23
SCLC in vitro cell lines morphological classification2
Type 1- tight floating aggregates with frequent central 
necrosis
Type 2- irregular, relatively dense aggregates without 
central necrosis
Type 3- very loose aggregates growing in small clumps 
Type 4- substrate-attached growth
Figure III.3: In vitro characteristics o f  the panel o f SCLC cell lines. Bright field images 
o f SCLC cell lines classified according to their morphology types (classification of 
Carney et al. (1985). Previously published typing of those cell lines, when available, is 
indicated in bracket, bailie-Johnson et a l (1985), 2Camey et al. (1985) and 3Fisher and 
Paulson (1978) and 4Koros et al. (1985). Calibration bar represents 50 pm.
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As described above, all SCLC cell lines in the panel, with the exception 
of COR-L51 and COR-L47, show a sub-population of cells that undergo 
spontaneous non-specific binding to standard tissue culture substrate. 
Adherence variants were obtained from minimal selection (1-2 month) for the 
attached phenotype. Bi-weekly, floating aggregates were removed from the 
culture dish and the attached cells were fed with fresh medium until a confluent 
flask of attached cells — that could only be detached with CDS — was 
obtained. Figure III.4 shows bright field images of the original cell lines and their 
phenotypic variants. All selected variants presented mixed populations of cells 
attached to the substrate and cells attached to each other. However, 
enrichment greatly increased the proportion of cell attached to the substrate.
All variants showed morphological changes toward an epithelial-like 
phenotype. Indeed variants cell showed a rounded shape and flattened 
morphology. Cells also appeared tightly aggregated and grew in cluster 
apparently retaining their cell-cell adhesion capacity. Moreover, monolayer 
growth was increased upon enrichment. However a few cells in NCI-H69 and 
COR-L279 adherent variants showed an elongated shape similar to a fibroblast­
like morphology (Vaughan and Trinkaus, 1966; Wiggan etal., 2002).
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Original phenotype Attached variant
NCI-H69
COR-L279
COR-L88
SHP-77
Figure III.4: SCLC cell lines and adherent variants. Bright field images o f the panel cell 
lines and their respective attached variants after 1 month of continuous culture (or 2 
months for NCI-H69 adherent). The calibration bar represents 50 pm.
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To determine the profile of the chosen marker for SCLC plasticity — the 
surface antigen PSA-NCAM — western blotting was performed on the panel of 
SCLC cell lines and their adherent variants (see figure ni.5). All original SCLC 
cell lines expressed PSA-NCAM, while PSA-NCAM or NCAM could not be 
detected for the large cells lung carcinoma, COR-L23, providing an 
immunoblotting biological control. COR-L51 appeared to be the higher 
expresser, while SHP-77 was the lowest expresser in agreement with previous 
intra-laboratory PSA detection analyses (see Appendix IV). All original cell lines 
had a relatively high proportion of non-polysialylated NCAM or low 
polysialylation, shown by a strong band detected around 140kDa, except for 
COR-L51. Interestingly both COR-L279 and SHP-77 adherent variants 
expressed more PSA than their respective original cell line, characterised by 
most of the NCAM being highly polysialylated. While a decrease in PSA 
expression was observed in NCI-H69 adherent cell line. Thus PSA expression 
cannot be directly correlated, across the panel, with the adherent phenotype per 
se.
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Figure III.5: SCLC cell lines and variants NCAM and PSA-NCAM expression. NCAM 
and PSA-NCAM detection by western blotting, the western blot is representative of two 
independent experiments.
The interesting linked characteristic of the NCI-H69 adherent cell line 
retaining NCAM expression, while down-regulating polysialylation, provides an
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opportunity to investigate the impact of PSA changes rather than loss of NCAM 
per se. Moreover, the observed phenotypic changes toward an epithelioid 
phenotype, combined with a relatively homogeneous parental cell line fitted the 
initial characteristic required for the plasticity model. Thus NCI-H69 and its 
attached variants were selected for further enrichment and model development.
III.3.2. NCI-H69 model phenotype characteristic
III.3.2.1. Variants enrichment
The NCI-H69 cells — hereafter referred to as NCI-H69 SP (to indicate 
suspension phenotype) — can be sub-cultured to enrich for the growth of cells 
with attached phenotype (AP) to the bottom of a standard cell culture substrate. 
This enrichment eventually produced after 3 passages (6 months of continuous 
culture) a new cell line, termed NCI-H69 AP3, capable of growth on its own and 
which could only be detached using an EDTA solution. Further passaging of the 
cell line for growth with an attached phenotype, over a period of >70 passages, 
produced a new sub-line NCI-H69 AP78, where the attached and flattened 
phenotype became more frequently expressed within the population and more 
pronounced in terms of the extent of cell spreading (figure III.6). The NCI-H69 
AP78 cell line showed a more pronounced epithelial-like phenotype, in that the 
cells grew as monolayers of tightly packed cells. However, some cells also 
showed spindle-shape morphology.
NCI-H69 AP78
In vitro culture passage 
 >
Figure III.6: In vitro appearance o f the NCI-H69 variants over increasing passage. The 
calibration bar represents 50 pm.
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These 3 cell lines were chosen for further characterisation. They 
represent the SCLC model variants referred to throughout the thesis. To avoid 
the complication of phenotypic drift, cells were frozen down at those stages to 
create a pool of passage 3 and 78 cultures. Cells were kept in culture for no 
more than 20-30 passages, before going back to cells from stock. Phenotype 
was confirmed each time after defrosting before proceeding with experiments.
III.3.2.2. Attachment properties
Attachment properties of the variants for standard plastic culture dish — 
the primary m eans of enrichment — were examined and quantified (figure III.7). 
Cells floating or cells attached to the substrate were imaged and counted at 6, 
24 and 48h. At 6h after seeding, NCI-H69 AP3 presented a similar phenotype 
as NCI-H69 SP (figure III.7a), while flattened cells could already be observed for 
the latest stage of selection, NCI-H69 AP78. From 24h, for both adherent cell 
lines, the adherent phenotype with an epithelioid morphology becam e 
predominant. NCI-H69 SP presented a side population of attached cells (3 to 
4%) present as early as 6h and that proportion was stable for the rest of the 
experiment (figure III.7b). After 6h, 66 % of the NCI-H69 AP3 cells were still in 
suspension. While, for NCI-H69 AP78, 67 % of the cells were already adherent 
to the substrate at 6h. Differences in number of cells floating and cells in 
suspension at 6h for all cell types were statistically tested for significance using 
one-way ANOVA (p-value < 0.0001) followed by Bonferonni’s multiple 
comparison test (all paired comparison p-values < 0.001). However, at 24h and 
48h the proportion of attached cells became equivalent (respectively 76 % and 
78 % at 24h and 92 % and 94 % at 48h).
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a.
6h
24h
48h
NCI-H69 SP NCI-H69 AP3
6H 24H 48H
NCI-H69 AP78
■  % o f  floating cells 
□  % o f  attached cells
Figure III.7: Attachment properties o f the different adhesion variants o f  the NCI-H69 
cell line. a. The images show the extent of cell spreading for each stage o f selection at 6 
hours and 24 hours after detachment. Calibration bar represents 50 pm. b. Adherence 
profile at 6, 24 and 48 hours after detachment. Graph depicting the mean +/- SD o f 3 
wells of one representative experiment out of 3.
NCI-H69 SP NCI-H69 AP3 NCI-H69 AP78
- 7 4 -
Chapter III— Characterization o f an in vitro SCLC model system
III.3.2.3. Cell size and DNA content
The evolution of the size of the cells and their nuclei throughout the 
selection process was evaluated. Individual cells in suspension were imaged; 
cell diameter was measured on the bright field image, while nuclear diameter 
was measured using the DRAQ5 fluorescent image. An increase in cell 
diameter was observed (figure III.8a) in both the NCI-H69 AP3 and NCI-H69 
AP78 cell lines (median diameter of 13.55 pm and 15.99 pm respectively) when 
compared to the parental cell line NCI-H69 SP (mean diameter of 12.28 pm). 
Although the data for each cell lines followed a Gaussian distribution, the 
variances were found to be statistically different, so a one-way-ANOVA test 
could not be performed and a non-parametric test — Kruskal-Wallis test — was 
applied. The test showed that the medians varied significantly (p-value < 
0.0001) and post hoc test showed that the differences between the medians 
were significant for all pairs (all p-value < 0.001).
Similar finding were obtained for nuclear diameter (figure III.8b). Due to 
the increase in both nucleus sizes and cell sizes, nucleus / cytoplasm ratio were 
found to be equivalent (~ 0.7) for all cell lines (figure III.8c).
- 75-
Chapter III —  Characterization o f an in vitro SCLC model system
a. b.
30-,
fe 2 0 -
”5
En
=  10-  0) o
I
X
20-,
©
E
5  10H
(A 3 0)O 
3 
C
NCI-H69 S P  NCI-H69 AP3 NCI-H69 AP78 NCI-H69 SP  NCI-H69 AP3 NCI-H69 AP78
c.
0  i . o n
g  0.9H
1
Q. 0.8- O
|  -  
3©
o  0 .6 -
0.5-
NCI-H69 SP  NCI-H69 AP3 NCI-H69 AP78
Figure III.8: NCI-H69 variants cell and nuclei diameters. Cell diameters (a.), nucleus 
diameters (b.) and nucleus / cytoplasm ratio (c.) are represented using a box-and- 
whisker diagram depicting medians, minimal and maximal values and 25% and 75% 
percentile for each data set. Data is representative of two independent experiments.
The results suggest that subtle changes in size have occurred upon NCI- 
H69 SP to NCI-H69 AP3 enrichment and a significant size increase upon 
enrichment to NCI-H69 AP78. To investigate this further, DNA content analysis, 
using flow cytometry and the DNA dye DRAQ5, was undertaken.
The pulse width versus area measurement shown in figure III.9a relates 
the time-of-flight of the object with the integrated fluorescence signal 
respectively, providing a means of discriminating doublets. The results permit 
an interpretation of the ploidy evolution during the enrichment process. The data 
show that all cell lines demonstrated profiles that suggest active proliferation 
with S phase fractions of 35. % for NCI-H69 SP, 28 % for NCI-H69 AP3 and 39 
% for NCI-H69 AP78. The presence of a minor fraction (< 2%) of > 4nSP cells 
could not be accounted for by doublets in the whole SP sample. NCI-H69 AP3 
shows a shift to higher DNA content for the whole population and again the
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presence of a minor fraction (< 2%) of > 4nAP3 cells. The data suggest a 
propensity to generate higher ploidy in the SCLC cell lines. A population of 
similar DNA content to NCI-H69 AP3 appear to be discernible in the AP78 
samples representing a minor fraction (< 10%) while the majority of cells show a 
DNA content clearly greater than a quasi-tetraploid state (compared to NCI-H69 
SP). The DNA profiles of the cell lines were stable among the passages and 
during the culture period across the experimental window.
NCI-H69 AP3 NCI-H69 AP78NCI-H69 SP1000
T0 800 0 800 0
DRAQ5 FL3-Width
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—  NCI-H69 SP
—  NCI-H69 AP3
—  NCI-H69 AP78
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Figure III.9: Flow cytometry determination o f NCI-H69 variants DNA content. NCI- 
H69 cell lines stained with DRAQ5 (FL3). a. FL3 is plotted (Area vs. Width), b. 
Overlay of DNA histogram to show G1 (peak 1) and G2 (peak 2) fractions. Data is 
representative o f two independent experiments.
III.3.2.4. PSA-NCAM
The SCLC marker NCAM and the polysialylated form of NCAM were 
detected by flow cytometry (figure 111.10), immunocytochemistry (figure III.11) 
and western blotting (figure III. 12). Specific antibodies were used to detect PSA- 
NCAM: the 12F8 antibody recognizes a neuraminidase-sensitive epitope on
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NCAM; the 2-2B antibody recognizes PSA chains with more than 10 sialic acid 
residues (Rougon etal., 1986) and B159 that recognizes NCAM.
Flow cytometry for NCAM revealed that 100% of cells in all variants 
express NCAM (figure III. 10a) and that NCAM expression did not significantly 
changed upon variants enrichment (figure Ill.lOb). NCI-H69 SP showed 
heterogeneity in the population, going from low decoration of NCAM to high 
decoration. NCI-H69 AP3 showed low decoration of NCAM. While for NCI-H69 
AP78, the signal for NCAM was equivalent to the signal for PSA-NCAM. Both 
the adherent variants showed a much narrower spread for PSA decoration of 
NCAM inside the population.
a.
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Fluorescence channel
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—  NCI-H69 AP3
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Figure III. 10: PSA and NCAM expression in the NCI-H69 variants. Expression of 
NCAM (antibody B159) and PSA-NCAM (antibody 22B) was detected by flow 
cytometry, a. Overlay histogram of NCAM and PSA-NCAM against background 
fluorescence for all variants, b. Overlay histogram of the variants NCAM and PSA- 
NCAM expression. Results shown are representative of at least two independent 
experiments.
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Dual channel immunofluorescence labeling of NCAM and PSA-NCAM 
(figure III. 11) confirmed the flow cytometry results, that all cells expressed 
NCAM and further showed that it was a membrane located signal. 
Immunofluorescence also confirmed the heterogeneity of the staining for PSA- 
NCAM throughout the NCI-H69 SP population. NCI-H69 AP3 showed many 
cells with no PSA-NCAM immunoreactivity and very few cells showed a strong 
signal. While for NCI-H69 AP78 cell line, PSA-NCAM staining was intense and 
homogeneously distributed.
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Figure III. 11: PSA-NCAM and NCAM expression in the NCI-H69 variants. 
Immunofluorescence detection of NCAM (antibody B159) and PSA-NCAM (antibody 
12F8) on cells prepared as cytospins. Calibration bar represents 50 pm.
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Western blotting experiments showed that for PSA-NCAM and NCAM 
(figure III. 12) all cell lines mainly expressed the 140 kDa isoform with weak 
expression of the 180kDa isoforms. No expression of the GPI-anchored form 
was detected, although the ability to detect the 120 kDa form with the B159 
antibody was not validated. Moreover, previous studies have shown that the 
NCI-H69 cell line does not express that form (120 kDa) of NCAM (Moolenaar et 
al., 1992). Western blotting confirmed that most NCAM is polysialylated in NCI- 
H69 AP78. Loss of most of the PSA signal after endoN digestion confirmed this 
specificity of the staining. After endoN digestion a faint signal was still detected 
for NCI-H69 SP and NCI-H69 AP78 cell lines, probably due to the fact that 
endoN digest the surface fraction of PSA-NCAM. Western blotting showed low 
detection of highly polysialylated NCAM in NCI-H69 AP78 with the B159 
antibody, maybe due to reduced accessibility of the antigen. Moreover, higher 
molecular weight PSA-NCAM (slower migration) was detected for NCI-H69 
AP78 suggesting longer chain of PSA in the adherent cell line (Seidenfaden et 
al., 2000).
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Figure III. 12: Immunoblotting detection o f NCAM and PSA-NCAM. Cells were treated 
overnight (15h) with 0.7 U of endoN or heat inactivated endoN (control / 80°C for 15 
min) and then processed for western blotting. The blot shown is representative of at 
least 3 independent experiments.
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To test whether PSA-NCAM loss in NCI-H69 AP3 can be designated as 
an early event or acquired later during the enrichment process. The adherent 
cells (from several flasks) and the suspension fraction of cells of NCI-H69 SP 
were isolated, cytospun and stained for PSA and NCAM. Fluorescent signal for 
NCAM and PSA were found to be similar for both cell populations (figure 111.13). 
No loss of PSA was detected in the adherent fraction, suggesting that the 
subsequent loss of PSA in the NCI-H69 AP3 variant is not an early event 
necessary for driving the cell-substrate interactions.
NCAM NCAM and nuclei
staining
Attached fraction
Suspension fraction
PSA PSA and nuclei
staining
Attached fraction
Suspension fraction
Figure III. 13: Fluorescence detection o f  NCAM and PSA-NCAM in NC1-H69 SP cells. 
The attached versus suspension fraction of cells were compared for membrane located 
signal. All images were taken using conventional wide-field microscopy. Bar represents 
50 pm.
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III.3.3. NCI-H69 model: gene expression changes
Evaluation of the gene expression across the variants was performed 
using HG_U133A_2.0 arrays and Affymetrix technology, allowing the study of 
the expression of 14500 well-characterised genes. The 2008 microarray study, 
comparing the NCI-H69 SP vs. NCI-H69 AP3 vs. NCI-H69 AP78 cell lines, 
served 2 purposes:
The first was to identify a set of genes with “large” variations between the 
variants and classification of those genes into relevant ontology and pathways. 
Mutual exclusion of genes predicted by contrasting methods was used to 
narrow down the list of candidate genes.
The second was to profile the expression of all genes in a specific 
pathway, the hypothesis is that small changes of a number of genes in a sam e 
pathway could be more relevant than big changes in unrelated pathways.
The identification of candidate genes and further functional analyses are 
presented below. While the interrogation of specific pathways or ontology is 
distributed throughout the thesis to retain a biological context and to embed the 
microarray outputs with further relevant studies.
111.3.3.1. Arrays quality assessment
The analysis of the expression of a large number of genes gives rise to a 
high potential for statistical error (exclusion and inclusion), therefore robust 
quality control (QC) is an essential first step in microarray analysis to determine 
if each array is of sufficient quality to be included in the study. Chip hybridization 
quality was tested using 2 packages from the BioConductor project (Gentleman 
et al., 2004): simpleaffy (Wilson and Miller, 2005) and AffyPLM (Bolstad, B; 
http://bmbolstad.com). Quality assessm ent showed that all arrays were of 
sufficient quality for inclusion in the analysis (Appendix V).
111.3.3.2. Statistical analyses
Data were first processed and normalised in GeneSpring 7.3.1 using 
RMA background subtraction and quantile normalisation followed by per gene
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normalisation. After filtering for present calls, 7283 probes were removed from 
further analysis due to lack of expression in all nine arrays. The data for the 
14994 remaining probes was then analyzed separately using 3 different 
statistical methods: Welch T-test, SAM and ANOVA. Results are shown in figure 
III. 14a.
Welch’s T-test followed by Benjamini and Hochberg False Discovery 
Rate was performed on the 14994 probes list using the GeneSpring software, a 
total of three pair-wise comparisons were performed. A change in gene 
expression was considered significant if the p-value was less than 0.05 and the 
fold change at least 2. Under those conditions, 813 probes were identified when 
comparing NCI-H69 AP3 and NCI-H69 SP, 702 probes when comparing NCI- 
H69 AP3 and NCI-H69 AP78 and 631 probes when comparing NCI-H69 AP78 
and NCI-H69 SP, for a total of 1325 probes up or down-regulated.
SAM was used to perform multi-class comparison on the 14994 probes 
list. A delta value that captured the largest number of significant genes with the 
lowest SAM-FDR was chosen. The delta value of 3.48 combined with a SAM- 
FDR of 0% generated 4134 probes. Pair-wise 2 fold change were then applied 
using GeneSpring and identified 737 probes when comparing NCI-H69 AP3 and 
NCI-H69 SP, 668 probes when comparing NCI-H69 AP3 and NCI-H69 AP78 
and 605 probes when comparing NCI-H69 AP78 and NCI-H69 SP, yielding a 
total of 1201 probes.
Finally, ANOVA followed by Benjamini and Hochberg False Discovery 
Rate were performed in GeneSpring, on the 14994 probes list, and a change in 
gene expression was considered significant if the p-value w as less than 0.05. 
Under those conditions, 7253 probes were identified and 1338 probes after 
filtering for at least 2 fold change. Pair-wise 2 fold change were then applied 
using GeneSpring and identified 813 probes when comparing NCI-H69 AP3 and 
NCI-H69 SP, 730 probes when comparing NCI-H69 AP3 and NCI-H69 AP78 
and 655 probes when comparing NCI-H69 AP78 and NCI-H69 SP.
In order to reduce the dimensions of the data and describe the general 
trend of gene expression changes induced upon the enrichment, only probes 
identified by the 3 techniques were selected for further analyses. Using this 
strategy a list of 1189 probes — representing 934 genes — w as defined for the 
rest of the analysis (figure III. 14b). The p-values used in the thesis were the
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scores taken from the Welch’s T-test method. Pair-wise comparisons (figure 
III. 14c) between the variants identified, out of the 1189 selected probes, 737 
probes with signal statistically different when comparing NCI-H69 SP and NCI- 
H69 AP78 (425 upregulation and 312 downregulation in NCI-H69 AP3), 658 
probes when comparing NCI-H69 AP3 and NCI-H69 AP78 (225 upregulation 
and 433 downregulation in NCI-H69 AP78) and 598 probes when comparing 
NCI-H69 SP and NCI-H69 AP78 (242 upregulation and 356 downregulation in 
NCI-H69 AP78).
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a. Comparison o f  statistical analysis methods used: b. 1189 gene list:
SAM ANOVA + BH
c. Pair-wise comparison o f  the selected remaining probes:
0  737 Q  . 3 ,  G
SP < AP3 425 AP3 < AP78 225
SP > AP3 312 AP3 > AP78 433>
SP < AP78 242 
SP > AP78 356
Figure III. 14: Microarray statistical analysis, a. Venn diagram comparing the results of 
the 3 statistical methods used: SAM, ANOVA followed by Benjamini and Hochberg 
False Discovery Rate (BH) and Welch’s T-test followed by BH. b. False-colour cluster 
view of the 1189 gene list representing the expression (average value of the triplicates) 
of each cell line. c. Variants pair-wise comparison.
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III.3.3.3. Overview of the ontology analysis
The biological functions of the differentially expressed genes were 
explored using the Gene Ontology Browser function in GeneSpring. The gene 
ontology (Ashburner et a/., 2000) associates each genes and their products with 
annotation referring to their biological processes, cellular components and 
molecular functions. Genespring automatic ontology analysis tool allows for the 
estimation of probes enrichment in GO categories and assigns p-value based 
on whether the number of genes in each category is greater than expected by 
random sampling, using a hypergeometric test without multiple testing 
correction. Amongst the 1189 selected probes, 1004 were annotated at the time 
of the analysis. Eight subcategories of biological process GO SLIM category, 3 
subcategories of GO cellular component and 8 subcategories of GO molecular 
function were significantly enriched (p-value cut-off of 0.05) amongst the 1004 
probes when compared to all the genes in the chip with GO annotation (table 
III.2). As expected for adherence variants, categories found significantly 
enriched were categories associated with cytoskeleton (as cellular component
11.12 % and molecular function of binding - 6.89 %) and extracellular region 
(15.27 %). Interestingly, cell differentiation (11.35 %) and death (8.96 %) 
categories were also found significantly enriched.
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Table III.2: Distribution and enrichment amongst the GO SLIM categories o f the 1004 
probes. Significantly (p-value < 0.05) enriched GO SLIM categories are represented in 
blue and ‘offspring* categories are noted below their parent categories within the GO 
hierarchy.
GO Category Genes in Category
% of Genes 
in List in 
Category
p-Value
GO:8150: biological process
GO:7275: development 3792 32.37 2.97E-16
GO:9653: morphogenesis 1585 12.85 2.34E-05
GO:9790: embryonic development 361 2.888 0.0419
GO:30154: cell differentiation 1402 11.35 7.58E-05
GO:7582: physiological process
GO: 16265: death 1242 8.964 0.0119
GO:8219: cell death 1232 8.964 0.00974
GO:7610: behavior 816 7.57 1.83E-05
G0:40007: growth 401 3.486 0.0088
GO:5575: cellular component
GO:5576: extracellular region 1767 15.27 2.09E-07
GO:5578: extracellular matrix (sensu Metazoa) 652 7.381 2.54E-08
GO:5623: cell
GO:5622: intracellular
GO:5856: cytoskeleton 1394 11.12 0.000297
GO:3674: molecular function
GO:4871: signal transducer activity 3746 24.11 0.000928
GO:5198: structural molecule activity 1178 7.656 0.0479
GO:5215: transporter activity
GO:5489: electron transporter activity 371 2.871 0.0308
GO:5488: binding
GO:5515: protein binding 9654 56.84 0.000994
GO:5102: receptor binding 1053 9.282 1.09E-06
GO:8092: cytoskeletal protein binding 674 6.89 1.33E-07
GO:3779: actin binding 455 5.263 8.01E-08
GO:30246: carbohydrate binding 377 3.254 0.00486
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III.3.4. NCI-H69 model: SCLC phenotype
Given that several of the NCI-H69 variants mentioned in the literature 
displayed v-SCLC morphology and biochemical characteristics (Kraus et a/., 
2002; Seddon et a/., 1998), the SCLC phenotype of the variants were 
investigated using the microarray data. During the analysis, NCI-H69 SP, a 
classic SCLC cell line, was considered to have maintained its SCLC 
characteristics under our laboratory culture conditions. To determine whether 
the enrichment process induced a loss of SCLC biochemical characteristics, the 
expression of several known-SCLC and NSCLC markers (Kraus et al., 2002) 
and of microarray-identified SCLC cancer specific markers (Pedersen et al., 
2003) was compared across the variants.
In their study, Kraus etal. (2002) investigated the expression of 15 SCLC 
markers, and 5 of them were downregulated in their adherent variant (L-dopa- 
decarboxylase, chromogranin A, NSE, c-kit and GRP). In this study (figure 
III. 15a/ Appendix VII), out of the 15 genes (represented by 33 probes), 3 genes 
were not detected (Cholecystokinin, progalanin and arginine vasopressin 
receptor 1 /  AVPR1), while 6 genes (8 probes) were found to be significantly 
modulated between the variants. Four of those genes had their expression 
downregulated in both NCI-H69 AP3 and NCI-H69 AP78, with expression level 
higher in the NCI-H69 AP78 cell line when compared to NCI-H69 AP3. The 
most drastic down-regulation was of gastrin-releasing peptide (84.7 fold SP / 
AP3 and 21.2 fold AP78 / AP3) and of neurotensin (18.11 fold SP / AP3 and 8.3 
fold AP78 / AP3). While enolase 2 (2.2 fold SP / AP3 and 1.4 fold AP78 / AP3) 
and dopa decarboxylase (2.1 fold SP / AP3 and 1.9 fold AP78 / AP3) were 
downregulated by around 2 fold. The expression of the oncogene KIT (v-kit 
Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) was 
downregulated in NCI-H69 AP3 when compared to NCI-H69 SP  (2.2 fold) and 
NCI-H69 AP78 (2.5 fold). Neuropilin 1 (nRP) was downregulated in NCI-H69 
AP78 when compared to NCI-H69 SP and NCI-H69 AP3 (2 fold and 5.3 fold 
respectively).
Kraus et al. (2002) also investigated the expression of 7 known NSCLC 
markers, and found that 5 of them were upregulated in their NCI-H69 adherent 
variant (CD44, Axl, endothelin, thrombospondin and cyclin D1). In the present
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study (figure III. 15b / Appendix VII), 2 of the SCLC markers were not detected 
(Axl and endothelin 1) and only CD44 was found upregulated in NCI-H69 AP3 
when compared to NCI-H69 SP and NCI-H69 AP78 (3 fold and 5 fold 
respectively).
a. SCLC markers b. NSCLC markers
Dopa decarboxylase 
Dopa decarboxylase 
Neurotensin
Gastrin-releasing peptide
Enolase 2
Galanin
KIT
Estrogen receptor 1 
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CD44 
Cyclin D1 
Thrombospondin 1
Figure III. 15: SCLC and NSCLC markers (Kraus et al., 2002) expression in the NCI- 
H69 variants. False-colour cluster representing the expression (average value of the 
triplicates) of each cell line for SCLC marker gene list (a.) and NSCLC marker gene list
(b.).
In order to further examine the SCLC characteristics in each of the 
variants, the expression of previously identified genes was compared across the 
variants. Pedersen et al. (2003), while profiling the transcriptional gene in 
expression of SCLC, identified 30 genes as SCLC cancer-specific with a 
median level of expression in SCLC tumour higher than the median of all the 
samples used in their study. Here, the list of genes (68 Affymetrix probes) was
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used to look for down regulation of expression in both adherent variants when 
compared to NCI-H69 SP (figure 111.16 / Appendix VII). One of the marker gene, 
PNPLA2 (patatin-like phospholipase domain containing 2 / TTS-2.2), w as not 
found expressed by all cell lines, however this result was perhaps not so 
surprising since, previously, NCI-H69 was found to express only a low amount 
of it (Pedersen et al., 2003). The expression of 6 genes (10 probes) in NCI-H69 
AP3 and 3 genes (4 probes) in NCI-H69 AP78 were found downregulated by at 
least 1.5 fold when compared to NCI-H69 SP. Alongside the previously 
identified GRP, 2 other genes were downregulated in NCI-H69 AP3 and NCI- 
H69 AP78 when compared to the suspension cell line, PTP4A3 (protein tyrosine 
phosphatase type IVA, member 3 — 2.5 and 1.9 fold respectively) and NK2 
homeobox 1 (NKX2-1 /TITF-1 / thyroid transcription factor 1 — 1.7 and 1.9 fold 
respectively). Three other genes were found downregulated in NCI-H69 AP3 
when compared to NCI-H69 SP: ASCL1 (achaete-scute complex homolog 1 —
6.5 to 9 fold), NCOR (nuclear receptor co-repressor 1 — 1.8 fold) and SCNN1A 
(sodium channel, nonvoltage-gated 1 alpha — 1.6).
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Figure III. 16: SCLC markers (Pedersen et al., 2003). False-colour cluster representing 
the expression (average value of the triplicates) of each cell line for SCLC marker gene 
list.
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III.3.5. NCI-H69 model: growth characteristics
As part of the characterisation process of the NCI-H69 model and to test 
whether the enrichment process provided a proliferation advantage, the in vitro 
growth properties of the variants were assessed (figure III. 17). All cell lines 
displayed an overall slow growth rate. NCI-H69 AP3 variant showed a similar 
doubling time to NCI-H69 SP (around 72h). However, NCI-H69 AP78 showed 
enhanced growth with a doubling time of around 48h. It is important to also note 
that in the NCI-H69 SP population there is a high fraction of dead cells (~50%). 
Therefore caution has to be taken when estimating cell number in this model 
system.
NCI-H69 SP
NCI-H69 AP3
go '  10  —  
o NCI-H69 AP78
c
3Oo
o
z.
0 24 48 72 96 120 144
Time (hours)
Figure III. 17: Growth properties o f  the different variants o f the NCI-H69 cell line. Each 
point, normalised to the starting number of cells, represents the mean +/- SD of 
triplicates wells. The experiment is representative of three independent experiments.
Microarray data were interrogated for cell cycle and growth-related gene 
expression changes in the variants.
Using the cell cycle GO gene list (GO: 7049), 74 probes (55 genes) 
overlapped with the 1189 gene list (figure III. 18 / Appendix VIII). The expression
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of 3 cell cycle effectors were found modulated in the variants. The expression of 
the cyclin A1 (CCNA1) was found downregulated in both NCI-H69 AP3 and 
NCI-H69 AP78 when compared to NCI-H69 SP (8 fold and 17 fold respectively). 
The expression of cyclin F (CCNF) was found upregulated in both NCI-H69 AP3 
and NCI-H69 AP78 when compared to NCI-H69 SP (1.7 fold and 2.4 
respectively). And, the cyclin-dependent kinase inhibitor 1C (CDKN1C / p57 / 
Kip2) was found upregulated in NCI-H69 AP78 when compared to NCI-H69 SP 
and NCI-H69 AP3 (1.7 fold and 3 respectively)
Using the cell growth GO gene list (GO: 40007), 35 probes (20 genes) 
overlapped with the 1189 gene list (figure III. 18 / Appendix VIII). The expression 
of the transforming growth factor, beta 2 (TGFB2) was found up-regulated in 
NCI-H69 AP3 when compared to NCI-H69 SP (1.9 fold) and NCI-H69 AP78 (3.6 
fold). The tumour suppressor glypican 3 (GPC3) was upregulated in NCI-H69 
AP3 when compared to NCI-H69 AP78 (41 fold) and NCI-H69 SP (15 fold). The 
bone morphogenetic protein 2 (BMP2) was upregulated in NCI-H69 AP78 when 
compared to SP (2.8 fold) and NCI-H69 AP3 (1.8 fold). The expression of the 
bone morphogenetic protein 7 (BMP7) was found down-regulated in NCI-H69 
AP3 (5 fold) and NCI-H69 AP78 (1.4 fold) when compared to NCI-H69 SP. The 
chemokines interleukin 8 (IL8) was downregulated in NCI-H69 AP3 (2.4 fold) 
and AP78 (2.6 fold) when compared to NCI-H69 SP. The retinoblastoma 1 gene 
(RB1) was upregulated in both NCI-H69 AP3 and NCI-H69 AP78 when 
compared to NCI-H69 SP (1.5 and 2.3 fold respectively). And finally the growth 
factor vascular endothelial growth factor (VEGF) was downregulated in NCI- 
H69 AP78 when compared to NCI-H69 AP3 (11 fold) and NCI-H69 SP (6 fold).
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GO: 40007: Cell cycle GO: 7049: Cell growth
Figure III. 18: Cell cycle and growth-related gene expression. False-colour cluster 
representing the expression (average value of the triplicates) of each cell line for the 
overlap between 1189 gene list and GO: 7049: cell cycle or GO: 40007 cell growth.
III.3.6. NCI-H69 model: cell adhesion
The microarray data was viewed from two general perspectives. The first 
addressing cell adhesion properties (figure III. 19 / Appendix IX -  table 1). The 
interesting outcome from this global analysis is that out of 110 probes 61 probes 
showed a higher expression in NCI-H69 AP3 when compared to NCI-H69 AP78 
and NCI-H69 SP. The second global analysis addressed cytoskeleton profiling 
of the variants (figure 111.19 / Appendix IX -  table 2) in this case all three 
variants took on different expression profiles suggesting that the enrichment 
process and selection for adherence resulted in different cytoskeletal 
composition. Further drill down addressed cell-cell interactions (called cell 
junction / figure III. 19 / Appendix IX -  table 3), where each of the variants took on 
slightly different profiles, although there was no statistically significant 
differences detected for the cell-substrate interactions (or integrins / figure III. 19 
/ Appendix IX -  table 4).
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Cell adhesion Cytoskeleton Cell junction
Integrins
Figure III. 19: Cell adhesion and cytoskeleton. Gene tree clustering representation of the 
expression (average value of the triplicates) of each cell line for the overlap of 1189 
gene list with GO: 7155: cell adhesion, cytoskeleton (GO: 5856: cytoskeleton and GO: 
7010: cytoskeleton organisation and biogenesis) or GO: 30054: cell junction and 
integrins expression.
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III.3.6.1. Cell-ECM adhesion: MSA
The interaction of cells with the extracellular matrix (ECM) plays 
important roles in cell survival, cell growth and cell differentiation. Therefore, a 
multiple substrate array (MSA) screen using simple substrate technology 
(BioCat, Heidelberg, Germany) enabling the parallel screening of interactions of 
cell to 14 proteins of the ECM (Kuschel et al., 2006). The reassembled full array 
in image format for every spot shows the acute adhesion of the SCLC variants 
to the array (Appendix X -  figure 3 to 5). Manual agitation of the slide every 10 
minutes provides a rigorous selection process for all the variants. Therefore 
overall there is very little cellular adhesion to the array, however NCI-H69 AP78 
display a better potential (figure 111.20). Poly-L-Lysine (PLL) is a synthetic 
molecule generally used to enhance cell attachment to plastic and glass 
surfaces. For many anchorage-dependent cells, the nature of the culture 
substrate has a major effect on cell growth and the requirement for serum 
proteins. Tissue culture plastic has a net negative surface charge which is 
produced by plasma treatment of the polystyrene. PPL has a net positive 
charge and could therefore be considered better at capturing PSA decorated 
cells. The PPL substrate was therefore effective at capturing the PSA positive 
cells NCI-H69 SP and NCI-H69 A78 cells, however clumping of the cells and 
therefore presence due to association with its neighbor rather than the substrate 
per se  maybe an artifact of the assay. Furthermore neuraminidase digestion of 
PSA did not change the adhesion pattern — cell number and cell morphology 
— of the variants on any of the ECM proteins present on the MSA slide 
(Appendix X -  figure 1 and 2) indicating that PSA decoration was not driving the 
selection to the substrate.
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Figure 111.20: Adhesion profile o f the NCI-H69 variants on ECM proteins. Cells were 
incubated for 2 h with manual agitation every 10 min. After processing and imaging of 
the slides, cells on each spot of ECM proteins were counted. The experiment is 
representative of 3 independent experiments.
Bright field images were acquired to determine general cell morphology 
and cell-cell interaction characteristics (figure ni.21); NCI-H69 SP cells showed 
significant clumping and a corresponding rounded cell morphology indication of 
perhaps a somewhat tenuous interaction with the surface; a similar outcome 
was apparent for NCI-H69 AP78 cells on the HSPG substrate. NCI-H69 AP78 
interaction with laminin EHS, vitronectin and cellular fibronectin showed cells 
with a flattened or lozenge shape indicating a ‘real’ interaction with the 
substrate. In all cases these were very due to the presence of a low number of 
cells (<100).
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Figure 111.21: Cell morphology on MSA ECM proteins spot. Calibration bar represents 
50 pm.
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III.3.6.2. Cell-cell adhesion
In order to determine if the adherent variants lost their ability to survive in 
suspension and to a ssess  whether the enrichment process reduced their ability 
to undertake cell-cell adhesion, cells were grown on hydrophobic surface (figure
111.22). Upon culture on hydrophobic surfaces (HOP), no cell adhesion was 
detected, and reversibility of the adherent phenotype was observed. Indeed, 
cells challenged with a hydrophobic surface did not undergo cell death, rather 
they retained normal light scatter characteristics and revert to suspension-form 
cell growth demonstrating the fundamental or essential property of phenotypic 
plasticity (figure III.22a). The NCI-H69 AP3 cell line reversed to a type 2 
morphology of cells growing in suspension and forming aggregates. Reversal of 
the phenotype - from loosely attached cells to floating aggregates -  can also be 
observed spontaneously in NCI-H69 AP3. The NCI-H69 AP78 cell line reversed 
to a type 1 morphology with growth as tightly packed clumps. Both adherent cell 
lines grown on HOP surfaces for 5 days retained the ability to attach to the 
plastic of the flask once transferred to a TCP surface (figure III.22b) 
demonstrating a maintenance of plastic behaviour.
Further examination of the phenotype of cells grown on HOP surfaces 
(figure III.22c), by H&E staining of paraffin section, showed that both NCI-H69 
AP3 and NCI-H69 SP cells grew as clumps with no particular organisation, with 
NCI-H69 SP forming tighter clumps. The NCI-H69 AP78 cell line clumps were 
found to be composed of tightly packed cells. A central ‘hole’ could be seen in 
all large clumps, suggesting the presence of central necrosis.
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NCI-H69 SP NCI-H69 AP3 NCI-H69 AP78
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Figure 111.22: Reversibility o f the attached phenotype. The NCI-H69 variants were 
grown on a hydrophobic substrate, a. Pictures depicting cells grown on hydrophobic 
surface for 9 days. b. Pictures depicting cells grown on hydrophobic surface for 5 days, 
transferred to a tissue culture treated dish and grown for 4 more days. c. H&E staining 
of paraffin section. Calibration bars represent 100 pm.
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The impact of the phenotype reversal on the growth characteristics was 
evaluated. All cell lines showed similar growth rate when cultured on HOP or on 
corresponding TCP surfaces (figure III.23a). Images acquired every 24 hours 
over six days showed that clump size increased with time (figure III.23b).
The extent of PSA decoration was also determined (figure 111.24) in these 
sam e cultures. In each case  there was no difference between cells grown on a 
hydrophobic surface after nine days and its corresponding tissue culture 
counterpart. This could be said for both NCAM and PSA-NCAM on the whole 
population (figure III.24a). Further investigation to determine spatial localisation 
effects within the clump structure again no differences were apparent (figure
III.24b).
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Figure 111.23: Growth properties o f  the NCI-H69 model cultured on hydrophobic 
substrate, a. Growth curve of the NCI-H69 model cultured on HOP or TCP dishes. Data 
represents the mean +/- SD of triplicates, representative of 2 experiments. Curves were 
fitted using nonlinear regression, b. Pictures of NCI-H69 cell lines grown on 
hydrophobic substrate taken at random fields every 24h. Calibration bar represents 50 
pm.
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Figure III.24: Expression and localization o f  NCAM and PSA-NCAM in the NCI-H69 
variants grown on hydrophobic surfaces (antibody 22B). a. Whole population 
expression using western blot detection, b. Spatial localization within the clump 
structure using immunofluorescence detection. Calibration bar represents 100 pm.
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III.3.7. NCI-H69 model: cell motility and invasiveness
The final variant characterisation addressed aspects of cell motility and 
invasiveness. A GO analysis was performed using the standard cell motility 
ontology (GO: 6928) yielding a list of 57 probes (figure III.25a / Appendix XI). In 
general the pattern showed an up-regulation of cell motility associated genes in 
the NCI-H69 AP3 variant and a down-regulation in NCI-H69 AP78 cells. 
Notably, the brain derived neutrophic factor (BDNF) was found up-regulated by 
2 fold in NCI-H69 AP3 when compared to the other 2 cell lines and the 
m etastasis suppressor 1 gene (MTSS1) was found down-regulated in NCI-H69 
AP3 (2.5 fold) and NCI-H69 AP78 (1.6 fold) when compared to NCI-H69 SP.
A simple assay to a ssess  the metastatic potential of cells is to look at 
their in vitro ‘invasive’ capacity through a reconstituted basem ent membrane 
matrix. The most common method currently employed to screen the invasive 
potential of cell lines in the current study the in vitro Cell Invasion Assay 
(Calbiochem, San Diego, CA, USA) was used (see methods). All cell variants 
show a poor ability to invade the basem ent membrane matrix after 48 hours. A 
low and similar invasive potential for all SCLC variants under the conditions 
employed was apparent (figure III.25b), therefore no modification of the invasion 
potential of the adherent variant was noted. A major draw back of the assay 
arises due to the inherent behaviour of the cells in suspension, i.e. their 
preference to clump with each other (cell-cell interactions) over a cell-substrate 
interaction. Images after a 48 hour incubation indicates this tendency (figure
III.25c).
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Figure III.25: Determination o f the invasion potential o f the NCI-H69 variants, a. False- 
colour cluster view representing the expression (average value o f the triplicates) o f each 
cell line for the overlap between GO: 6928 cell motility and 1189 gene list. b. Relative 
fluorescence unit value of calcein AM stained cells that have passed through the 
membrane alongside relative fluorescence unit value for 5000 cells. The data represent 
the mean +/- SD of 3 wells and is representative of 2 independent experiments, c. 
Images from the top chamber of the invasion assay after 48 h incubation. Calibration 
bar represents 50 pm.
-  105 -
Chapter III— Characterization o f an in vitro SCLC model system
III.4. Discussion
In summary, a unique SCLC in vitro model has been developed and 
characterised at multiple levels, comprising SCLC sublines with differing ability 
to attach to standard culture plastic. The model is therefore maintainable by 
culture technique alone. Thus this chapter describes: the scoping of the NCI- 
H69 characteristics and consequences of the selection / enrichment procedure 
for adhesion NCI-H69 adhesion variants; the establishment and 
characterisation of three new SCLC sub-lines and an assessm ent of this 
defined in vitro system for the study of SCLC plasticity.
NCI-H69 variants enrichment:
The study on the panel of SCLC cell lines showed the ability of the local 
cell culture protocols to re-iterate the morphological classifications previously 
described with the exception of COR-L47, previously classified as a type 1 
morphology (tight floating aggregates with frequent central necrosis). Using our 
protocols, SHP-77, previously described as mixed type 2 and 4 SCLC cell line 
(Fisher and Paulson, 1978; Koros et al., 1985), shared feature of NCI-H69 
showing only a few cells lightly attached to substrate and not displaying an 
epithelial phenotype. This morphological distinction of NCI-H69 provided part of 
the rationale for its selection for further study. Importantly, the majority of SCLC 
cell lines in the panel, with the exception of COR-L51 and COR-L47, show a 
propensity for sub-populations of cells to undergo spontaneous non-specific 
binding to TCP substrate indicating that it is an intrinsic property and that the 
experiments described have established a rationale for the adoption of NCI-H69 
as a representative a classical cell line.
The adhesion variants varied in their ability to attach to the substrate as 
demonstrated by the adhesion assay developed as a quantitative m eans of 
assessing culture status revealing that acute attachment to TCP is a robust 
method for assessing variant status. This metric is not dependent upon 
observational assessm ent of morphology and therefore applicable to multi- 
laboratory studies scheduled for future collaborations with drug discovery and 
development groups. Moreover, it will offer the possibility to determine the
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variants’ attachment properties to various ECM proteins in a time-dependent 
manner and to determine the heterogeneity among the population.
NCI-H69 variants characterisation:
Gene expression — The chapter reports a  successful establishment of a 
NCI-H69 state transition model and a  methodology for the enrichment of 
adherence variants for the molecular studies -  recognizing that microarray 
analysis provides ambivalent results when dealing with mixed populations. The 
results describe an assessm ent of the stability of the adhesion variant 
phenotype in the absence of ECM-based cues. To establish a  firm basis for our 
study and to determine the extent of variation between the variants, we have 
used the expression arrays to investigate the differences between NCI-H69 
cells cultured as micro-spheroids and cultures sequentially selected for 
adherent growth. As expected gene expression modulation w as most frequently 
linked to gene products located in the extracellular region, membrane, 
associated with cell adhesion and components of the cytoskeleton.
Microarray analysis found downregulation of neuroendocrine 
characteristics in NCI-H69 AP3 GRP, ASCL1, EN02 and DDC. All of these 
SCLC markers are often downregulated in variant SCLC cell lines (Carney et 
al., 1985; Gazdar et al., 1985; Kraus etal., 2002). Moreover the NSCLC marker, 
CD44 (Kondo et al., 1998), was upregulated in NCI-H69 AP3. Transition from 
SCLC to NSCLC observed in vivo and in vitro, associated with H-ras and c-myc 
function, has been shown to comprise these  phenotypic changes (Barr et al., 
1996; Risse-Hackl et al., 1998). Interestingly, those changes were not found in 
the late adherent variant.
Although the adherent-variants showed increased epithelioid morphology 
with increasing passage, no modulation of epithelial markers such a s  cadherin 
were detected and two claudins (3 and 5) were found down-regulated in both 
adherent cell lines. As expected frequent modulation of cytoskeleton-related 
genes was found, including actin beta, actin gamma 2 and actinin a1. 
Interestingly, the tetraspanin CD9 was found downregulated in both adherent 
cell lines. Absence of CD9 has recently been shown to enhance adhesion- 
dependent morphologic differentiation of SCLC cells (Saito et al., 2006).
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PSA-NCAM expression — The NCI-H69 cell line was used in the 
development of the SCLC variant model because of the hypothesized complex 
link with PSA decoration (see Introduction). The decrease in PSA decoration of 
the NCI-H69 AP3 variant was an acquired feature rather than one driving 
substrate adherence. Furthermore PSA loss is unrelated to a sustained 
adherence variant since the NCI-H69 AP78 variant shows an increased PSA 
decoration.
Although PSA expression cannot be related, across the panel, with the 
adherent phenotype per se, a  decrease in PSA expression was observed in 
NCI-H69 AP3 ceil line. Thus plasticity for PSA decoration of NCAM is 
independent of acquisition of the adherence phenotype and therefore provides 
for plasticity to be expressed at each stage of the transition to variant 
appearance. Importantly no positive selection for PSA-NCAM is imposed in the 
enrichment process and we have not adopted a clonal selection method. Thus, 
the system as described proved a  holistic view of the ability of cells to show 
enrichment preference and what features naturally co-enriched. The interesting 
characteristic of NCI-H69 adherent cell line of retaining NCAM expression, while 
down-regulating polysialylation, provides an opportunity to investigate the 
impact of PSA changes rather than loss of NCAM per se.
The panel study established that there was not a simple relationship 
between in vitro TCP adherence properties and the expression of the 
nominated plasticity marker PSA-NCAM. This neither confirms nor rejects the 
view the polysialylation of NCAM may provide, through phenotypic plasticity, 
opportunities for SCLC cells to generate variation which is resolved, through 
selection, as changes in adherence. This underlies the need to evaluate the 
stages of transition and the associated plasticity of expression, rather than 
seeking a  correlation of ‘end-stages’ which may be more representative of 
clonal variation.
Cell-ECM adhesion properties — In order to a sse ss  matrix-adhesion 
properties of the variants, we chose a screening technique (MSA) allowing 
comparative profiling studies (Kuschel et al. , 2006). The limited time frame (2 h) 
allowed testing of inherent ECM-adhesion capacity rather than adaptation 
capacity. Agitation every 10 min leads to resuspension and redistribution of
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unattached cells (Kuschel et al., 2006) while allowing sufficient time for the 
molecular response to be initiated (Lotz et al., 1989). However, with the NCI- 
H69 system, culture agitation provides mean of promoting cell-cell attachment. 
This is not dissimilar to the formation of microspheroids in standard spinner 
cultures. Therefore, presence of cells on the array due to cell-cell association 
rather than cell-substrate per se (cell clumping) provided ambivalent results. 
Despite these technical complications, the MSA experiment showed low affinity 
of the variants to the used ECM proteins. These results were consistent with 
previous findings showing that only few NCI-H69 cells adhered to laminin after 1 
day, but after 5 days virtually all cells were adherent to laminin showing a 
flattened morphology (Tsurutani et al., 2005). The MSA experiment also clearly 
showed the increased affinity of NCI-H69 AP78 to fibronectin, laminin, HSPG 
and vitronectin. Fibronectin and laminin have been shown to surround SCLC 
tumour cells (Sethi et al., 1999), suggesting an in vivo relevance for the ECM 
responses of the NCI-H69 variants system.
PSA removal did not affect cell adhesion to ECM proteins. This result is 
consistent with previous findings, where NCI-H69 variants selected for high or 
low PSA expression showed no modulation of attachment to the ECM proteins 
heparan sulfate, laminin, collagen IV and poly-L-lysine (Scheidegger et al., 
1994).
Cell-cell adhesion — We have established an in vitro methodology to test 
the impact of acute reversal of substrate adhesion opportunities and to test 
reversal of phenotype and the impact on the capacity of SCLC cells to retain 
variant growth characteristics. The aim w as to a sse ss  the impact of variation on 
cell interactions to interpret in vitro growth patterns.
Clearly, long-term enrichment for epithelioid growth did not result in loss 
of the ability for suspension growth. Even the NCI-H69 AP78 cell line, which 
offers limited heterogeneity in term of adhesion (under normal conditions only 
5% of the NCI-H69 AP78 cells do not adhere to the substrate — these cells do 
not form clumps and could be dead) was capable of suspension growth with no 
indication of proliferation disadvantage. Moreover, reversibility of the adherence 
phenotype in NCI-H69 AP3 resulted in similar growth to the parental cell line, 
while NCI-H69 AP78 formed tighter clumps.
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PSA was also not found to inhibit cell-cell contact. Indeed, NCI-H69 
AP78 when forced to grow in suspension formed tightly packed aggregates. 
The large excluded volume of NCAM-PSA has the potential to control general 
cell-cell interactions through the hindrance of overall membrane apposition 
(Rutishauser et al., 1988) or by modified charge and surface dielectric 
properties. Indeed, sialic acid residues and the proteoglycans (PGs) are 
considered to be major contributors to the negative charge at the surface of 
cells a s  revealed by electrokinetics (Vargas et al., 1990; Vargas et al., 1989). 
When NCAM with a low PSA content is expressed, adhesion is increased and 
contact-dependent events are triggered. Recently, Johnson et al. (2005) have 
provided direct evidence that NCAM polysialylation increases intermembrane 
repulsion and abrogates adhesion. These molecular force m easurem ents show 
quantitatively that NCAM polysialylation increases the range and magnitude of 
inter-membrane repulsion. Clearly, PSA-NCAM can regulate both cell-cell and 
cell-substrate interactions (Acheson etal., 1991).
A previous study showed modulation of cell-cell interactions by PSA. 
Indeed, NCI-H69 variants (isolated using limiting dilution exploiting NCI-H69 
PSA expression heterogeneity) expressing high level of PSA were found to form 
fewer clumps (Scheidegger et al., 1994). This suggests that if PSA modulates 
cell-cell adhesion in NCI-H69 SP, others mechanisms must be capable of 
overriding the exclusion volume effect of PSA-NCAM in permitting NCI-H69 
AP78 cell-cell adhesion to be so effective.
Invasion potential — Microarray analysis identified two invasion-related 
genes of interest: BDNF upregulated in NCI-H69 AP3 and MTSS1 down­
regulated in both adherent cell lines. The in vitro invasion assay  showed no 
difference between phenotypes, however, because invasion in vivo is ultimately 
more complex, involving both trans-endothelial cell invasion and degradation 
and migration through extracellular matrix (ECM) components and basem ent 
membrane, a more realistic model system would include each of these barriers.
In a corresponding recent study (Kraus et al., 2002), spontaneously 
adherent SCLC sublines were shown by differential gene expression analysis to 
provide an in vitro model of variant differentiation in SCLC, with down-regulation 
of neuroendocrine markers and up-regulation of epithelial differentiation
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markers cyclin D1, endothelin, the cell adhesion molecules CD 44 and integrin 
subunits a2, p3 and p4. A phenomenon of enhanced m etastasis is also thought 
to relate to the induction of tumour differentiation, resulting in apoptosis- 
resistant, morphological variants that lack the neuroendocrine expression of 
classic (c-) SCLC cells. Sub-cultivation of the adherent sublines on uncoated 
surfaces reversed their adherent phenotype immediately and under these 
conditions Akt activity reverts to low levels (Kraus et a/., 2002). Understanding 
the events involved in such a  switch in adherent/suspension tumour cell 
characteristics could suggest the nature and the plasticity of the steps involved 
in the spreading of this highly metastatic type of lung cancer.
In vitro growth characteristics — Growth characteristics of the variants 
were determined in order to test the operation of proliferation advantage in 
variant selection and to provide the interpretation param eters for the NCI-H69 
model for the assessm ent of hypothesized modulation of PSA and 
chemosensitivity characteristics for cell adhesion.
Microarray analysis found that the tumour suppressor RB1 was found to 
be up-regulated in both adherent cell lines. The P16-cyclin D1-CDK4-RB 
pathway, central for G1/S cell cycle transition control, is disrupted in most lung 
cancer. The pathway is disrupted through RB inactivation in SCLC, while cyclin 
D1, CDK4 and p16 abnormalities are rare in SCLC but common in NSCLC 
(Wistuba et al., 2001). NCI-H69 has been previously shown to only express 
traces of non-altered RB1 (Harbour et al., 1988).
Overall, microarray profiling genes has revealed no major changes in cell 
cycle and cell growth regulators. To explain NCI-H69 AP78 increased 
proliferation advantage, it is possible that this might arise from the inability to 
determine the true proliferation kinetics of the NCI-H69 SP due to the lower live 
fraction.
Determination of variation in cell size and DNA content — Further 
features were also revealed by the continuous enrichment process for SCLC 
variants. The NCI-H69 AP78 variant showed an increase in DNA content and a 
corresponding increase in cell size although the nucleus/cell size ratio remained 
unchanged. It is clearly evident that minimal and sustained culture of cells can
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allow for the appearance of clonal variants (e.g. shown here in terms of ploidy 
levels in NCI-H69). The conclusion is that the NCI-H69 SP to NCI-H69 AP3 
transition is an equilibrium shift between two populations with slight differences 
in ploidy while the NCI-H69 AP3 to NCI-H69 AP78 represents the 
predomination of a hyper-ploidy clone with some selective advantage. The 
assumption is that this hyperploidy clone arises from the NCI-H69 AP3 pool as 
a consequence of a proliferative advantage within a  range of adherent cells. 
This shift in cell and nucleus size is likely to influence on the 
micropharmacokinetic properties of the variants. To be also noted is the 
presence of a  sub-fraction of NCI-H69 AP78 with similar DNA content to NCI- 
H69 AP3 cells, underlying the heterogeneity of the population.
NCI-H69 variants clinical context:
Recent global gene expression analyses using oligonucleotide 
microarrays on many SCLC cell lines have showed that all of the xenografts 
clustered closest to the cell lines from which they originated and had the sam e 
expression levels a s  the cells grown in culture for the majority of genes 
(Pedersen et al., 2003). This suggests that SCLC in vitro biology presents 
relevant gene expression profiles and target opportunities. Indeed, comparison 
of array profiles of resected tumours (Bhattacharjee et al., 2001) has revealed 
that many potential drug targets expressed by SCLC cell lines and xenografts 
are also expressed in the tumours.
Interestingly we have discovered a  large (>15 fold) and apparently 
specific increase in Glypican-3 (GPC3) mRNA abundance in adherent versus 
suspension NCI-H69 cells. This result was further confirmed by immunoblotting 
and FACS analysis (data not shown). GPC-3 is a  candidate tumour suppressor 
gene in SCLC. While increased GPC3 expression has been found in melanoma 
and hepatocellular carcinoma (Capurro et al., 2005; Nakatsura et al., 2004), 
GPC3 expression is known to be associated with decreased lung metastasis, 
less local invasiveness and increased sensitivity to apoptosis (Peters et al., 
2003). The encoded glypican has been linked with the control of tumour growth 
and cell migratory activity through Wnt-signalling (Capurro et al., 2005). 
Recently, GPC3 has been found to inhibit Hedgehog (Hh) signalling during 
development (Capurro etal., 2008) and to mediate oncogenecity through insulin
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growth factor (IGF)-signalling pathway (Cheng etal., 2008). Thus altered GPC3 
expression seem s to be highly tissue specific, suggesting that GPC3 could 
stimulate proliferation in tumours with Wnt signalling influence is dominant and 
GPC3 inhibit proliferation in tumours with Hh signalling predominant (Filmus 
and Capurro, 2008). This hypothesis is consistent with the fact that GPC3 is 
downregulated in breast, ovarian and lung cancer, tumours where Hh pathway 
is hyperactivated (Filmus and Capurro, 2008).
GPC-3 has been proposed to represent a  potential lung tumour 
suppressor in non-small cell lung carcinoma with reduced expression of GPC-3 
reported in a panel of non-small cell lines and a limited number of 
adenocarcinomas resected from patients with non-small cell lung carcinoma 
(Kim et al., 2003). Furthermore, these latter studies demonstrated that the 
expression levels of GPC-3 in normal respiratory bronchiolar epithelial cells (the 
cell type assum ed to give rise to adenocarcinomas) are sensitive to cigarette 
smoke, with its loss upon exposure proposed as an initiating factor in the 
aetiology of NSCLC. GPC3 role in lung cancer has yet to be determined. 
Indeed, a  recent study showed that GPC3 was overexpressed in lung 
squamous cell carcinoma, and again GPC3 expression correlated with cigarette 
smoking (Aviel-Ronen et al., 2008). To date no information regarding the 
expression of GPC-3 in clinically defined SCLC tissue sam ples and how these 
correlate to the metastatic potential of the primary tumour exists.
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IV. Chemosensitivity and heterogeneity of the NCI-H69 variants 
IV.l. Introduction and aims
SCLC is a very aggressive disease with 5 years survival of 10% for 
limited disease and less than 5% for extensive disease. Although surgery and 
radiotherapy play a  great role in managing SCLC, chemotherapy remains the 
main form of treatment. The combination of cisplatin or carboplatin with 
etoposide has been used to treat SCLC for over 25 years, and still remains the 
standard treatment (Murray and Turrisi, 2006). Despite a good initial response 
to therapy, most SCLC patients suffer from the development of 
chemotherapeutic resistance and relapse. Therefore, there is a need to apply 
second-line chemotherapy, which however, frequently results in only a  low 
survival increase. To improve the outcome of SCLC, there is a further need for 
new therapies, and new drugs such as topotecan, iritonecan, paclitaxel have 
been studied (Fischer and Arcaro, 2008). Moreover progress in the 
understanding of SCLC biology has led to the development of new specific 
targeted therapies. However, to date, no targeted therapy has been approved 
for use in the treatment of patients with SCLC (Rossi et al., 2008). The 
topoisomerase I (TOP1) inhibitor topotecan (TPT) is the only single agent 
approved for the treatment of recurrent SCLC (Garst, 2007), and recent studies 
suggested that TPT in combination with etoposide or cisplatin could be effective 
for first line therapy in untreated SCLC (O'Brien et al., 2007). Hence, this 
indicates the relevance for investigating the action of the agent on later phases 
of SCLC cancer biology as represented by the SCLC variant models under 
analysis in the current study. Furthermore, pharmacological aspects of TPT, 
including the mechanisms of action, metabolism, activity- and toxicity-profiles, 
are under scrutiny to provide an insights into how to "fine-tune" anticancer 
treatment and address the mechanisms of resistance (Mathijssen et al., 2002). 
The availability of a variant SCLC system has the potential to contribute to that 
knowledge base. Indeed, sublines of the classic small cell lung cancer NCI-H69 
line have proven useful in studies on drug resistance and its circumvention with 
alternative agents such as paclitaxel (Davey et al., 2004) or in assessing the
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micropharmacokinetic features of multi-drug resistant cell lines (Coley et a/., 
1993).
The camptothecin class of agents, such a s  that represented by TPT 
(figure IV.la), induce their pharmacodynamic effects through the targeting of 
DNA topoisomerase I, an enzyme capable of removing DNA supercoils. The 
consequences of enzyme inhibition include the engagem ent of genetic 
programs leading to cell cycle arrest and apoptosis (Daoud et al., 2003; 
Pommier, 2004; Pommier et al., 1998). Topotecan stabilizes a covalent 
topoisomerase-DNA complex, then converted into double-strand DNA breaks 
by collisions of DNA replication fork, during replication, or progressing RNA 
polymerase molecules, during transcription (Pommier, 2006). TPT is therefore 
considered to be S-phase specific, but more recent studies have shown that 
TPT differentially targets cells in G1, S or G2, with G2 cells presenting the best 
opportunity for drug resistance (Feeney et al., 2003).
The mechanisms of dam age induction, molecular sensing of lesions, the 
functional and structural impact on cellular processes such a s  DNA metabolism, 
together with the transmission of signals to repair, cell cycle or cell death 
pathways are complex -  especially in tumour cell system s in which there is 
frequently dysfunction in one or more components. Both Topi and TOP2 DNA 
topoisomerases solve topological problems during chromosome metabolism, 
counteracting the accumulation of torsional stress and sister chromatid 
entanglement at replication forks and preventing the diffusion of topological 
changes along large chromosomal regions (Bermejo et al., 2007). In the 
presence of topotecan, TOP1 cleaves the DNA but is unable to religate the 
single-strand break. This leads to stabilization of TOP1-DNA-bound complexes 
and the accumulation of DNA strand breaks that may interfere with DNA 
replication. The origin of strand breakage is thought to reflect the discontinuous 
nature of DNA replication. A role for the Werner syndrome helicase/3'- 
exonuclease (WRN), a major component of the DNA repair and replication 
machinery, has also been recognised. For example, cells not expressing WRN 
are hypersensitive to topotecan, but not to the TOP2 inhibitor etoposide. The 
evidence suggests that WRN is involved in the repair of TOP1, but not TOP2- 
induced DNA dam age - most likely via preventing the conversion of DNA single­
strand breaks into DSBs during the resolution of stalled replication forks at
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T0P1-DNA complexes (Christmann et al., 2008). There has been recent insight 
into the complexity of the damage induction process and mechanism of action 
of topotecan, extending the view of the stabilized covalent topoisomerase-DNA 
complex acting as obstacles to DNA replication forks. Using single-molecule 
nanomanipulation to monitor the dynamics of human top 1 in the presence of 
topotecan an accumulation of positive supercoils ahead of the replication 
machinery causing potentially lethal DNA lesions was demonstrated (Koster et 
al., 2007)
Cell cycle checkpoints are pivotal mechanisms safeguarding genome 
stability and their failure impacts on the evolution of variation in tumour 
populations and drug responsiveness. Two structurally-unrelated protein 
kinases, CHK1 and CHK2, are implicated in several major checkpoints of the 
cell cycle, transmitting signals from damage sensing processes to the cell cycle 
engine. Variations of the ATM/ATR-CHK1/CHK2-CDC25-CDK pathways 
contribute to the replication checkpoint, to the intra-S phase checkpoint, and to 
the G2 DNA dam age checkpoint (Chen and Poon, 2008). TOP1-mediated DNA 
lesions elicit checkpoint responses in the DNA damage-activated checkpoint 
signalling pathways. The tumour suppressor p53 is considered to play a key 
role in restricting proliferation of abnormal cells. It is activated in response to a 
variety of cellular stresses, including DNA damage (for review se e  Levine, 
1997). Following TPT treatment, the activation of p53 is most pronounced in S- 
phase, as observed in A549 cells human lung alveolar cell carcinoma (Zhao et 
al., 2008). S-phase arrest induced by top 1 inhibition arises from an activation of 
Chk1 (Zhang et al., 2008) and degradation of Cdc25A phosphatase that occurs 
independent of p53 status (Levesque et al., 2008). This independence of p53 is 
pertinent to SCLC since this tumour suppressor gene (TSG) is mutated in more 
than 90% of SCLCs and more than 50% of NSCLCs (Wistuba et al., 2001). 
Furthermore, the retinoblastoma TSG is inactivated in over 90% of SCLC but 
only 15% of NSCLCs, and p16, the other component of the retinoblastoma/p16 
pathway, is almost never abnormal in SCLC but is inactivated in more than 50% 
of NSCLCs (Wistuba et al., 2001). NCI-H69 cells shows evidence of p53 mutant 
expression, therefore affirming that a strategy using a topoisomerase I inhibitor 
for arresting in the late-cell cycle. The prognostic significance of p53 mutations 
in lung cancer is not entirely clear although there is evidence to suggest that
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lung cancers with p53 alterations carry a  worse prognosis and may be relatively 
more resistant to chemotherapy and radiation (Campbell etal., 2002; Campling 
and El-Deiry, 2003).
Several reports have described the hydrolysis reactions of camptothecins 
in physiological buffers a s  measured by high performance liquid 
chromatography (HPLC). Indeed, the maintenance of intracellular active drug 
for DNA targeting is opposed by the hydrolysis, at the physiological pH, of the 
active lactone form to the inactive ring-opened form (Chourpa et al., 1998). 
Therefore any bias in the intracellular equilibrium and the export of drug 
molecules from the cell impose micropharmacokinetic limitations on TPT 
availability at the cellular level (Chappell et al., 2008; Cheung et al., 2008; 
Evans et al., 2004). Moreover, the fluorescent properties of topotecan (figure 
IV.lb) allows for drug tracking and fluorescence reporting of the drug using the 
convenient UV absorbance and visible range fluorescence signature of the drug 
(Burke etal., 1996; Gryczynski etal., 1999).
a. b.
Figure IV. 1: Topotecan — a camptothecin derivative, a. Structure of the lactone form of 
topotecan. b. Fluorescence spectral properties of topotecan in PBS (from Burke et al., 
1996), dose dependent increase of excitation (first peak, maximum at 390 nm) and 
emission (second peak, maximum at 540 nm).
Topotecan shows effectiveness in a range of cancers, most notably in 
ovarian cancer and SCLC, but is subject to cellular efflux by membrane-located 
ABC transporters (Pommier, 2006). The half transporter ABCG2, containing 
only a single putative transmembrane region and ATP binding motif, has been 
linked to resistance to TPT. First discovered in multi-drug resistant human
TOPOTECAN IN PBS 
so/um
Topotecan
WAVELENGTH ( n m )
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breast (MCF-7) cancer cell line, showing high cross resistance for mitoxantrone, 
daunorubicin and topotecan (Litman et al., 2000), ABCG2 is found to be 
expressed in epithelial cells of intestine, colon, liver, and renal tubules, where it 
acts to reduce the plasma level, and therefore bioavailability of orally 
administered anti-cancer drugs (Jonker et al., 2000; Maliepaard et al., 2001). 
The fungal toxin fumitremorgin C (FTC) is a potent inhibitor of the ABCG2 
transporter (Rabindran et al., 2000), providing a  selective pharmacological tool 
to evaluate the activity of the transporter in SCLC variants. The roles for ATP- 
binding cassette (ABC) transporter superfamily members in conferring drug 
resistance have been extensively described. In a  recent study on NSCLC cells it 
was found that ABCG2 levels accounted for between 80 and 90% of the 
variation in the resistance to topoisomerase I inhibitors, including topotecan 
(Nagashima etal., 2006).
ABCG2 has also been identified a s  a marker for cancer stem cell (CSC) 
activity, with sub-population expression found in multiple tumour cell types (Wu 
and Alman, 2008). While the presence of surface markers selectively expressed 
on CSCs are used to isolate these cells, in many cases exploitation of stem cell 
characteristics can be used to identify CSCs. One such characteristic is the 
capacity to extrude dyes, such as  Hoechst 33342, via the ABCG2 transporter. 
Cells that exclude this dye are referred to as side population cells (Challen and 
Little, 2006). Isolation or identification of stem cells based on the efflux of 
fluorescent dyes has also been an efficient method to study stem cells, for 
instance it has been demonstrated that Rhodamine 123 (Rho123) retention is 
low in the most primitive hematopoietic cells. Indeed, cells with low Hoechst 
33342 and Rho123 are highly enriched for stem cell activity (Leemhuis et al., 
1996; Wolf et al., 1993). The biological basis for the differential efflux of these 
dyes in the stem cell compartment is due to the activity of ATP-binding cassette 
transporters.
The AT-specific DNA minor groove ligand (MGL) 2',5'-bi-1H- 
benzimidazole, 2',(4-ethoxyphenyl)-5-(4-methyl-1 -piperazinyl), trichloride 
(Hoechst 33342) is used extensively for the labeling of DNA in both live and 
fixed cells. A significant advantage is the enhanced fluorescence shown by the 
dye molecule upon binding to DNA in the minor groove and more extant to the 
groove as  more molecules bind. The dye has both cytotoxic and mutagenic
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properties (Durand and Olive, 1982). In identifying modified intracellular 
maintenance of Hoechst 33342 dye in side population cells, use is made of the 
spectral shift in the dye’s emission spectrum as the ligand effectively titrates 
sites on DNA with different binding modes (Smith et al., 1985; Watson et al., 
1985). At low dye: DNA base ratios, as experienced at early uptake periods or 
imposed by enhanced dye efflux, there is an initial favouring of high affinity 
binding within the minor groove, yielding a  violet-biased emission spectrum. The 
spectral shift allows side population discrimination, by comparing emission at 
the violet and red regions of the spectrum, on the basis of high level dye 
exclusion, the side population phenotype is associated with low blue and low 
red fluorescence (Goodell et al., 2005). Therefore, dye exclusion provides a 
valuable technique a s  it identifies a unique population of cells with stem-like 
characteristics (Sung etal., 2008).
The overall aim of the study was to determine the impact of variant status 
on the chemosensitivity of SCLC cells with specific reference to the highly 
relevant agent TPT. The concept was to a ssess sensitivity (pharmacodynamic 
response) as an innate property of the variants without the imposition of ECM- 
driven factors as discussed in the main Introduction chapter. Further, the study 
sought to search for evidence of the modulation of known mechanisms of 
resistance for TPT, particularly those related to drug exclusion. The SCLC 
variants provide a characterised cell system in which to a sse ss  changes in the 
ability to deliver TPT (pharmacokinetic activity) to an intracellular target 
especially regarding the potential heterogeneity within cell populations. A linked 
concept was possibility that the variant enrichment process had selected cells 
with CSC-like properties, in the absence of drug selection that might favour 
CSC survival, through robustness for establishing proliferative capacity under 
changed conditions for cell-cell/cell-substrate interactions. Accordingly, an 
assessm ent was also undertaken to search for ‘CSC-like’ sub-compartments in 
the variants that might impose chemoresistance phenotype given that this 
feature might not be apparent in short-term bulk population studies but would be 
highly relevant to Darwinian fitness under selection in vivo.
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The experimental aims were:
> To survey for variation in the expression of ABC transporters and to 
functionally determine if the NCI-H69 variants display altered pharmacokinetic 
properties, i.e. whether the delivery of drug to the target was affected. 
Fluorescence tracking and the use of inhibitors allowed for detection of altered 
sensitivity versus topotecan uptake and efflux properties. To address the 
problem of tracking and parameterising rapid cellular drug dynamics time series 
flow cytometry was used to monitor uptake, delivery and stability of the TPT 
signal in cells.
> To determine if there was evidence of changes in subfractions of cells 
with CSC-like properties. The human lung alveolar cell carcinoma, A549 (Lieber 
et al., 1976), was used as a control for ABCG2 expression and to provide a 
technical validation of the side population phenotype m easurem ent by flow 
cytometry, given that the A549 cell line displays a strong side population 
phenotype due to functional ABCG2 expression (Scharenberg et al., 2002). 
Recent studies have identified and isolated a stem cell-like sub-population 
(24%) from the A549 cell line using the FACS / Hoechst 33342 approach with 
FTC (Sung et al., 2008) and have revealed differential sensitivity to DNA 
dam age agents.
> To determine the long term consequences of a 1 hour bolus exposure 
to topotecan on cell viability. Due to inherent heterogeneity of the SCLC 
variants (i.e. size, shape and substrate adhesion), determining growth curves 
using a cell count approach proved to be unreliable and an insensitive 
approach. A simple colourimetric test, called alamarBlue, was adapted to 
provide a screening method suitable for both suspension and adherent cells 
alike, to provide a non-invasive high-throughput format and therefore potentially 
providing a continuous readout over time.
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IV.2. Specific Material and Methods
IV.2.1. Drugs and inhibitor
Hoechst dye No. 33342 (Sigma-Aldrich Ltd, Dorset, UK) w as prepared as 
an aqueous stock solution and added directly with mixing to culture media 
containing cells. Topotecan (Hycamtin®; GlaxoSmithKline, Brentford, UK) was 
prepared in sterile water and the stock was stored at -80°C until required. 
Fumitremorgin C (FTC / Rabindran et al., 1998) was purchased from Sigma (St 
Louis, MO, USA) resuspended in DMSO (to a stock concentration of 10 mM) 
and used as previously described (Robey etal., 2001).
IV.2.2. Cell lines
NCI-H69 variants cell lines (NCI-H69 SP, NCI-H69 AP3 and NCI-H69 
AP78 — described in chapter III) and the human lung alveolar cell carcinoma, 
A549 (Lieber et al., 1976), were routinely cultured a s  previously described (see 
Materials and methods).
IV.2.3. ABCG2 immunodetection
Immunofluorescence was conducted as previously described (see 
Materials and methods). Cells were cytospun, fixed with 100% methanol and 
stained with ABCG2 antibody (Chemicon international, Millipore, Temecula, CA, 
USA).
IV.2.4. Hoechst side population assay
Single cell suspensions, with or without FTC pretreatment (10 pM /1  h), 
of A549 cells and of each NCI-H69 variants in complete medium supplemented 
with 20 mM HEPES were incubated with Hoechst 33342 (5 pM). Hoechst 
fluorescence was assessed  on the FACS Vantage system at various time points 
on the sam e sample. Samples were kept at 37°C in a  dry-block heater (Techne, 
Barloworld Scientific Ltd, Stone, UK) between time points. Signals were
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acquired with CELLQuest software (Beckton-Dickinson Immunocytometry 
Systems). Forward scatter (FSC) and side scatter (SSC) were acquired in linear 
mode. Hoechst 33342 signals derived from UV excitation were detected in 
linear mode at FL4 via a 620 LP filter (Hoe red) and via a FL5 424 / 44 filter 
(Hoe blue). All signals were collected for 10000 cells using the forward light 
scatter as the m aster signal. Data were analysed using FlowJo (Tree Star, San 
Carlos, CA, USA).
IV.2.5. TPT uptakes
Time series: the assay was conducted by incubating single cell 
suspension of each NCI-H69 variants and SU-DHL-4 cells (used a s  biological 
control) — at a concentration of 4.3 x 105 cells / mL in fresh medium 
supplemented with 20 mM HEPES — with 10 pM TPT. TPT fluorescence was 
measured on the FACS Vantage system at various time points on the sam e 
sample (t = 0; 5; 10; 20; 30; 40; 50 and 60 min). Sam ples were kept at 37°C in a 
dry-block heater (Techne, Barloworld Scientific Ltd, Stone, UK) between time 
points. Signals were acquired with CELLQuest software (Beckton-Dickinson 
Immunocytometry Systems). Forward scatter (FSC) and side scatter (SSC) 
were acquired in linear mode. TPT signals derived from 488 nm excitation were 
detected in logarithmic mode at FL1 via a 530/30 filter and TPT signals derived 
form UV excitation were collected in logarithmic mode at FL4 via a 530/30 filter. 
All signals were collected for 10000 cells using the forward light scatter as the 
m aster signal. TPT uptakes at each time point were corrected to control 
autofluorescence and normalised to the SU-DHL-4 cells TPT uptake at 10 min. 
Data are expressed a s  m eans of normalised median fluorescence intensity for 5 
data sets. All data were analyzed with FlowJo (Tree Star, San Carlos, CA, USA) 
and GraphPad Prism (GraphPad Software, San Diego, CA, USA).
Continuous time series: Cells were incubated with 10pM TPT for 10 min 
with or without FTC. Fluorescence w as acquired on the sam e sample 
continuously for 15 min using the FACS Vantage and the settings described 
above.
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Single time-point analysis: Cells were preincubated with or without 10 pM 
FTC followed by 10 min incubation with TPT (10 pM). Fluorescence w as then 
acquired on 10000 cells using the settings described above.
IV.2.6. alamarBlue assay
IV.2.6.1. Method design: continuous exposure vs. end-point assay
Continuous exposure: alamarBlue (Ahmed et al.) was purchased from 
AbD Serotec (Kidlington, UK) and used according to the manufacturer’s 
instructions. Confluent cells (~ 70 %) were detached with CDS (adherent cells) 
or harvested (suspension) from T75 flasks, spun down and resuspended in 2 
ml_ of full medium. Cells were counted and volumes were adjusted to obtain 
concentrations of 1 x 104; 5 x 104 or 10 x 104 cells / mL. Cell solutions (180 pL) 
were added to 96-well plates and cells were allowed to settle down for 24 h, 
before adding 20 pL of AB (to a final concentration of 10 %). Controls with 
medium only or medium and AB were included. Plates were incubated at 37°C 
under 5% C 0 2 in a humidified incubator. Cellular proliferation w as a ssessed  at 
24 h intervals during 72 h under aseptic conditions, by measuring absorbance 
using POLARStar OPTIMA plate reader (BMG Labtech, Offenburg, Germany). 
The plate reader was first blanked with the medium only well and absorbance at 
540 nm (reduced form) and 600 nm (oxidized form) were m easured.
End-point assay: the optimum AB incubation time was determined by 
plating various concentrations of cells (1 x 104; 5 x 104 or 10 x 104 cells / mL) 
96-well plates and incubation as described previously. After 48 h, AB w as 
added to the wells with cells a s  well as the control wells. Absorbance w as 
measured at 540 nm and 600 nm as described previously at various time after 
AB addition. The optimum starting cell number was determined by plating 
various concentrations of cells (1000; 2500; 5000; 10000; 30000; 50000 or 
70000 cells / well) in 96-well plates as described previously and overnight 
incubation prior AB addition. Absorbance at 540 nm and 600 nm was m easured 
15 h after AB addition.
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IV.2.6.2. Chemosensitivity testing
Cells were prepared as previously described and plated at a 
concentration of 5000 cell / well. Cells were allowed to settle down for 24 h 
before adding various concentrations of TPT to the cells. TPT w as also added 
to control wells without cells. After 4 days of incubation under standard culture 
conditions, AB was added to the test and control wells. Absorbance was 
measured 15 h after the addition of AB as previously described.
IV.2.6.3. % reduction calculation
Due to an overlap between the absorption spectra of the oxidized and 
the reduced form, results are expressed as percentage of reduced AB and the 
calculation is — when sam ples are read at: A,i = 540 nm and A* = 600 nm — as 
follows:
(sox X2 ) x (A A/|) — (sox A/j) x (A X2)
% reduced = ------------------------------------------------  x 100
(Cred A*i) X (A X2) ~~ (Bred ^2 ) X (A A,i)
Where:
8red A.1 = molar extinction coefficient of reduced AB at 540 nm = 104,395 
8red A* = molar extinction coefficient of reduced AB at 540 nm = 14,652 
80X A.1 = molar extinction coefficient of oxidized AB at 540 nm = 47,619 
sox A* = molar extinction coefficient of oxidized AB at 600 nm = 117,216 
AAi = absorbance of test well at 540 nm 
A A* = absorbance of test well at 600 nm
A’ A.1 = absorbance of negative control (medium and AB) well at 540 nm 
A’ A* = absorbance of negative control (medium and AB) well at 600 nm
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IV.3. R esults
IV.3.1. ABC transporters expression
Microarray analysis showed that, among the ABC transporters known to 
be involved in drug efflux, only ABCC1 and ABCC5 were expressed above the 
detection threshold in all variants. ABCG2 signal was found equivalent and 
flagged as absent for all variants (see figure IV.2).
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Figure IV.2: ABC transporters expression in NCI-H69 variants. Graph representing the 
raw intensity (without per gene normalisation) of the average value o f the triplicates for 
ABC transporters known to be involved in drug resistance. Grey bars represent genes 
whose expression was flagged as absent.
ABCG2 expression and localisation was further examined using 
immunofluorescence (figure IV.3). The human lung alveolar cell carcinoma 
A549 cell line, previously shown to express ABCG2 (Scharenberg et al., 2002) 
was used as the positive control for ABCG2 detection. All A549 cell appeared to 
express ABCG2, however the population showed heterogeneity, with some 
cells expressing elevated amounts of the transporter protein, possibly 
representing the side population phenotype cells. All of the variants showed 
positive staining for ABCG2. The signal seemed to be higher for both adherent
- 125 -
Chapter IV —  Chemosensitivity and heterogeneity o f  the NCI-H69 variants
variants compared to the suspension cell line. Again, all variants showed 
heterogeneity in ABCG2 expression in their cell populations. However, western 
blotting, using the same antibody, failed to detect ABCG2 in all the NCI-H69 
variants and the A549 cell lines, reinforcing the need for a functional analysis of 
ABCG2.
A549
NCI-H69 SP NCI-H69 AP3 NCI-H69 AP78
Figure IV.3: ABCG2 immunofluorescence detection. Images representing the 
immunodetection of cytospined, methanol fixed cells stained for ABCG2 (x 40 oil 
magnification). Calibration bar represents 50 pm.
IV.3.2. ABCG2 profiling and function
Functional profiling of ABCG2 activity was performed using flow 
cytometry detection of the uptake/exclusion of the reporter dye Hoechst 33342 
with or without the presence of the ABCG2 inhibitor — Fumitremorgin (FTC). 
This was initially performed and validated in ABCG2-expressing A549 cell line. 
Uptake of Hoechst 33342 was significantly higher in cells treated with FTC 
compared to the non-treated cells (median fluorescence of 195 vs. 232) 
consistent with functional ABCG2 expression. A clear cell cycle distribution 
could only be seen on the A549 samples treated with FTC (figure IV.4),
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suggesting that stoichiometry was only reached when the efflux pumps were 
blocked. In addition, 37.5% of non-FTC treated cells had a lower signal than 
that of the cells in G1 in the treated samples, indicating a sub-fraction of low 
loading cells.
The Hoechst 33342 profiles for all NCI-H69 cell lines were equivalent for 
the untreated sample and its corresponding treated counterpart, indicating that 
no functional ABCG2 could be detected within the limits of the assay. 
Consistent with previous findings (see chapter III), median fluorescence 
increased with the degree of enrichment (NCI-H69 SP/132, NCI-H69 AP3/202 
and NCI-H69 AP78/320) essentially reflecting the increase in cellular DNA 
content. The NCI-H69 SP DNA profile was consistent with previous finding (see 
chapter III), while, NCI-H69 AP3 and NCI-H69 AP78 profiles were slightly 
skewed. However, this was not sensitive to FTC addition and therefore was not 
ABCG2 related.
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Figure IV.4: Hoechst 33342 uptake profiles in the A549 and each o f the NCI-H69 
variants. The cells were preincubated for lh  with 10 pM FTC or DMSO, before 
incubation with 5 pM Hoechst 33342 (60 min). Data shown are representative of n=2.
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IV.3.3. Identification and analysis of the side population phenotype
In order to determine if a rare CSC-like fraction, so far not detectable with 
the conventional techniques, was present in the NCI-H69 variants, the side 
population analysis approach was applied, since the extent of spectral shift 
used to identify the side population phenotype is relatively independent of 
cellular DNA content per se. The technique was set up and validated using the 
A549 cell line. Dual-wavelength Hoechst fluorescence was acquired, and after 
quality gating (R1/ figure IY.5a), data were plotted on a dot-plot of Hoechst 
33342 blue vs. Hoechst 33342 red fluorescence emission. As described above, 
FTC enhanced Hoechst 33342 uptake in A549 cells. The rate of uptake was 
also affected by ABCG2 inhibition, indeed the maximum median intensity was 
reached after 20 min (figure IV.5b) in the treated sample, while the untreated 
sample plateau seem ed to be reached after a 60 min uptake. This can be 
explained by the number of cells (figure IV.5c and d) being recruited into the R2 
sector — the side population gate defined as the diminished region in the 
presence of FTC — indeed 93% of the treated cells were in R2 after 20 min 
against 34.8% in the untreated sample. Moreover, after 1h of uptake 99.5% of 
cells of the FTC treated sample were in R2 against 62.8% in the non-treated 
sample, making an estimated side population size of around 37.5% for the A549 
cells.
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Figure IV.5: A549 Hoechst 33342 uptake profiles, a. Scatter plot of side vs. forward 
scatter after quality gating (R l). b. Median fluorescence intensity o f the FL5-H / 
Hoechst 33342 blue channel (high affinity binding sites) taken from the whole 
population (Rl gate) over time. c. Recruitment of cells to the R2 segmentation gate (% 
of whole R l population) over time. d. Time series scatter plot showing the uptake and 
distribution of the Hoechst 33342 (blue channel) fluorescence vs. Hoechst 33342 (red 
channel) fluorescence. R2 indicates the segmentation gate for positive labelled cells. 
Numbers indicate the fraction o f cells in the R2 gate. Left column represents control 
conditions, right column indicates FTC treated cells. All curves were fitted using a non­
linear regression.
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Following the sam e procedure, the NCI-H69 variants were used in 
Hoechst 33342 uptake experiments and the data gated on SSC vs. FSC for 
quality (R1 / figure IV.6a, figure IV.7a and figure IV.8a). Overall for each variant 
no difference in accrual or mean fluorescence was observed when comparing 
control with FTC-treated samples (figure IV.6b / c, figure IV.7b / c and figure IV.8b 
/ c). Thus, there was no evidence for the presence of a side population in any of 
the variants. However, the variants did show different profiles to each other. As 
shown previously, a large fraction (~ 30 %) of the NCI-H69 SP cells consisted of 
debris (figure IV.6d). Uptake of Hoechst 33342 was very fast, so fast that the 
design of the experiment did not enable the resolution of uptake kinetics. The 
maximum uptake was reached and all of the cells were recruited to the 
designated R2 fraction within a few minutes, we postulated that this is due to 
leaky plasma m embranes and easy access to exposed nuclei. Therefore, the 
maximum of cells in R2 was obtained when sampled at 21 min (75 %). Uptake, 
however, can be considered much slower for the NCI-H69 AP3 cell line, after 
1.5 min, 8 % of cells were displaced to R2 (figure IV.7d) and all cells (98 %) 
were in R2 after 21 min. Finally, for the NCI-H69 AP78 cell line, after 1.5 min, 
13% of the cells were located in R2 and the maximum of cells in R2 (98 %) was 
obtained after 21 min (figure IV.8d). No differences were observed upon FTC 
treatment for all NCI-H69 cell lines and no side population could be detected.
Having established the non-operation of the ABCG2 transporter with 
respect to the surrogate reporter in each of the variants, we then considered the 
overall uptake of Hoechst 33342 of the three variants (figure IV.6b, figure IV.7b 
and figure IV.8b). Median fluorescence for the R2 gated cells showed an 
increase of overall uptake as the cells were enriched for substrate adherence 
(120, 200 and 350 respectively), probably due to the increase of volume of each 
of the cell populations (see chapter III). Indeed, volume increments (NCI-H69 
AP78 = NCI-H69 AP3 x 1.7 = NCI-H69 SP x 1.4) correlate with Hoechst 33342 
median fluorescence increments (NCI-H69 AP78 = NCI-H69 AP3 x 1.75 = NCI- 
H69 SP x 1.6). This indicates that the concentration of dye per cell is probably 
equivalent. Therefore, there is no indication that the uptake of the minor groove 
ligand Hoechst 33342 differs across the variants. This provided the foundation 
work for the topoisomerase I inhibitor topotecan. In the case  of TPT there is no 
evidence of fluorescence enhancem ent upon DNA binding (Gryczynski et al.,
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1999) although the affinity will be significantly lower than for the Hoechst 33342- 
DNA complex. Parallel studies in the laboratory had indicated the rapid loss (> 
50% loss of intracellular fluorescence 5 min after drug removal) of TPT from the 
cell suggesting that TPT may provide a more sensitive responding molecule for 
subtle changes in drug efflux capacity. The hypothesis is that the 
pharmacokinetics of TPT is the sam e across all the variants and any differences 
are not ascribable to ABCG2 function.
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Figure IV.6: NC1-H69 SP Hoechst 33342 uptake profiles, a. Scatter plot of side vs. 
forward scatter after quality gating (R l). b. Median fluorescence intensity of the FL5-H 
/ Hoechst 33342 blue channel (high affinity binding sites) taken from the whole 
population (Rl gate) over time. c. Recruitment o f cells to the R2 segmentation gate (% 
of whole R l population) over time. d. Time series scatter plot showing the uptake and 
distribution o f the Hoechst 33342 (blue channel) fluorescence vs. Hoechst 33342 (red 
channel) fluorescence. R2 indicates the segmentation gate for positive labelled cells. 
Numbers indicate the fraction of cells in the R2 gate. Left column represents control 
conditions, right column indicates FTC treated cells. All curves were fitted using a non­
linear regression.
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Figure IV.7: NCI-H69 AP3 Hoechst uptake profiles, a. Scatter plot o f side vs. forward 
scatter after quality gating (R l). b. Median fluorescence intensity o f the FL5-H / 
Hoechst 33342 blue channel (high affinity binding sites) taken from the whole 
population (Rl gate) over time. c. Recruitment of cells to the R2 segmentation gate (% 
of whole R l population) over time. d. Time series scatter plot showing the uptake and 
distribution of the Hoechst 33342 (blue channel) fluorescence vs. Hoechst 33342 (red 
channel) fluorescence. R2 indicates the segmentation gate for positive labelled cells. 
Numbers indicate the fraction o f cells in the R2 gate. Left column represents control 
conditions, right column indicates FTC treated cells. All curves were fitted using a non­
linear regression.
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Figure IV.8: NCI-H69 AP78 Hoechst uptake profiles, a. Scatter plot of side vs. forward 
scatter after quality gating (R l). b. Median fluorescence intensity o f the FL5-H / 
Hoechst 33342 blue channel (high affinity binding sites) taken from the whole 
population (Rl gate) over time. c. Recruitment of cells to the R2 segmentation gate (% 
of whole Rl population) over time. d. Time series scatter plot showing the uptake and 
distribution of the Hoechst 33342 (blue channel) fluorescence vs. Hoechst 33342 (red 
channel) fluorescence. R2 indicates the segmentation gate for positive labelled cells. 
Numbers indicate the fraction o f cells in the R2 gate. Left column represents control 
conditions, right column indicates FTC treated cells. All curves were fitted using a non­
linear regression.
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IV.3.4. TPT Pharmacokinetics
Inhibition of ABCG2 efflux of TPT was tested with the A549 cell line 
(figure IV.9), increasing doses of FTC were used in order to determine the 
optimal inhibition of ABCG2 and thus inhibition of TPT efflux. All chosen FTC 
doses increased the median TPT intracellular fluorescence of the treated cells 
by 1.7 times.
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Figure IV.9: Modulation o f  TPT uptake with the ABCG2 inhibitor FTC, A549 cells were 
pretreated for lh  with increasing concentrations of FTC and followed by a 10 min 
treatment of TPT (10 pM).
The pharmacokinetic properties of TPT in the NCI-H69 variants were 
assessed after a 10 min exposure to 10 pM of TPT by flow cytometry (figure 
IV. 10). Median fluorescence signals were similar for the NCI-H69 SP and NCI- 
H69 AP3 (161.3 and 157.3 respectively). As expected due to higher DNA 
content and cell volume, overall uptake in the NCI-H69 AP78 population was 
greater (median fluorescence of 217.7). Interestingly, the spread of 
fluorescence across the entire population was narrow for the NCI-H69 AP3, 
while NCI-FI69 SP and NCI-H69 AP78 population displayed a broader 
distribution, probably a reflection in heterogeneity in cell volume, while the NCI- 
H69 AP3 variant represent an acutely selected population (as indicated by the 
forward scatter signal).
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Figure IV. 10: Differences o f TPT uptake for the NC1-H69 variants. Cells were treated 
with 10 pM of TPT for 10 min. The left column represents the forward scatter vs. TPT 
fluorescence detected at 530 nm for each NCI-H69 variant. The right column represents 
the fluorescent intensity distribution profile (the dotted line represent the background 
fluorescence). The figure represents a typical experiment (n=5).
Topotecan uptake was observed over time by extracting the fluorescence 
signal at designated time intervals from the same sample (figure IV. 11). As 
observed above, similar levels of fluorescence were detected for the NCI-H69 
SP and NCI-H69 AP3 and a higher median signal for the NCI-H69 AP78 cell 
line throughout the entire 60 min uptake experiment. TPT fluorescence peaked 
after 10 minutes followed by a slow decline in TPT fluorescence in all cell lines,
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this is due to the removal of the lactone form of TPT (active pool of TPT) in the 
medium and predicted by HPLC analyses and pharmacokinetic modelling 
(Evans etal., 2004).
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Figure IV. 11: Profiles o f  TPT uptake for variant NCI-H69 cells. Cells were treated with 
10 pM of TPT. Each value o f median fluorescence was background corrected and 
normalised to the value o f the control at 10 min uptakes. Each point represents the mean 
± SD of 5 experiments and the curves were fitted using non-linear regression.
As expected, inhibition of ABCG2 had no effect on TPT uptake for all the 
variants, while TPT uptake was significantly increased in the control A549 cell 
line upon FTC pre-treatment (figure IV.12a). FTC also had no effect on the 
overall rate of the uptake (figure IV.12b). For all variants, a plateau was reached 
after 8 min, with or without FTC. It is important to note that in this experiment 
the assay was conducted at room temperature, the overall effect was that TPT 
fluorescence was maintained over the entire 15 minutes, as opposed to the 
findings in figure IV. 11.
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Figure IV. 12: FL4 signal o f TPT uptakes with or without FTC. a. Cells were 
preincubated lh  with 10 pM FTC or DMSO followed by incubation with lOpM TPT for 
10 min. b. Continuous TPT uptake over 15 min with or without 10 pM FTC. Curves 
were fitted using non-linear regression.
IV.3.5. TPT pharmacodynamics -  the overall response to topotecan
IV.3.5.1. Topoisomerase expression
Microarray analysis showed that all subclasses of topoisomerase were 
present in all the variants and that their expression levels were equivalent in all 
NCI-H69 cell variants (Figure IV.13a). Western blotting confirmed the microarray
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results for T0P1 expression, indeed bands of similar intensity were detected at 
the expected size of 91 kDa (Figure IV.13b).
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Figure IV.13: Topoisomerase expression across all NCI-H69 variants, a. Microarray 
analysis of topoisomerases expression. Graph depicting the raw intensity value of the 
value of the triplicates (without per gene normalisation), b. Western blotting detection 
o f topoisomerase I. Western blot shown is representative o f 2.
IV.3.5.2. alam arBlue method implementation and optimisation
The alamarBlue (AB) assay is a cell proliferation assessment method 
based on the reduction of the tetrazolium salt, alamarBlue, in cells. The 
molecule is soluble, stable in culture medium and putatively non-toxic allowing 
continuous monitoring (Ahmed etal., 1994). However, alamarBlue was revealed 
to be toxic for NCI-H69 variants. Indeed, cells exposed over 72h to alamarBlue
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showed a significant decrease in growth (figure IV. 14a). Snap-shots taken after 
72h showed that cells died upon exposure to alamarBlue (figure IV.14b). 
Furthermore, addition of AB for the last 24 h of a 72 h experiment also caused a 
reduced cell growth. However, phase contrast images showed that the 
morphology of the cells remained unchanged.
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Figure IV. 14: Continuous alamarBlue exposure is toxic for all NCI-H69 variants. Cells 
were incubated in a 96-well dish for 72h without alamarBlue (AB), with AB added at t 
= 48h or t = Oh. Data is representative of two independent experiment, a . After 72h cells 
were harvested and counted, b. Phase contrast images of the variant cells captured at t = 
72h to show the overall morphology. Calibration bar represents 50 pm.
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Continuous incubation with AB w as too invasive and therefore not a 
viable option, because of its cytotoxic effects. Therefore an end-point assay  was 
developed, ensuring the optimization of the start cell number and minimising 
overall exposure to AB. In addition the assay had to be able to discriminate 
different cell numbers (assay sensitivity), by avoiding a shortage of substrate 
and further reagent reduction to a colourless substrate (figure IV. 15). The 
exposure time was determined by incubating 3 different concentrations of cells 
and measuring the absorbance over 24h (figure IV. 15a). Discrimination was 
possible after a 4h exposure and was most sensitive and optimal after 12h-24h, 
however a plateau w as reached after 24h for the NCI-H69 AP78 cell line. 
Therefore, an overnight exposure of 15h was chosen to provide an optimal 
detection of cell number.
In order to determine the dynamic range and relationship of cell number 
versus detection of reduced tetrazolium salt, the assay  w as performed with 
various cell concentrations (from 103 to 7 x 104 cell / mL). The aim was to 
determine the optimum cell number range, providing the dynamic range to 
detect both decreased and enhanced cell growth (figure IV. 15b). From the plot it 
was clear that 5 x 104 cells / mL represented the optimal starting cell number, 
as the assay was sensitive to small changes in cell number for all variants in 
that cell number range.
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Figure IV. 15: AlamarBlue method optimization, a. 1800, 9000 and 18000 cells / well 
were exposed to alamarBlue and absorbance was measured at various times over 24h. 
Results are representative o f 2 experiments. Each point represents the mean +/- SD of 
n=4. b . Increasing cell numbers were exposed to alamarBlue for l5 h . Results are 
representative o f 2 experiments. Each point represents the mean +/- SD  o f n=4. Curves 
were fitted using non-linear regression.
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IV.3.5.3. Chemosensitivity to TPT
The alamarBlue assay was used to determine the variants sensitivity to 
TPT. Each NCI-H69 variant population were treated continuously for 4 days 
with increasing concentrations of TPT (figure IV. 16). No differences in 
chemosensitivity to TPT were observed; cell numbers were equivalent for 
treatment with 25 nM, 50 nM and 100 nM TPT. The fifty-percent inhibitory 
concentrations (IC5o) were estimated from the graph and were found to be 
similar (10 nM for NCI-H69 SP and NCI-H69 AP3 and 6 nM for NCI-H69 AP78).
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Figure IV. 16: Dose response to continuous TPT treatment. Cells were treated with 
increasing concentration o f TPT (10 nM, 25 nM 50 nM or 100 nM) for 4 days before 
addition o f AB. Each point represents the mean +/- SD o f n=4. Results are 
representative o f 3 experiments.
IV.3.5.4. Effect of the variant phenotype on TPT chemosensitivity
Alongside the alamarBlue studies, another approach was undertaken to 
determine the consequences of TPT treatment on the NCI-H69 variants, simply 
by observing cell morphology, cell-substrate interactions and the extent of cell­
cell adhesion using phase contrast microscopy. There were two designs of the
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treatment experiments performed to decipher the effect of substrate-adhesion 
on the chemosensitivity of the variants to TPT. The first scenario entailed the 
removal of the cells from the plastic substrate (i.e. NCI-H69 AP3 and NCI-H69 
AP78 cells were detached) and treatment as a single cell suspension (figure
IV. 17) for 1h with 10 pM TPT and then re-seeded into a plastic well. Here the 
aim was to remove conformation-based limitations on drug access. For the 
second scenario, cells were seeded for a full 24 hours (enabling them to 
assum e their normal cell-cell or cell-substrate phenotypic behaviour) prior to a 1 
hour treatment with 10 pM TPT (figure IV. 18). In all cases cell death was 
apparent from 48h onwards for all cell lines treated before or after reseeding. 
Evidence of cell survival was also observed after 5 days for all cell lines and 
both treatment. Interestingly, NCI-H69 AP3 and NCI-H69 AP78 cells treated as 
single cell suspension were also able to attach within 24 h post-treatment (figure 
IV.17).
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Figure IV. 17: TPT treatment o f  all NCI-H69 variants as single cell suspension. Single 
cell suspensions were treated for lh  with 10 pM TPT and then seeded into individuals 
wells. Images were taken at random separate fields for each time point. Calibration bar 
represents 50 pm.
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Figure IV. 18: TPT treatment o f all NCI-H69 variants pre-seeded into wells. Cells were 
seeded 24 h prior lh  treatment with 10 pM TPT. Images were taken at random separate 
fields for each time point. Calibration bar represents 50 pm.
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IV.4. Discussion
SCLC is an aggressive disease with a  high initial response rate but 
typically relapses (Okuno and Jett, 2002). Here the study focused on TPT, as 
the lead agent for evaluation of chemosensitivity in the SCLC system. TPT is 
the first TOP1 inhibitor to be approved for second-line treatment of SCLC and is 
the only single-agent approved for the treatment of recurrent SCLC (Garst, 
2007; Ormrod and Spencer, 1999). Furthermore, recent studies have been 
conducted in the first-line setting and oral TPT shows to be a good candidate for 
combination therapy with intravenous agents such a s  small tyrosine kinase 
inhibitors (O'Brien et al., 2007). Chemoresistance/sensitivity has been studied 
by development of in vitro system based on drug-resistant variant selection. 
Recently more importance has been given to the possibility of a small fraction of 
cancer cell populations with stem-like properties, which may define drug 
resistance properties.
NCI-H69 is not a recognised multi-drug resistant cell line (Campling et 
al., 1997; Jensen et al., 1997). However, several multi-drug resistant variant of 
NCI-H69 have been developed. NCI-H69 selected for resistance to etoposide 
(H69/VP) has been reported previously to sequentially overexpress both the 
MRP and MDR1 multi-drug conferring genes (Brock et al., 1995). While NCI- 
H69 selected with daunorubicin (H69/DAU) was found to overexpress ABCB1 
(Jensen et al., 1989) and NCI-H69 selected for resistance to 
adriamycin/doxorubicin (H69AR) w as found to overexpress ABCC1 (Cole et al., 
1992; Mirski etal., 1987).
ABC transporters expression — Members of the ABC transporter 
superfamily known to be involved in multi-drug resistance, ABCC1 and ABCC5 
are the ones most expressed in the NCI-H69 variants. ABCC1 is frequently 
expressed in SCLC cell lines and tumours, while ABCB1 can be detected in 
tumours but rarely in cell line (Campling et al., 1997).
FTC efflux-inhibition assays showed that ABCG2 is not functional in any 
of the NCI-69 cell lines. This is consistent with a  negative literature search on 
ABCG2 expression and SCLC cell lines. To our knowledge no multi-drug
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resistant NCI-H69 subline overexpressing ABCG2 has been selected so far. 
However, the expression of functional drug resistance-related members of the 
superfamily of ABC transporters, such a s  ABCB1, ABCC1, or ABCG2 may be 
affected by drug exposure, although it is likely that cellular pharmacokinetic 
protection is effected through a single dominant extrusion pump (Nieth and 
Lage, 2005).
Pharmacokinetics properties of TPT — With no detectable ABCG2 
activity in any of the NCI-H69 variants it was hypothesized that equivalent 
amounts of drug are been delivered to intracellular targets in the NCI-H69 cell 
lines. Hoechst 33342 fluorescence, as a  surrogate reporter of DNA targeting 
rates, shows variation between the sub-lines in a  manner that corresponds to 
the increment in cell volume of the variants. TPT uptakes, however, did not 
reflect the volume increment in NCI-H69 AP3 compared to NCI-H69 SP, 
probably due to the low affinity of TPT for DNA and the potential modulation by 
lactone ring opening changing the ability to export the drug.
A common feature associated with camptothecin resistance is the 
reduction of the target enzyme activity by downregulation, mutation or a 
combination of both (Losasso et al., 2008; Sorensen et al., 1995). No variation 
of TOP1 expression was observed in the NCI-H69 system. Functional assays 
could find no evidence of changes in drug efflux in the NCI-H69 variants, 
although positive controls using the ABCG2 expressing lung adenocarcinoma 
cell line A549 demonstrated the sensibility of the assay. The conclusion is 
therefore, that the pharmacokinetic of TPT is the sam e across all the variants 
and any differences are not ascribable to ABCG2 function. Further, the 
adherent phenotype state perse  does not confer drug resistance.
Cell adhesion-mediated drug resistance — Although the CAM-DR 
(Rintoul and Sethi, 2002; Sethi et al., 1999) potential in the NCI-H69 variants 
has not been tested in the thesis, a  poly-L-lysine adherent variant previously 
developed w as found to be resistant to several drugs, through survival 
signalling, indicating the possibility to enrich drug resistant variants through non­
specific substrate adherence (Kraus et al., 2002). Again the conclusion is that 
variant enrichment does not confer drug resistance.
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Side population phenotype — ABCG2 shows an intriguing linkage with 
the CSC phenotype, given that enhanced ABCG2 transporter expression 
contributes the defining ability of pluripotential side population of cells to 
exclude the DNA minor groove-binding dye Hoechst 33342 (Hirschmann-Jax et 
al., 2004). Hoechst 33342 has been proven to be a  useful approach to for 
identification and purification of stem-like cells, side population phenotype 
(Kruger et al., 2006; Yano et al., 2005).
A549 side population fraction was detected by variation in 
immunofluorescence staining and Hoechst dye exclusion. According to the 
findings here, the side population fraction represented up to 37.5% of the cells, 
consistent with previous finding showing that A549 displays a strong side 
population (Scharenberg et al., 2002; Sung et al., 2008). Recently, gene 
expression profiles of A549 side population cells showed up-regulation of 
ABCG2 (-2.5-fold) compared to non-side population cells, together with other 
genes (AKR1C1/C2, TM4SF1 and NR0B1) potentially indicative of a  poor 
prognosis in anti-cancer therapy (Seo et al., 2007).
According to the CSC theory, significant ABCG2 function may be 
restricted to cell sub-populations that may vary considerably in frequency in 
human tumours and may have uncertain representation in established cell lines 
from solid tumours. A recent study showed the presence of the side population 
phenotype in six human lung cancer cell lines (NSCLC adenocarcinoma, 
squamous cell carcinoma and lung alveolar cell carcinoma) ranging from 1.5 to 
6.1% of the total population. This side population showed increased resistance 
to multiple chemotherapeutic drugs, notably cisplatin, gemcitabine, and 
vinorelbine, although TPT was not a ssessed  (Ho et al., 2007). No ABCG2- 
dependent Hoechst 33342 side population was observed in any of the variants 
and it is reasonable to conclude that CSCs, as defined by side population 
fractions, are essentially absent from the NCI-H69 system.
Cancer stem cells characteristics — CSCs may contribute to 
tumourigenic and chemoresistant subfractions in a  variety of malignancies, 
including brain tumours, leukemias, and breast carcinomas. Cancer stem cells 
might be of clinical relevance, indeed it could explain why when 99% of cells are 
killed by therapy, the tumour is able to grow again (Vezzoni and Parmiani,
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2008). Therefore, there is a continuing drive to identify functional markers of 
neoplastic cells with stem-like properties (Visvader and Lindeman, 2008). Thus 
there is the possibility that stem-like cells may exist in the NCI-H69 system but 
are defined by markers and function different from ABCQ2. A search for stem ­
like cell markers, not necessarily defining a  stem-like population, that might 
change upon enrichment w as undertaken (figure IV.19). The results revealed 
modulation ALDH1 (aldehyde dehydrogenase 1 family, member A1) with 
reduced expression in NCI-H69 AP3. The family of aldehyde dehydrogenases 
(ALDH) catalyzes the oxidation of aldehydes to carboxylic acids, considered a 
general detoxification process. ALDH1 has a  role in the conversion of retinol to 
retinoic acid, which is important for proliferation, differentiation and survival 
(Vasiliou et a/., 2000). The heavily glycosylated adhesion molecule CD24, is as 
yet the only known ligand for P-selectin. Although CD24 is not a  specific marker 
of cancer stem cells, low levels can characterise breast tumour-initiating cells 
(Visvader and Lindeman, 2008). CD24 expression shows a similar modulation 
to that of ALDH1 with reduced expression in NCI-H69 AP3. CD44 is an 
adhesion molecule with multiple isoforms with roles in signalling, migration and 
homing. The CD44V form is known to confer metastatic properties and was 
found to show elevated expression in NCI-H69 AP3 (Visvader and Lindeman, 
2008). PROM1 (prominin 1 / CD133) is a  transmembrane glycoprotein with a 
potential role in the organization of plasma membrane topology (Bidlingmaier et 
al., 2008) and show a consistent increase in expression from NCI-H69 SP to 
NCI-H69 AP78.
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Figure IV. 19: Solid tumours cancer stem cell markers (from Visvader and Lindeman, 
2008) expression in the NCI-H69 model. Graph representing the raw intensity (without 
per gene normalisation) expression of the average value o f the triplicates from the 
microarray analysis o f selected markers o f cancer stem cells in solid tumours. ABCG5 / 
ATP-binding cassette, sub-family G, member 5, THY1 / Thy-1 cell surface antigen, 
TACSTD1 / tumour-associated calcium signal transducer 1, PROM1 / prominin 1, 
ALDH1A1 / aldehyde dehydrogenase 1 family, member A l.
So far, to our knowledge, no SCLC cell line has demonstrated a Hoechst 
33342 side population phenotype. However, a recent study suggested that a 
SCLC cancer stem cell type could be defined as a PLAUR (uPAR / urokinase 
plasminogen activator receptor) positive. The PLAUR+ cells were also found to 
express CD44 and ABCB1. Those cells were found to demonstrate significant 
resistance to 5-fluorouracil, cisplatin and etoposide (Gutova et al., 2007).
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V. Focus on PSA-NCAM
V.l. Introduction and aims
The PSA-NCAM glycocalyx is subject to modulation under embryonic 
and physiological conditions, altering cell behaviour, cell-cell interactions and 
cell-substrate interplay within a multicellular environment (Johnson et al., 2005; 
Wang et al., 1994). Aberrant expression of the embryonic form of NCAM by 
tumour cells, changing their adhesion, detachment and aggregation properties, 
has been linked with increased invasion and metastatic spread (Daniel et al., 
2000; Suzuki et al., 2005). The sialic acid (Sia, N-Acetylneuraminic Acid, 
Neu5Ac) pathway, with respect to its specific role in PSA decoration of NCAM 
(Bork et al., 2005), is therefore a  potential target for the development of new 
tools and anti-cancer treatments. A focus on the importance of PSA decoration 
of NCAM in SCLC cells could offer drug design opportunities for post- 
translational modification, given its restricted expression in normal adult tissues 
(Walmod eta!., 2004). The inhibition of the polysialic acid synthesis pathway, to 
reduce the metastatic potential of tumour cells, is an exciting new area with very 
little research published to date.
The pathway for sialic acid biosynthesis comprises a succession of 
steps. A/-acetylmannosamine (ManNAc) is the first precursor biosynthesized 
from UDP-A/-acetylglucosamine (UDP-GlcNAc) obtained from the extracellular 
environment. UDP-GlcNAc is then committed to a  series of transformation 
resulting in CMP-sialic acid (CMP-Neu5Ac) production in the nucleus. After 
transport to the Golgi compartment, CMP-Neu5Ac serves a s  a donor for 
glycosylation by one family of sialyltransferases (Wang et al., 2006).
The sialic acid pathway shows tolerance for unnatural ManNAc, indeed 
several enzymes, including the 2 polysialyltransferases, in this pathway can 
accept unnatural substrates. This enzymatic permissiveness can be exploited in 
order to deliver unnatural analogues of sialic acid to the cell surfaces (Charter et 
al., 2000; Jacobs et al., 2001). Recently, Bertozzi and co-workers have 
demonstrated that incorporation of unnatural substrates, for example, N- 
butanoylmannosamine (ManBut), can lead to reversible inhibition of polysialic 
acid expression via this metabolic mechanism. ManBut is subsequently
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converted (via the biosynthetic pathway described above) to an unnatural sialic 
acid derivative that effectively leads to chain termination (Mahal et al., 2001).
The experimental therapeutics them e addressed in this current chapter, 
is the identification and validation of the 2 alpha-2,8-polysialyltransferases as 
drug targets for the development of inhibitors of tumour cell surface polysialic 
acid decoration. In collaboration with medicinal chemists, we have sought to 
explore the catalytic domain of the sialyltransferases in order to develop tools to 
assist in validation of assays for inhibitors of NCAM polysialylation. Our 
collaborators, Prof Patterson and Dr Falconer (Institute of Cancer Therapeutics, 
Bradford), have undertaken the design and synthesis of the carbohydrate-based 
probes informed by computational chemistry. Using molecular modelling of the 
‘sialyl motif active site they sought to explore the catalytic domain of the two a- 
2,8-polysialyltransferases (ST8SIA) in order to develop probes with the potential 
for inhibition of NCAM polysialylation. Since no structural information is 
available on either ST8SIA4 (PST) or ST8SIA2 (STX), they identified the a- 
2,3/a2,8-sialyltransferase of Campylobacter jejuni (Cstll) a s  an appropriate 
alternative model for informing the synthesis of agents to probe the enzyme 
active site 101. Significantly, all sialyltransferases accept the sam e glycosyl 
donor and the “sialyl motif L”, a  sequence of 48-49 amino acids is conserved 
amongst the different enzym es and is potentially required for substrate donor 
binding (Angata and Fukuda, 2003; Datta et al., 1998). In collaboration with Dr 
Mire Zloh (University of London) the Cstll protein structure w as extracted from a 
complex with a  substrate analogue (PDB code 1R07) and used it a s  a  target for 
unbiased docking. Given the close homology of the active binding site of Cstll 
and that of both ST8SIA4 and ST8SIA2, this provided useful information as to 
potential interactions between agents to be synthesised and the human 
polysialyltransferases. This process w as used dock small molecule substrate 
mimics into the active site. Two probes, R1108 (and R890), occupied this space 
preferentially when the computer was asked to dock the molecule through 
energy minimisation anywhere on the protein. Further agents were synthesised 
to explore other design concepts.
Potential ST8SIA4 inhibitors — analogues of sialic acid — are being co­
developed and modelled (Institute of Cancer Therapeutics, Bradford) for 
screening and identifying cellular consequences of modulation. The hypothesis
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is that modulation of polysialic acid decoration of the neural cell adhesion 
molecule (NCAM) using inhibitors of ST8SIA4 (PST) and ST8SIA2 (SIX) a-2,8- 
polysialyltransferases will suppress its capacity to express changes in tumour 
cell-cell adhesion, that promote the opportunity, i.e. for phenotypic alterations 
associated with metastatic potential. Key to this is an exploration of the NCI- 
H69 system as a mean of assessing changes associated with a  restriction of 
PSA decoration of NCAM. The goal is to apply specific inhibitors of NCAM 
polysialylation a s  molecular “tools” to explore the impact of post-translational 
changes in PSA decoration of NCAM on cell-cell contacts, cell adhesion and 
chemosensitivity.
Here the experimental aims were:
>  To analyse and a ssess , using predominantly microarray analysis, 
changes in glycosylation pathways in the NCI-H69 system, with a  focus on the 
sialic acid pathway -  the aim is to a sse ss  the extent of changes in the 
expression of key pathway m embers to determine underlying influences that 
contribute to variation in polysialylation.
> To a sse ss  the relative expression of ST8SIA4 (PST) and ST8SIA2 
(STX) in the NCI-H69 variants -  the aim being to provide evidence of availability 
for inhibition by targeted inhibitor molecules.
> To undertake cellular studies using the NCI-H69 model in order to 
understand the impact of exposure to candidate PST inhibitors with a  focused 
library of modified sialic acid derivatives rationalised to penetrate cellular 
systems and completely inhibit PSA production -  the aim being to a sse ss  the 
impact on PSA expression.
>  To a sse ss  any evidence of apparent off-target activity -  here studies 
involved the microarray analysis to identify candidate off-target activity and the 
selection of a second cellular system to provide supporting evidence.
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V.2. Specific materials and methods
V.2.1. Inhibitors and treatment
ST8SIA4 potential inhibitors were developed and provided by Dr Robert 
Falconer (Institute of Cancer Therapeutics, Bradford). Each compound was 
shipped lyophilised and kept at -20°C upon resuspension. R1108 was 
resuspended in 35% methanol to a  stock concentration of 20 mM. The other 
compounds (ICT 2551 / ICT 2553 / ICT 2554 / ICT 2555) were resuspended in 
50% methanol to a concentration of 10 mM. Benzyl alcohol and benzyl acetate 
were purchased from Sigma Aldrich (St Louis, MO, USA) and kept at room 
temperature.
For treatment with R1108 and the other compounds, cells were seeded 
in standard culture dish and allowed to attach for 24 h prior addition of drugs. 
Every treatment experiment included a control treated with methanol.
V.2.2. Cell lines
NCI-H69 variants cell lines (NCI-H69 SP, NCI-H69 AP3 and NCI-H69 
AP78 — described in chapter III) were used to test the inhibitors. Another variant 
— NCI-H69 AP55 — w as also used to perform the microarray analysis (see 
Appendix e).
The mouse CHO-K1 (Kao and Puck, 1968) and the mouse 
metallothionein-1 (mMT-l)-overexpressing CHO K1 (mMT-CHO-K1) — 
described in Appendix b — were provided by Dr John H Beattie at the Rowett 
Research Institute (Beattie etal., 2005). Following removal of first passage cells 
from liquid nitrogen, single layer cultures of mMT-CHO-K1 and CHO-K1 cells 
were maintained, routinely detached, split and resuspended a s  described 
previously (see H.2.2.).
V.2.3. RT-PCR
Primers were purchased from Eurofins MWG (Ebersberg, Germany) 
shipped lyophilised, resuspended with H20  at a  concentration of 100 pM and
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stored at -2 0  °C. Table V.l describes the primers used to amplify ST8SIA2 and 
ST8SIA4.
Table V.l: RT-PCRprimers (from Seidenfaden et al, 2000).
Name Primers Product size
ST8SIA2 U: 5’ -  TACATCTTCGATCGAGACAGCA- 3’
421 bp
L: 5’ -  TGCTTCAGGATAAGCTCGTTGA-  3*
ST8SIA4 U: 5’ -  TCCGTCATTGAGACTTATTCAT -  3*
262 bp
L: 5’ -  CACATTTAATGTTTTGAATTCT -  3’
Total RNA were extracted (see II.3.2) with TRIZOL (Invitrogen, Carlsbad, 
CA, USA). Reverse transcription w as performed using Reverse-IT™ 1st Strand 
Synthesis Kit (ABgene, Cambridge, UK), according to the manufacturer 
instruction. Briefly, 1.5 pg total RNA w as added to 500 ng of oligodT in a final 
volume of 13 pL and incubated at 70°C for 5 min. Then, 5 mM of each dNTP 
(Bioline, London, UK), 4 pL of 5x reaction buffer and 50 units of Reverse-IT™ 
reverse transcriptase were added to the mix. Reaction w as carried out at 47°C 
for 30 min followed by reverse transcriptase inactivation at 75 °C for 15 min. 
The reverse transcription reaction w as then diluted by 10 and stored at -20°C.
PCR reaction was performed by mixing in a final volume of 20 pL: 1 pL of 
reverse transcription dilution with 2 mM of dNTP mix (Bioline, London, UK), 2 pL 
of 10x reaction buffer (New England Biolabs, Ipswich, MA, USA), 5 pM of each 
primer and 1 unit of Taq DNA polymerase (New England Biolabs, Ipswich, MA, 
USA). The reaction w as carried out in a  thermocycler (MJ Research DNA 
Engine PTC-200, Bio-Rad, Hemel Hempstead, UK) and the cycling parameters 
were: Initial denaturation 95°C / 5 min followed by 40 cycles of denaturation 
95°C /1 5  sec, annealing 55°C / 30 sec  and extension 72°C / 30 sec  and a final 
cycle of extension 72°C / 5 min.
Amplifications were visualised by running 10 pL of the PCR reaction 
along with 2 pL of non-denaturing loading buffer (see Appendix III) on a non- 
denaturing gel. Sam ples were loaded on an agarose gel which w as prepared
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with 1% (w/v) agarose (VWR International Ltd, Lutterworth, UK) in 1x TAE 
buffer (see Appendix III). Gels were electrophoresed at 70-90 V for 30-60 min 
and subsequently visualised under a  UV transilluminator (UVP, Upland, CA, 
USA).
V.2.4. Time lapse imaging
Images were collected over 72 h, every 15 min, for 3 fields per conditions 
(0.5% methanol /  0.03 mM / 0.1 mM or 0.3 mM R1108). Time-lapse images 
were analyzed manually using Metamorph software (Molecular Devices). Each 
cell in the field was tracked individually (figure V.l) and the time to mitosis, 
duration of mitosis and other key cellular events detected by morphology were 
recorded. The classification of the event was determined according to key 
outcomes: a successful mitosis to two daughter cells, a  tripolar or quadripolar 
division, mitosis followed by unsuccessful cytokinesis (polyploidy) event, cell 
death or unknown (for example, cell leaving the field). The duration of the 
mitotic event was also extracted (Marquez et al., 2003).
-158-
Chapter V —  Focus on PSA-NCAM
Event duration
Polyploidy
Event end time
Event s ta rt time
2 daughters Cell death
N ,
Intermitotic time
Outcom e
Figure V .l: Time-lapse imaging analysis. Schematic representation o f the pragmatic 
approach used to analyze time-lapse images, enabling morphometric extraction of cell 
behaviour and delivery to mitosis.
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V.3. Results
V.3.1. Surface glycocalyx modulation
Changes in the cell surface decoration of molecules by complex 
carbohydrates (forming the glycocalyx) is an important m eans by which the 
modulation of cell-cell adhesion and cell-matrix adhesion can be achieved. In 
order to determine if major glycosylation pathways were modulated at the 
transcriptional level, the microarray analysis previously described (2008 arrays) 
was interrogated and compared across the established variants (NCI-H69 SP, 
NCI-H69 AP3 and NCI-H69 AP78) focusing on the known pathways for 
glycosylation and glycan biosynthesis with a  further drill-down on CMP-Neu5Ac 
synthesis and sialylation.
V.3.1.1. Major glycosylation pathways
The list of 1189 probes (representing 2 fold statistically different changes 
in gene expression among the variants) was compared to a well-defined 
pathway obtained from Kyoto encyclopedia of genes and genom es (Kanehisa et 
al.) for glycans biosynthesis and metabolism. Figure V.2 show s the partitioning 
of the changes between the variants (for full list of modulations see  Appendix 
XI). In summary, out of the 302 probes defining the KEGG glycan biosynthesis 
and metabolism pathway, 12 probes differed in their expression profile by at 
least 2-fold when NCI-H69 SP and NCI-H69 AP3 were compared, 13 when 
comparing NCI-H69 AP3 to NCI-H69 AP78 and 4 modulations between NCI- 
H69 SP and NCI-H69 AP78. Of the modulations, 10 represented an increased 
mRNA expression in NCI-H69 AP3 compared to NCI-H69 S P  and NCI-H69 
AP78 (6 and 8 statistically different upregulation by at least 2-fold, respectively). 
Moreover, 7 showed decreased mRNA expression in NCI-H69 AP73 compared 
to NCI-H69 SP and NCI-H69 AP78 (6 and 5 statistically different upregulation 
by at least 2-fold, respectively).
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Figure V.2: Venn-diagram representation o f  glycosylation-related genes expression 
modulation in the NCI-H69 variants. The list o f 2-fold statistically different changes in 
expression in the 3 variants (1189 gene list) was compared to the pathway for glycans 
biosynthesis and metabolism.
To determine if major changes in the sialic acid pathway were 
responsible for the decreased PSA decoration of NCAM in the NCI-H69 AP3 
variant (see chapter III), and to determine if any of those changes occurred in 
the NCI-H69 AP78 with a regain of PSA expression. Microarray analysis was 
undertaken to profile the sialic acid pathway, therefore providing the means to 
map the relative expression. The analysis was performed by determining the 
comparative mRNA expression of enzymes catalysing the steps of the sialic 
acid pathway as well as transporters involved in the transport of the metabolites 
from the different cell compartments (Wang et al., 2006).
Figure V.3 represents the sialic pathway. The expression of only 1 of the 
3 enzymes catalysing the first 4 steps of the biosynthesis was statistically 
changed by over 2-fold. Indeed, the signal for the N-acetylneuraminic acid 
synthase (NANS / sialic acid synthase / SAS), converting ManNAc-6-P to 
Neu5Ac-9-P, was slightly higher for NCI-H69 AP3 when compared to NCI-H69 
SP (1.3 fold increase) and NCI-H69 AP78 (1.5 fold increase) and the
V.3.1.2. Sialic acid pathway in the variants
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differences were statistically different (p-value <0.05). The expression of the 
enzyme responsible for the conversion of Neu5Ac-9-P to Neu5Ac could not be 
determined as there were no probes for EC: 3.1.3.29 on the HG_U133A_2.0 
array. The expression of the bifunctional enzyme GNE (UDP-GlcNAc 2- 
epimerase / ManNAc 6-kinase), known to control the sialic acid production, was 
found to be lower in both adherent cell lines. GNE expression was down by 1.7 
fold in NCI-H69 AP3 and 3.5 fold in NCI-H69 AP78 when compared to NCI-H69 
SP (statistically significant differences). GNE mRNA expression was also 
downregulated in NCI-H69 AP78 when compared to NCI-H69 AP3 (2 fold 
difference, statistically significant). The expression of the nuclear localized 
CMAS (cytidine monophosphate N-acetylneuraminic acid synthetase / CMPNS / 
CMP-sialic acid synthetase / CSS) was unchanged amongst the variants. The 
expression of the transporter involved in CMP-Neu5Ac transport form the 
nucleus to the Golgi — SLC35A1 (solute carrier family 35 member A1 / CMP- 
sialic acid transporter / CMPST / CST) — was statistically significantly 
downregulated in NCI-H69 AP3 when compared to NCI-H69 AP78 and NCI- 
H69 SP (1.5 fold decrease in both cases).
Finally, of the 14 sialyltransferases with probes present on the array, 3 
had unreliable signals (flagged as Absent), 8 showed an unchanged expression 
and 3 had their expression statistically altered. Those 3 enzym es were 
upregulated in NCI-H69 AP3 when compared to NCI-H69 AP78 and NCI-H69 
SP. Moreover, the expression of ST8SIA1 (ST8 alpha-N-acetyl-neuraminide 
alpha-2,8-sialyltransferase 1 / GD3 synthase) was downregulated in NCI-H69 
AP78 when compared to NCI-H69 SP. None of the two sialyltransferases 
involved in NCAM polysialylation were found to have statistically significant 
different expression amongst the variants. ST8SIA2 (STX) had unreliable 
signals (flagged as Absent) on each array. The signal for ST8SIA4 (PST) was 
lower in the NCI-H69 AP3 compared to NCI-H69 AP78 (1.7 fold decrease) and 
NCI-H69 SP (1.5 fold decrease). However, the differences were not statistically 
different.
One other enzyme has been indirectly linked to the polysialylation of 
NCAM, FUT8 (a 1-6 fucosyltransferase) is responsible for the transfer of a core 
fucose on N-glycans (Kojima et a /., 1996). This enzyme had its expression 
significantly downregulated in both NCI-H69 AP3 (10 fold decrease) and NCI-
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H69 AP78 (8 fold decrease) cell lines when compared to NCI-H69 SP (both 
adherent cell lines had every FUT8 measurement flagged as absent).
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Figure V.3: Sialic acid biosynthesis pathway and sialylation o f  glyconjugates (adapted 
from Wang et al., 2006). Figure depicting the comparative microarray analysis of the 
sialic pathway in each of the variants (false-colour view representing the average 
expression of the triplicates). Only sialyltransferases with expression flagged as present 
in at least one sample are represented here. The gene called 3.1.3.2.9 does not have an 
associated probe in the H G U 1 3 3 A 2 .0 . * indicates statistically different expression by 
over 2-fold (p<0.05).
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As no antibodies were available for the detection of ST8SIA2 and 
ST8SIA4 proteins, mRNA expression was confirmed by RT-PCR (figure V.4) 
using primers described by Seidenfaden et al. (2000). ST8SIA2 flagged as 
absent in microarray analysis could only be amplified in NCI-H69 SP, after 40 
cycles and only a weak band could be detected around the expected size of 
421 bp. ST8SIA4 sequence was amplified after 40 cycles for all variants. A 
weak band was detected for NCI-H69 AP3 and stronger band was amplified for 
NCI-H69 SP and NCI-H69 AP78 around the expected size of 262 bp, confirming 
the downregulation of mRNA expression by NCI-H69 AP3 observed by 
microarray analysis.
ST8SIA4
ST8SIA2
Figure V.4: ST8SIA4 and ST8S1A2 expression. Ethidium bromide stained gel depicting 
RT-PCR products, after 40 PCR cycles, for ST8SIA2 and ST8SIA4 for each of the 
NCI-H69 variants.
V.3.2. Chemical-biology approach to intervention on PSA synthesis
Putative PST inhibitors are being developed at the Institute of Cancer 
Therapeutics at Bradford University. Those compounds are designed to target 
the CMP-Neu5Ac binding site on the polysialyltransferases. A compound 
(R1108) was first developed, and despite poor in vivo stability (R1108 had a 
plasma half-life of less than 2 min), was used to inform the development of
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other compounds. Four other compounds were tested (ICT 2551 / ICT 2553 / 
ICT 2554 / ICT 2555) in a preliminary screen for their effect on the NCI-H69 
variants system. Because the last compounds (ICT) were only available in a 
limited quantity only an essential preliminary screen was performed according 
to the findings from the R1108 data.
Each compound was sent to Cardiff after quality controls were performed 
at the Institute of Cancer Therapeutics of Bradford. All compounds are either 
purified by flash chromatography or HPLC or both. All compounds are then 
subject to NMR analysis, which gives identity as well a s  indication of purity. 
Compounds identity is then checked by m ass spectrometry. Therefore all 
batches were used with the confidence that they had the required quality for 
biological screening.
V.3.2.1. First generation compound: R1108
Four batches of R1108 were received over 3 years. Table V.2 presents 
the nomenclature used here to describe the various batches along with their 
date of resuspension, method of purification and stability at -20°C.
Long-term effect of storage on R1108 batches was tested by Dr Andy 
Humphrey (Institute of Cancer Therapeutics, Bradford). Two of the resuspended 
batches (2 and 3) were sent back to Bradford in order to determine compound 
stability and evidence of contamination and/or breakdown products of R1108 
was present. HPLC analysis revealed that R1108 was stable for longer than a 
year at -20°C. Indeed, in the 2 batches resuspended in March 2006 and 
September 2007, R1108 was the major component indicating that the molecule 
has largely remained intact during storage and transit
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Table V.2: R1108 batches.
Batch
number
name used in the 
thesis date of resuspension purification
1 R1108/2005 March 2005 HPLC
2 R1108/2006 March 2006 HPLC
3 R1108/2007 Sept 2007 HPLC
4a R1108/2008a Feb 2008 HPLC
4b R1108/2008b Feb 2008 none
V.3.2.2. Other compounds.
At this point, real concepts of derivative design were being pursued at 
Bradford. The intellectual property behind these compounds was also 
confidential hence each compound was given a  unique code ensuring 
appropriate audit trailing and reporting. Cardiff received one batch of each ICT 
compound in 2007 (table V.3).
Table V.3: ICT compounds.
name
ICT 2551 
ICT 2553 
ICT 2554 
IC T 2555
date of 
resuspension
March 2007 
March 2007 
March 2007 
March 2007
purification
HPLC
HPLC
HPLC
HPLC
V.3.3. Effect on NCAM decoration 
V.3.3.1. R1108
Previous in-lab screening for R1108 effect on NCAM decoration with 
increasing concentration of R1108 (0.03 mM; 0.1 mM and 0.3 mM) showed 
decreased PSA levels after 24 h treatment with R1108. Therefore, the 
consequence of R1108 treatment on PSA decoration w as determined by
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western blotting (figure V.5) using 0.3 mM of R1108/2006. The western blot 
assay showed comparable amounts of PSA after 6 h and 10 h continuous 
treatment. Neither NCI-H69 SP nor NCI-H69 AP78, cell lines with innate 
constitutive PSA decoration of NCAM, showed a response to ST8SIA4 putative 
inhibitor. The tight bands observed on figure V.5 as opposed to the smears seen 
on figure III.5 or V.6, when immunoblotting for PSA-NCAM, can be explained by 
a shorter migration time.
NCI-H69 AP78 NCI-H69 SP
/■---  "V
OH 6H 10H OH 6H 10H
PSA-NCAM
MMNfe Antibody
clone 12F8
Figure V.5: Effect o f R1108 treatment on PSA levels. Western blotting showed no effect 
on PSA decoration o f NCAM after 10 hours treatment o f NCI-H69 SP and NCI-H69 
AP78 with 0.3 mM R1108/2006.
An investigation was undertaken, testing 2 of the batches at 2 doses. No 
effect on the PSA decoration of NCAM could be observed with different batches 
of R1108. Table V.4 details concentrations and length of treatment used.
Table V.4: Effect o f  R1108 different batches on PSA decoration o f  NCAM.
Name treatmentduration
R1108
concentration cell line used
effect on PSA- 
NCAM
R1108/2005
R1108/2006
R1108/2007 
R1108/2008a 
R1108/2008b
/
0/2/4/6/8/10 h
48 h
/
/
/
0.3 mM
0.3 mM /1  mM
/
/
/
NCI-H69 SP and 
NCI-H69 AP78
NCI-H69 AP78
/
/
/
none
none
/
/
V.3.3.2. ICT compounds
The ICT compounds effect on PSA decoration of NCAM was investigated 
by western blotting. NCI-H69 SP cells were treated for 24h with 0.3 mM or 1
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mM of compounds. As shown in figure V.6, in the absence of compounds 
(control lanes) PSA-NCAM was detected as a smear spreading around 250 
kDa. Of the 4 compounds, only ICT 2555 showed a band with reduced intensity 
after 0.3 mM treatment. Upon 1 mM treatment, while ICT 2551 and 2253 still 
showed no effect on PSA decoration of NCAM, ICT 2555 and ICT 2554 both 
showed a reduced PSA-NCAM detection.
0.3 mM 1 mM
^
i/~>  i n  m
GAPDH
Figure V.6: Effect o f  24h ICT compounds treatment on NCAM decoration. NCI-H69 SP 
cells were treated for 24 h continuous treatment with a final concentration o f 0.3 mM or 
1 mM of compound.
V.3.4. Cytotoxicity
As in many biological system, the modulation of a single factor can have 
unexpected side-effect. In order to determine if the compounds had any related 
cytotoxicity on the NCI-H69 cell lines, cells were incubated with various amount 
of compounds and monitored.
V.3.4.1. R1108: dose-dependant cytotoxicity
NCI-H69 AP3 and NCI-H69 SP cells were treated continuously over 48 h 
with 0.3 mM R1108/2006. After 48 h, most cells showed a rounded and 
shrunken morphology indicating that cells were undergoing cell death (figure 
V.7). The collected images clearly showed an unexpected response to the
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exposure to R1108/2006. The toxic effect also seemed to be independent from 
ST8SIA4 expression since NCI-H69 AP3 expresses low level of ST8SIA4.
N C I-H 6 9  A P 3  N C I-H 6 9  A P 7 8
control
a*
v $
%
0.3  m M  
R 1 1 0 8 /2 0 0 6
Figure V.7: Effect o f  a 48h R1108 treatment on NC1-H69 variants cell lines. NCI-H69 
AP3 and NCI-H69 AP78 cells were treated for 48 h continuous treatment with a final 
concentration of 0.3 mM R1108/2006. Calibration bar represents 50 pm.
The biological effects of treatment with the unnatural carbohydrate 
R1108 at different doses were observed using time lapse microscopy. Figure 
V.8 shows representative phase-contrast images from a time-lapse movie. This 
investigation was undertaken with NCI-H69 AP3, the adherent variant allowing 
time lapse analysis and isolation of any possible ST8SIA4 effect due to R1108 
treatment. The intention was to record growth (increase in cell number) and to 
record morphology / combined retractile properties. The control fields showed 
normal mitotic progression throughout the experiment with cells reaching 
confluence at 70 h. Cells from the control field had the appearance of bright 
cells with distinct dark edges. Upon treatment with 0.3 mM R1108/2006 there 
was no increase in cell number over 70 h. Further, cells showed a change of 
contrast to a dull / black appearance, probably indicating a highly stressed dying
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cell as early a s  10 h with clear signs of cell death occurring from 20 h. When 
lowering the dose, no cell growth w as recorded upon treatment with 0.1 mM, 
while at 0.03 mM som e cell growth occurred (10-20 h) however slower than the 
control fields. After this period of mitotic arrest, cells underwent cell death, 
observed at 30 h (0.1 mM) and 50 h (0.03 mM). No cell survival w as observed 
for the two highest doses with every cell dead and detaching from the substrate 
at 40 h for the 0.3 mM dose and all cells dead at 70 h for the 0.1 mM dose. 
While for the cells incubated with the low dose (0.03 mM), a sub-population of 
cells was still alive after 70 h of treatment.
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Figure V.8: R1108 toxicity. NCI-H69 AP3 cells were treated continuously over 70 h 
with 0.03; 0.1 or 0.3 mM R 1108. Calibration bar represents 100 pm.
These results indicate that R1108 has a cytotoxic, dose-dependent effect 
that seems to be independent of the PSA content of the cells, as the response 
was similar for all variants. However, the cytotoxicity impact has varied across
control 0.03 mM 0.1 mM 0.3 mM
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all the batches and to som e extent in one of the  batch over time (Table V.5). The 
inconsistency has not been associated with R 1108 stability.
Table V.5: R1108 batches — toxicity profile.
N Toxicity upon Toxicity in R1108 concentration
ame resuspension Oct 2007 Nov 2007
R1108/2005 yes no /
R1108/2006 yes yes > 95%
R1108/2007 no no > 95%
R1108/2008a no / /
R1108/2008b no / /
V.3.4.2. A role for R1108 metabolic products in cytotoxicity?
Due to its chemical structure, R1108 is expected to be labile when 
exposed to e ste rases within cells. An es te rase  reaction would metabolise 
R1108 and release benzyl alcohol. To determ ine the potential anti-proliferative 
effects of R1108 breakdown products, the time lapse assay  was repeated as 
before. NCI-H69 AP3 cells were treated continuously with 0.3 mM R1108/2007, 
0.3 mM benzyl alcohol (Sigma-Aldrich, St Louis, MO, USA) and 0.3 mM benzyl 
acetate (Sigma-Aldrich, St Louis, MO, USA) for 96h. Figure V.9 indicates 
snapshot at 0 h, 48 h and 96 h of the treatm ent. Over the 96 h of treatment all 
cells showed normal growth characteristics, a s  a result of normal mitotic 
progression. Furthermore, cellular morphology including cell-cell and cell- 
substrate interactions showed that the cells w ere unaffected by the addition of 
R1108/2007 and any potential breakdown products.
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benzyl benzyl
control alcohol acetate R1108
Figure V.9: Benzyl alcohol effect on cells. NCI-H69 AP3 cells were treated with 
methanol, 0.3 mM benzyl alcohol, 0.3 mM benzyl acetate or 0.3 mM R1108. 
Calibration bar represents 50 pm.
V.3.4.3. A role for purification regimen of R1108 compound?
As a result of feedback from the medicinal chemists and discussion on 
the potential source for R1108 cytotoxicity, further analysis was undertaken to 
address if the cytotoxicity was due to an incomplete purification process. 
Therefore, un-purified R1108 was tested on the NCI-H69 cell system alongside 
its fully HPLC-purified counterpart (figure V.10). Time-lapse microscopy analysis 
showed that long-term incubation with either compound had no cytotoxic 
effects. NCI-H69 SP cells maintained a highly clustered and retractile 
morphology, with normal growth characteristics, while NCI-H69 AP78 showed 
the characteristic flattened adherent phenotype producing monolayer of cells 
after 120 h (figure V.lOa). A higher dose was also tested in order to determine if 
the lack of cytotoxicity could be concentration-related. NCI-H69 AP3 and NCI- 
H69 AP78 were treated continuously with 1 mM of R1108/2008a and 
R110872008b over 48 h (figure V.lOb). Both cell lines showed normal
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morphological cell attributes and an unchanged growth characteristic upon 
treatment with both compounds.
n
control HPLC-purified Non-purified
R1108 R1108
NCI-H69 SP
NCI-H69 AP78
k* control HPLC-purified Non-purified
R1108 R1108
NCI-H69 AP3
NCI-H69 AP78
Figure V.1Q: R1108 purification batches, a. NCI-H69 SP and NCI-H69 AP78 were 
treated continuously with 0.3 mM R1108/2008a or R1108/2008b for 120 h. b. NCI-H69 
AP3 and NCI-H69 AP78 were treated continuously with 1 mM R1108/2008a or 
R1108/2008b for 48 h. Calibration bar represents 50pm.
V.3.4.4. IC T  compounds
As R1108 had an unexpected toxic effect on cells, the other unnatural 
sialic acid analogues were tested for toxicity. Cells were initially treated with the 
same high concentration used for R1108 treatment. Images (figure V .lla ) at 24 
h after a 0.3 mM treatment showed that NCI-H69 SP cells were unaffected by
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treatment with any of the compounds. Indeed, comparable cell growth and cell 
retractility between the controls and treated wells were observed.
To investigate whether those compounds could induce death at a higher 
dose, cells were also treated with 1 mM of agent. When treated with 1 mM 
compound a change in contrast could be observed for 3 compounds, ICT 2553, 
ICT 2554 and ICT 2555. However, cell numbers remained similar to the control 
wells. Moreover, flow cytometry cell viability analysis of cells treated with either 
0.3 mM or 1 mM indicated that there was no detectable increase in cell death 
upon treatment (figure V .llb ). Indeed, around 50% of the control cells and 
between 40- and 55% of treated cells were positively stained with PI.
control ICT 2551 ICT 2553 ICT 2554 ICT 2555
control ICT-2551 ICT-2553 ICT-2554 ICT-2555
Figure V. l l :  Induction o f  cell death by candidate PST inhibitors. NCI-H69 SP cells 
were treated for 24 h with 0.3 mM or 1 mM of each compound (n=l). a. Snapshots at 24 
h showing cell morphology and cell growth. Calibration bar represents 50 pm. b. Flow 
analysis o f PI treated cells.
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V.3.5. R1108 toxicity: microarray study
Microarray analysis was performed to determine if the compound- 
induced cell death w as due to specific and/or non-targeted effects and to 
identify possible mechanism s of cell death. In order to separate the toxicity 
effect from other possible effects, the drug concentration (0.3 mM R1108/2005) 
resulting in rapid and total growth inhibition and cell death was chosen. Cells 
were given sufficient time for a transcriptional response but short enough to 
avoid the occurrence of cell death. Therefore, NCI-H69 SP and NCI-H69 AP55 
were treated continuously for 6 h with 0.3 mM R1108/2005. After 6 h, cells did 
not show any cell death event, therefore treated and untreated cells were 
processed for analysis of transcriptional responses with high-density 
oligonucleotide microarray on Human Genome U133A arrays. Arrays were then 
probed and scanned as  previously described (see chapter II).
Quality control of hybridizations performed as previously described 
(chapter II and III) identified a chip with high background and noise (see appendix 
XII —  figure 1 and 2). Therefore, two analyses were performed: one with and 
one without the lesser quality chip. Microarray analysis w as performed as 
described in chapter II. The analysis including the outsider showed only little 
difference when compared to the analysis excluding it (see appendix XII —  figure 
3). Indeed, only 4 more probes passed  the statistical analysis in the study 
including the high background array. The following w as based on the analysis 
performed with all arrays, therefore including the 4 probes identified as less 
reliable properly indicated (see also appendix XII —  Table 1).
Application of statistics (T-test) to the microarray data revealed that the 
signal of 485 probes w as significantly altered upon R1108 treatment in NCI-H69 
AP55 and 1081 probes in NCI-H69 SP. After filtering for probes for a 
requirement of a 2-fold change or greater in signal, 15 in NCI-H69 SP and 17 in 
NCI-H69 AP55 probes remained (figure V.12). Among those alterations, there 
was only 1 downregulation in NCI-H69 SP and none in NCI-H69 AP55. 
Moreover, 12 of these alterations were common upregulation in both cell lines. 
Therefore microarray analysis revealed similar responses to R1108 by both cell 
lines having different ST8SIA4 expression.
-176-
Chapter V  —  Focus on PSA-NCAM
NCI-H69 SP NCI-H69 AP55
b.
1  20000■o
£
2 18000 ■o
S
|  16000
o u
£ 14000a.
<§ 12000 
10000 
8000 
6000 
4000 
2000 
0
NCI-H69 SP NCI-H69 SP NCI-H69 AP55 NCI-H69 AP55
control R1108 control R1108
Figure V.12 Transcriptional responses to R1108. Only 15 (NCI-H69 SP) and 17 (NCI- 
H69 AP55) probes were found to have a statistically significant increase or decrease 
signal upon R1108 treatment, a . Venn diagram representing the change in expression 
profile, b. Co-plot o f the raw data expression (average value o f the triplicates) profile 
across all treatment regimen. From left to right: KIF18A, ZNF323, GDF15, GCLM, 
SLC30A1, MT1E, MT1M, AF078844, HSPA1B, HMOX1, MT1F, HSPA1A, MT1F, 
HSPA1A, MT1X, MT1G, RPL35, MT1H, MT1X and MT2A.
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V.3.5.1. Induction of stress-related genes
The 20 identified probes, listed in table V.6, represent 17 genes. These 
genes are mainly represented by molecules involved in response to oxidative 
stress pathway. The most highly induced gene in the NCI-H69 SP cell line upon 
R1108 treatment w as heme oxygenase 1 (HMOX1), while metallothionein 1X 
(MT1X) was the highest upregulation in NCI-H69 AP78 cell line. Seven of the 
identified genes were metallothionein (MT) isoforms. The list of differentially 
expressed genes upon R1108 treatm ent was compared to the expression 
profile of the NCI-H69 variants (2008 arrays). Analysis showed that there was a 
downregulation of constitutive expression of 10 of the genes identified as 
inducted by R1108 treatment.
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Table V.6: Transcriptional responses to R1108. List o f the genes with their expression 
statistically altered. Shaded cells show statistically significant > 2-fold changes, (a) fold 
change R1108 vs. control for NCI-H69 SP. (b) fold change R 1108 vs. control for NCI- 
H69 AP55. (c) fold change NCI-H69 SP control vs. NCI-H69 AP55 control. Genes that 
passed only one of the analyses are indicated in italics. The false-colour cluster view 
represents the expression (average value o f the triplicates) for each cell line on the 2008 
arrays.
1 5
Aflymetrix gene
name symbol descritpion
NCI- 
H69 SP
(a)
fold change 
NCI-
H69 controls 
AP55 (c)
_________
2008 array
SP AP3 AP78
203665 at HMOX1 heme oxygenase (decycling)
1
204326_x_at M T1X metallothionein IX
204745_x_at MT1G metallothionein 1G
20858 l_x_at M T1X metallothionein IX
206461_x_at MT1H metallothionein 1H
217165_x_at MT1F metallothionein IF
212185_x_at M T2A metallothionein 2A
213629_x_at MT1F metallothionein IF
211456_x_at RPL35 ribosomal protein L35
210524_x_at A F078844 similar to metallothionein
IF
212907_at SLC30A1 solute carrier family 30
(zinc transporter), member 
212859_x_at MT1E metallothionein IE
216336_x_at MT1M metallothionein 1M
221577_x_at GDF15 growth differentiation
factor 15
221258_s_at KIF18A kinesin family member 18A
200800_s_at HSPA1A heat shock 70kDa protein
1A
20258 l_at H SPA 1B heat shock 70kDa protein
IB
200799_at HSPA 1A  heat shock 70kDa protein
1A
203925_at GCLM glutamate-cysteine ligase,
modifier subunit 
222016_s_at ZNF323 zinc finger protein 323;
ZNF310P, ZNF20-Lp
16.95 14.2 0.995
13.71 43.13 0.239
13.38 19.5 0.415
12.62 22.37 0.406
10.62 19.08 0.409
9.161 9.966 0.784
8.901 17.77 0.388
8.293 6.456 0.59
6.567 8.533 0.746
5.43 3.154 0.535
3.988 5.258 0.867
3.563 1.253 0.31
3.493 2.516 0.639
2.524 1.677 0.0993
0.447 0.794 1.637
4.009 3.142 0.756
2.687 2.494 0.829
2.15 2.464 1.172
1.553 2.135 2.321
2.036 2.104 0.959
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V.3.5.2. MT induction validation
V.3.5.2.1. MT induction upon R1108/2006 treatment
Induction of metallothionein at the protein level was confirmed by 
western blot analysis on the whole cell lysate of NCI-H69 SP and NCI-H69 
AP78 cells treated with 0.3 mM R1108/2006 for 0, 6 or 10 h, using the E9 
antibody that recognizes MT isoforms 1 and 2 (figure V.13a). Down regulation of 
MT basal level in NCI-H69 AP78, suggested by the microarray analysis, was 
not confirmed by western blotting. Whereas, induction in both cell lines was 
confirmed. Indeed, a similar increase in MT protein expression was observed 
from 6h after treatment for NCI-H69 SP and NCI-H69 AP78. Moreover, 
treatment of NCI-H69 AP3 cell line with a non-toxic batch of the compound 
(R1108/2007) did not induce MT (figure V.13b), confirming that toxicity and MT 
pathway induction were linked.
NCI-H69 A78 NCI-H69 SP
lOkDa
Oh 6h lOh Oh 6h lOh mMT-CHO
MT E9
benzyl 
control alcohol
benzyl
acetate R1108
10 kDa —►
MT E9
Figure V.13: Immunoblotting detection o f  metallothionein induction, a. NCI-H69 AP8 
and NCI-H69 SP treated with 0.3mM o f R 1108/2006 for 0, 6 or 10 h. Data is 
representative o f 2 independent experiments, b. NCI-H69 AP3 treated for 24 h with 0.3 
mM of R 1108/2007, benzyl alcohol or benzyl acetate (n=l).
V.3.5.2.2. ICT compounds
In order to assess whether induction of the metallothionein pathway is 
related to the type of compound, western blotting detection of metallothionein 
after 6 h treatment with the ICT compounds (data not shown) was performed 
and showed no induction. However, ICT compounds were found not as toxic as
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R1108, therefore a higher concentration of compounds was used along with 
higher incubation time. After 24 h treatment with 1 mM of the compounds, 2 of 
the compounds (ICT 2553 and ICT 2554) — who induced changes in contrast 
of treated cells after 24 h treatment — also induced MT when treated with 1 mM 
ICT 2553 and ICT 2554 (figure V.14), therefore showing similarity with R1108.
1oo
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— cn mm in in min in m
fN ts CN <N
H H E-1 H
U y U b
* .......
1 mM
m  inm  m
(N CM
H HU U
Tf min  mm  m<NE—1 
V
E—1 O
lOkDa 
35 kDa
Figure V.14: Immunoblotting detection o f  metallothionein induction after 24 h 
treatment. NCI-H69 SP cells were treated with 0.3 or 1 mM of each PST compounds for 
24 h (n=l).
V.3.6. M etallothionein
The discovery of the metallothionein induction effect, irrespective of the 
mechanism of induction per se, raises the issue of whether cells may have 
different capacities to demonstrate induction (off-target effects) -  complicating 
the assessment of future second generation agents. Therefore, to test the 
hypothesis that enhanced constitutive metallothionein expression leads to 
reduced toxicity of R1108, we used the mouse metallothionein-overexpressing 
CHO, mMT-CHO-K1 (Smith et a/., 2008). The mMT-CHO-K1 cell line 
overexpresses MT1 (figure V.15). R1108 effects on the transfected and parental 
CHO-K1 were studied using time-lapse microscopy.
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 MT E9
lOkDa 9
Figure V.15: mouse Metallothionein-1 overexpressing CHO. Immunoblot showed the 
relative expression o f MT-1 and MT-2 by wild-type and MT-1 transfected CHO-K1. 
Data is representative o f 3 independent experiment.
V.3.6.1. Inhibition of CHO growth by R1108
We compared the growth of cells treated with various concentrations of 
R1108/2006. Figure V.16 shows the growth profile derived from time-lapse 
analysis. Increasing concentrations of R1108 caused a dose-dependent 
decrease in growth of parental and transfected cell lines treated in vitro for 3 
days. No effect on population growth was observed for the low dose of R1108. 
Growth rate was slower for the transfected cell line at 0.1 mM R1108, as seen 
by the 70% inhibition of growth rate for the WT and 85% inhibition of growth rate 
for the transfectant cell line after 60 h. Complete inhibition of the population 
growth for both cell types was observed at 0.3 mM R1108.
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Figure V.16: Effect o f  a range o f  R1108/2006 concentrations on the growth o f  the 
population o f  CHO-Kl and mMT-CHO-Kl. Cells in each field were counted every ten 
hours (equivalent to 40 frames). Cell numbers for each field were normalised to the 
number o f cells at the beginning o f the experiment for that field. Each point represents 
the mean ± SD o f n = 3 fields.
However, both CHO-K1 cell lines appeared to be more resistant to 
R1108 than the NCI-H69 variants. Indeed, even with 0.3 mM R1108 treatment, 
cell survival could be observed for the transfected as well as for the parental cell 
type (figure V.17). The control fields of each cell types showed normal mitotic 
progression with confluence reached at 60 h. Observation of the mitotic process 
showed that cells treated with 0.3 mM of R1108 underwent mitosis resulting in 
polyploidy.
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Figure V.17: Effect o f  various concentrations o f  R1108 on cell growth. Still images 
from the time-lapse sequence taken at 0 h, 30 h and 60 h. Cells were treated with 0.3 
mM R1108/2006. Calibration bar represents 50 pm.
V.3.6.2. Effect on mitosis
In-depth analysis of time-lapse by tracking single cells through 3 
successive events revealed that R1108 treatment induced a higher incidence of 
polyploidy events (Figure V.18). Cells in control fields and cells in fields treated 
with 0.03 mM R1108 (data not shown) progressed normally through the cell 
cycle (more than 95% of events resulted in successful mitosis). When treated 
with 0.1 mM R1108, 85% of the first generation of CHO-K1 cells went through a 
normal mitosis, while 8% of cells underwent polyploidy. The second generation 
of cells continued mostly through normal mitosis (47%). There was, however a 
higher polyploid induction (39%). Around half the cells of the third generation 
still went through normal mitosis. The analysis also showed an increase of cell 
death throughout the events (3% at first event, 11% at third event). A decreased 
rate of successful mitosis (73% mitosis at the first event decreased to 30-20%
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at event 2 and 3) w as observed in fields of mMT-CHO-K1 cells treated with 0.1 
mM R1108 while there w as an increase in the occurrence of the polyploid event 
(60% polyploidy for the second generation and 40% for the third). Similar to the 
CHO-K1, an increase of cell death w as observed (0% at first event, 7% at the 
second event and 8% at third event). When treated with the high dose of 
R1108, no events were recorded for ~32% of the initially seeded CHO-K1 
throughout the 90h time-lapse, while the proportion is ~1.5% for the mMT-CHO- 
Kl cells. Moreover, 17% of the first generation of CHO-K1 cells died and only 
1% for the mMT-CHO-K1. Around 2% of first generation cells went through 
normal mitosis for both cell types. Finally, 94% of the first generation of mMT- 
CHO-Kl cells, followed by 82% of the second generation, engaged in polyploid 
event (40% and 20% for CHO-K1 cells).
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Figure V.18: Effect o f  increasing concentrations o f  R1108 on the mitotic outcome o f the 
CHO cell lines over three generation. Data is representative of two independent 
experiments.
Time-lapse analysis also showed an increase of intermitotic time (IMT / 
mitosis to mitosis) and mitotic duration. Figure V.19 graphically shows the 
duration of mitosis and the mean intermitotic time for progenitor cells and 
subsequent progeny. The data show no significant impact of MT-1 expression 
on intermitotic time or mitotic duration (controls). Control cells and cells treated
- 186 -
Chapter V  —  Focus on PSA-NCAM
with 0.03 mM R1108 showed comparable intermitotic time (-14 h) and mitotic 
duration (-48 min). Upon treatment with 0.1 mM R1108, a slight increase of the 
intermitotic time (-17 h) and the mitotic duration (3 h, CHO-K1 and 4 h, mMT- 
CHO-K1) could be observed for both cell types. Treatment of CHO-K1 cells with 
0.3 mM R1108 induced a much larger increase in mitotic duration (-8 h) and 
intermitotic time (28 h, IMT1 and 24h IMT2). Transfected cells also showed a 
longer IMT (-22 h), however shorter than the CHO-K1. Mitotic duration of the 
mMT-CHO-K1 was also elongated upon 0.3 mM R1108 treatment (7 h / 6 h / 5 
h).
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Figure V.19: Effect o f  various concentrations o f  R1108 on the mitotic duration and the 
intermitotic time (IMT). Data is representative o f two independent experiments.
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V.4. Discussion
PSA decoration of NCAM, by directing tumour growth, invasion and 
m etastasis (Daniel et al., 2001; Seidenfaden et al., 2003; Suzuki et al., 2005) 
and given its restricted expression in normal adult tissues (Walmod et al., 
2004), offers drug design opportunities for post-translational modification. 
Developmentally, PSA is assem bled on the surface of NCAM in the developing 
brain and facilitates neural tissue development by modulating the inhibition of 
cell-cell contact -  a  function potentially re-iterated in micro- and macro-SCLC 
cell m asses. Importantly, in normal cells by adulthood PSA-decorated NCAM is 
virtually non-existent, only occurring at limited defined sites in the brain, 
increasing the potential for selective targeting.
Here the approach w as to reversibly inhibit the polysialyltransferases 
activity. The development of the small cell lung cancer cell-adherence 
phenotype system  provides a  model for measuring the consequences of 
enforced changes in NCAM polysialylation through the targeting of the 
biosynthesis pathway for NCAM decoration. In collaboration with the medicinal 
chemistry drug discovery group at ICT (University of Bradford) a series of 
studies have been performed to support the design and synthesis of 
carbohydrate-based agents, informed by computational chemistry, targeted at 
the biosynthesis pathway for NCAM decoration. Such investigational tools 
(ST8SIA inhibitors) may also shed light on the validity and rationale for targeting 
the pathway for the development of new anticancer strategies. Thus a 
secondary purpose of the studies reported here w as to explore the NCI-H69 
model further for possible deployment in candidate drug evaluation programmes 
given the potential to translate the model into xenograft system s.
NCI-H69 variants and glycosylation — Microarray analysis identified 
mostly variation in expression of glycosylation-related genes in the NCI-H69 
AP3 variant. Interestingly, heparanase (HPSE) w as found upregulated in NCI- 
H69 AP78 when com pare to NCI-H69 SP and NCI-H69 AP3 (1.8 and 3.7 fold 
respectively). HPSE has been shown to degrade heparan sulfate (HS) on the 
cell surface and extracellular matrix, with physiological functions in wound
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healing, development and HS turnover (Nasser, 2008). Moreover, HSPE has 
been found to mediate cell adhesion to ECM, integrin-dependent cell spreading 
and reorganisation of the actin cytoskeleton. HSPE w as also found to function 
as  an adhesion molecule independently of its enzymatic function (Goldshmidt et 
a/., 2003). HPSE overexpression is found in a  variety of cancers, where it is 
implicated in tumour growth, angiogenesis, m etastasis and inflammation 
(Nasser, 2008). Another intriguing identification w as the downregulation of the 
glucuronic acid ep im erase (GLCE) in NCI-H69 AP3 when compared to NCI-H69 
SP and NCI-H69 AP78 (1.4 and 2.3 fold respectively). GLCE has been 
previously found to be downregulated in breast cancer (Grigorieva et a/., 2008).
NCI-H69 variants and the sialic acid pathway — GNE (UDP-GlcNAc 2- 
epimerase /  ManNAc 6-kinase), a  key determinant of the sialic pathway was 
found downregulated in both adherent cell lines. GNE is known to control sialic 
acid pathway. Indeed, GNE regulates the sialic acid synthesis with an inhibitory 
feedback from CMP-Neu5Ac. Therefore controlling the cellular sialic acid 
concentration, limiting both polysialyltransferases and regulating the 
polysialylation of NCAM (Bork et al., 2005; Keppler et at., 1999). However GNE 
downregulation in NCI-H69 P78 (the variant cell line with high PSA) showed not 
effect on PSA expression.
FUT8 (fucosyltransferase 8 (alpha (1,6) fucosyltransferase) w as found 
downregulated in both adherent cell lines. FUT8 adds a  fucose in a 1 ,6 linkage 
to the Asn-linked GlcNAc in the A/-glycan core. FUT8 is the only mammalian 
protein responsible for core fucose on glycans (Wang et al., 2005b). While early 
studies suggested that the presence of an a  1,6 core fucose w as required for 
PSA decoration of NCAM by the two transferases (Kojima et al., 1996), in mice 
in vivo various combinations of glycans were found to be polysialylated 
(including unfucosylated A/-glycans) (Galuska etal., 2008).
Several factors have been suggested to influence the 
polysialyltransferases expression level, such a s  retinoic acid (Angata and 
Fukuda, 2003). A study also uncovered a  role for the developmental 
transcription factor PAX3 (3 paired box 3) in NCAM polysialylation. Indeed, 
PAX3 overexpression w as linked with increased NCAM polysialylation through
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regulation of STA8SIA2 expression (Mayanil et a/., 2000). PAX3 expression 
levels across all the NCI-H69 variants were similar.
NCI-H69 variants and polysialyltransferases — Consistent with previous 
finding (Scheidegger et al., 1995), NCI-H69 SP w as found to express both 
ST8SIA2 and ST8SIA4. ST8SIA2 mRNA could not be detected in both adherent 
cell lines while low levels were detected in NCI-H69 SP. ST8SIA4 w as found to 
be downregulated in NCI-H69 AP3 but still detectable by RT-PCR. ST8SIA4 
mRNA level were found to be equivalent in NCI-H69 SP and NCI-H69 AP78, 
suggesting ST8SIA4 alone is not responsible for higher PSA content in NCI- 
H69 AP78. The implications of NCI-H69 SP, expressing both
polysialyltransferases while NCI-H69 AP3 and NCI-H69 AP78 express only 
ST8SIA4 remain to be elucidated.
These results confirm the presence of the enzym e target in all 3 cell 
types, with different expression level and population heterogeneity, suggesting 
the usefulness of the NCI-H69 model for inhibition and target validation studies. 
Moreover, unlike an engineered system  with a high expression level of 
sialyltransferase, the NCI-H69 variant model provides a range of endogenous 
levels of sialyltransferases expression leading to the dynamic range of PSA 
decoration found in tumours. This offers the possibility to study the implication 
of variation in the sialic acid pathway, a s  well a s  polysialyltransferases 
expression, on PSA decoration. NCI-H69 AP3 could also provide a  test of 
potential off-target activity of inhibitors.
NCI-H69 variants and polysialyltransferases inhibition — New 
therapeutic strategies are urgently needed that contain the m etastatic disease 
state without further compromising tumour chemosensitivity. The linked 
therapeutic concept that underpins the experimental therapeutics context of the 
thesis is that m etastatic potential may be m anaged for critical periods in 
therapeutic regimens by limiting the natural exploration of phenotypic plasticity 
even in tumour cells that have accrued critical genetic lesions. The specific 
proposal is to engineer features of the tumour cell glycocalyx (in this case  PSA 
decoration of NCAM) to reduce the potential for the expression of critical drivers
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for metastatic spread and to extend therapeutic windows for other agents 
without the accrual of drug resistance. The control of glycocalyx ‘plasticity’, 
operating through changes in NCAM decoration, is an attractive proposition 
both in terms of tools to explore the consequences of plasticity and as  a 
rationale for drug discovery through in vitro target validation and m echanism s of 
action studies. An early model (Acheson et al.} 1991) of glycocalyx dynamics 
makes the striking prediction that PSA could affect not only NCAM function, but 
also other ligands not directly involved in NCAM-mediated adhesion -  widening 
the possible functional impact of PSA targeted agents.
The chapter primarily focuses on an exemplar first generation compound, 
while techniques for agent purification and synthesis were also undergoing 
optimisation. A practical objective of the work w as to a sse s s  the potential for 
inhibition of polysialylation and thereby inform the design and synthesis of 
second generation related compounds. This first compound — R1108 — 
showed, in an initial screen, knockdown of cell surface detectable PSA-NCAM, 
with no apparent effects on NCAM expression, but induction of a  toxic 
response. Due to low in vivo stability R1108 could not be considered as a  
possible in vivo agen t and the synthesis route w as not pursued. Nevertheless, 
in order to inform the synthesis of other compounds, investigations on the 
cellular consequences and PSA-NCAM of R1108 expression in the SCLC 
variants were completed.
Studies using R1108 were limited essentially by the quantity of 
compound available and the inconsistency between the batches, combined with 
the fact that early analysis were performed while establishing in parallel the 
NCI-H69 variant system . However, despite the limitations of such a study, 
undertaking this chemistry-biology collaboration provided the necessary 
foundation for establishing (i) compound handling, (ii) adequate quantities for 
analysis and (iii) audit trailing. Four other compounds were also received and, 
due to restricted quantities, allowed for a  single screen for PSA down-regulation 
and cellular toxicity. It w as not possible to ascertain the reason for the inter­
batch variability -  chemical integrity w as assured by NMR, MS and elemental 
analysis although the  possible p resence of a  minor (less than 1%) impurity 
contributing to som e observed effects cannot be ruled out.
-191-
Chapter V — Focus on PSA-NCAM
NCI-H69 variants and polysialyltransferases inhibitors development — 
Overall, with the exception of ICT 2555, there w as no indication of PSA 
decoration of NCAM knock-down upon treatm ent with any of the  Bradford 
compounds.
NCI-H69 variants and R1108 toxicity — Despite inter-batch variability, 
two of the batches showed an intriguing dose-dependent toxicity. R1108 toxicity 
could not be linked to breakdown products. Therefore, using microarray 
analysis, we investigated the perturbation of the system  with an agent targeting 
a specific step in the polysialic acid pathway. Interestingly, after 6 hours of 
treatment, no death-related transcriptional activity w as detected and there was 
no-sialic acid pathway-related g en es  expression modulation.
The microarray signature of R1108 treatment can be linked to stress- 
pathways. Indeed, heat shock proteins A1 (HSPA1 / HSP70), hem e oxygenase 
1 (HMOX1 and metallothioneins (MT) are well know actors involved in stress 
responses, such a s  oxidative s tre ss  (Ferrandiz and Devesa, 2008; Palmiter, 
1998; Schmitt et al., 2007). Also, common induction of som e of these  proteins 
could be found — such a s  HMOX1 and MT2A induction caused by the 
antineoplastic, gallium nitrate (Yang and Chitambar, 2008) or induction of 
HMOX1, MT and HSP70 after cadmium exposure — only one study showed a 
similar signature to R1108. Interestingly, this study showed the induction of 
HSPA1A, GCLM, MT1, MT2, GDF15, SLC30A1 and HMOX1 in 
biochemechanically stretched cardiomyocytes (Frank etal., 2008). Interestingly, 
cell death and metallothionein seem ed to be provoked by the other ICT 
compounds. However, higher concentration and longer compound/cell contact 
time were necessary, perhaps reflecting differences in cell membrane 
penetration of the agen ts investigated.
Metallothionein —  Metallothioneins (MTs) play a  role in both zinc and 
copper hom eostasis and com prise a class of ubiquitously-occurring low 
molecular weight cysteine- and metal-rich proteins, containing conserved sulfur- 
based metal clusters, with diverse functions including potentially protective 
effects against oxidative stress and highly toxic m etals such a s  cadmium (Miles 
et al., 2000). The metal ions, for which MT has a  high affinity, are zinc, copper,
-192-
Chapter V — Focus on PSA-NCAM
cadmium and mercury (Maier et a/., 1997; Vallee, 1991). Mice deficient in MT 
were found to be more susceptible to cadmium (Klaassen and Liu, 1998), 
supporting it having a function in heavy metal detoxification.
The two main isoforms, MT1 and MT2 are expressed in almost all 
mammalian tissues (Jin et al., 1998). They are generally expressed at basal 
levels, while being inducible by a  number of factors, such a s  metals, hormones, 
inflammatory cytokines and xenobiotics (Jasani and Schmid, 1997). Humans 
have at least 16 MT genes and seven different genes in hum ans encode MT1 
(Garrett et al., 1998; Jasani et al., 1998). Human MT1E and MT1A levels are 
increased with Cd2+, Zn2+ or Cu2+ pre-treatment (Garrett et al., 1998). The 
most widely expressed mammalian MT1 and MT2 isoforms are rapidly induced 
in the liver by a wide range of metals, drugs and inflammatory mediators (Coyle 
etal., 2002).
Although detoxification of heavy metals seem s to be a  property of MTs, it 
may not be their primary function. Cells with lower levels of MT are more 
sensitive to DNA dam age while overexpression of MT appears to reduce 
spontaneous m utagenesis. Using a derivative of the CHO-K1 cell line (Kao and 
Puck, 1968) overexpression w as achieved using an autonomously replicating 
expression vector. CHO-K1 cells were chosen because of their low endogenous 
expression of MT even after treatm ent with metals. The pBPV vector, with a 
non-inducible promoter, w as used here to generate transfectants that 
overexpressed MT to obtain an induction-independent evaluation of MT 
protection against R1108 effects. Resistance to exogenously supplied Cd2+ 
was established for the present study (Smith et al., 2008) to confirm that the 
MT-1 overexpressed w as functional. Furthermore, a  previous study had shown 
that the endogenous antioxidant status of transfectant and parental cells was 
similar (Wallace et al., 1996), showing similar levels of glutathione peroxidase, 
catalase, superoxide dism utase and reduced glutathione. Although, R1108 
induced cellular toxicity in the CHO cell line, toxicity levels were lower than for 
the NCI-H69 cell lines. Indeed, cell death w as not observed at the lower dose. 
Moreover, no significant differences were found between the MT-expressing 
CHO and the parental cell line, suggesting that R1108 cytotoxicity is not 
provoked by heavy metal contaminants.
-193-
Chapter V — Focus on PSA-NCAM
Therefore, R1108 toxicity remains to be explained. Intriguingly a  recent 
study links a  possible R1108-gene expression signature to a similar profile 
induced by biomechanical stretching leading to hypertrophy (Frank et at., 2008). 
Therefore it would seem  appropriate during the next agent synthesis phase of 
R1108 and the new ICT derivatives to undertake a screen alongside other 
known agents that c au se  cell hypertrophy and cell cycle arrest such as  
sialylated gangliosides (M asson et at., 2005). This would provide further insights 
on the toxic affect of R1108 and related agents.
The study led to the  discovery of potential biomarkers for R1108 agent- 
related death; provided biological information on the requirements and hence 
the synthesis of new agents. Therefore in this context the SCLC variant system 
provides an ideal drug screening model system.
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VL Discussion
New SCLC therapeutic strategies are  urgently needed that contain 
spreading disease without further compromising tumour chemosensitivity. 
Variation in the ability of a  tumour cell to interact with the extracellular matrix 
and adjacent cells reflects complex changes at the cell surface and is an 
evolving theme in attem pts to link m etastasis and chem oresistance (Sethi et al., 
1999). Therapies aimed at the containment of variation in adhesion properties 
could provide opportunities for the m anaged suppression of metastatic 
behaviour, the collateral recruitment of previously unavailable therapeutic 
targets and the extension of windows of chemosensitivity for novel combination 
treatments. Cancers result from the accumulation of inherited and somatic 
mutations in oncogenes and tumour suppressor genes and consideration of 
how these might evolve in a  population has been addressed  in modelling 
studies a s  potential origins for drug resistance (Iwasa et al., 2006; Michor et al., 
2006). At least two models, potentially co-existent, have been put forward to 
account for heterogeneity and inherent differences in tumour-regenerating 
capacity: the cancer stem  cell (CSC) and clonal evolution models (overview in 
Vezzoni and Parmiani, 2008; Visvader and Lindeman, 2008). Within the SCLC 
study, evidence of clonal evolution/selection w as uncovered together with 
findings pertinent to the origins of drug resistance a s  driven in CSCs through 
efflux-based drug resistance.
The aims of this thesis were restricted to the development and 
characterisation of a model SCLC system to address the nature and 
impact of variant generation within classical SCLC cell populations on the 
possible origins of drug resistance arising from phenotypic plasticity and 
to develop a therapeutic model for limiting the cellular consequences of 
plasticity. The approach was technically different from that explored by 
Sethi and co-workers (Sethi et a/., 1999) and that of Kraus et al. (Kraus et 
al., 2002) and Salge et al. (Salge et al., 2001) who focused on the impact of 
ECM interactions, Akt-signalling and changes in matrix 
metalloproteinases respectively. The overview of the findings is mapped 
to the adherence plasticity concept in a summary schematic (figure VI.1).
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Figure VI. 1: Overview o f  the thesis highlights addressing the stated aims o f  the study.
Developm ent and charac terisa tion  of a novel SCLC cellular system : 
Cellular dynam ics
Phenotypic plasticity and SCLC variants — Several NCI-H69 variants 
systems have been previously developed and characterised to initiate and 
address phenotypic variants, in relation to plasticity, signalling status and 
chemoresistance. BrdU induced NCI-H69 differentiation resulted in the 
development of substrate adherence, increases in cell-cell adherence junctions 
and up-regulation of epithelial markers (Gilchrist et al., 2002; Prindull and Zipori, 
2004). Poly-L-lysine adherent variants selection has resulted in an apoptosis-
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resistant cell line development, with decreased NE characteristics and
increased NSCLC characteristics (Kraus et al., 2002). Plastic substrate 
adhesion variants have been identified with reduced neuroendocrine
characteristics including NCAM expression down-regulation (Seddon et al.,
1998). Clearly an ability to generate variants with different properties from the 
NCI-H69 SCLC cell line underlines innate NCI-H69 plasticity. However in all 
those studies, heterogeneity of the population was not addressed and the 
potential for clonal evolution and selection -  explored here using extended
passage in culture -  were not examined. The use of microarray analysis
provides here for the most complete study to date.
Acute pro-adherence selection resulted in expansion of NCI-H69 AP3 a 
SCLC variant with many features different from the NCI-H69 SP variant such as 
low growth rate (attributable to the proportion of apoptotic cell in the case  of the 
NCI-H69 SP). Progression to NCI-H69 A78 results in an increase in growth rate 
-  a state connected with the selection for proliferative advantage. It is likely that 
the selection represents the direct enrichment of a sub-population of the NCI- 
H69 SP cultures a s  evidenced by the differences in G1 DNA content observed 
for NCI-H69 SP, NCI-H69 AP3 and NCI-H69 AP78. A pragmatic view of the 
dynamics is that multiple variants with propensity to show adherent properties 
and different marker profiles exist at different frequencies in the NCI-H69 SP. A 
general selection for the suspension phenotype is maintained by the method of 
culture and the microniches formed by cell-cell association. This general 
selection does not confer any proliferative advantage for cells capable of 
plasticity and early expression of adherence upon presentation of a suitable 
substrate. If PSA expression were to impose a negative advantage to 
proliferation or survival in suspension then expression would be lost. This is 
clearly not the case. Upon variant selection at NCI-H69 AP3, cultures are now 
subject to new selection pressures relating to m aintenance of the adherence 
phenotype (demonstrably plastic given its reversibility) and som e proliferative 
advantage. T hese selection principles upon extended passage  result in the 
overgrowth of the NCI-H69 AP78 sub-population. The microarray analyses 
therefore define SCLC gene expression profiles (NCI-H69 SP  versus NCI-H69 
AP78) that conserve SCLC markers irrespective of adherent growth. 
Furthermore, NCI-H69 AP3-restricted gene expression may therefore represent
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pathways for initial microniche exploitation before proliferative advantage 
becomes a principle of selection.
Thus it is suggested that a lower growth rate in NCI-H69 AP3 (versus 
NCI-H69 AP78) may be attributable to an active repression, operating even in 
variants harboured within the NCI-H69 SP population. Candidates for this would 
be the tumour suppressor GPC-3 and lower neuroendocrine expression (such 
as GRP) easily identifiable by loss o f the marker PSA. Long term enrichment of 
NCI-H69 AP3 provided an opportunity for proliferative/survival advantage to 
assert an influence and to allow for a clonal evolution/ expansion. The process 
produced the hyperploid, fast growing NCI-H69 AP78 variant that sustains the 
neuroendocrine and SCLC features presented by the NCI-H69 SP culture. The 
proposed NCI-H69 variant model for heterogeneity and plasticity is represented 
in figure VI.2.
Selection Selection based on Enrichment based on a
principle adhesion properties proliferative advantage
Morpho-
features
NCI-H69
AP3-like NCI-H69AP78-like
NCI-H69 SP NCI-H69 AP3 NCI-H69 AP78
Fundamental
underlying
molecular
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GPC3
PSA'
NE'
GPC3+
PSAr
NE+
GPC3"
Figure VI.2: NCI-H69 variant model.
The model provide a framework for considering the impact of limiting the 
expression of PSA (originally with the aim of reducing the range of 
survival/growth support for within a NCI-H69 SP population) and whether this 
would be synonymous with the phenotype shown by NCI-H69 AP3. If PSA 
modulation drives cells to a NCI-H69 AP3 state the model predicts enhanced 
adhesion without generating resistance or proliferative advantage.
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NCI-H69 variants — Implications on metastasis — The underlying 
processes governing the various patterns of m etastasis observed in different 
tumour types remains unclear. It appears likely that there are som e common 
features for both phenotypic behavioural changes and the impact of genetic 
alterations. Studies on dissem inated tumour cells found in the bone marrow of 
patients with various types of solid tumours, including lung tumours, suggest 
that the cells seem  to first dissem inate from the early primary lesions and then 
acquire additional genetic defects (Pantel and Brakenhoff, 2004). The 
amalgamation of intravital imaging and gene expression profiling methods has 
started to place into context behavioural processes occurring at early invasion 
stages (Wang et al., 2005a). Such approaches have highlighted the role of 
enhanced motility for successful tumour cell invasion of the microenvironment. 
Changes in specific integrin signals appear to enable cancer cells to detach 
from neighbouring cells, facilitate matrix remodelling and re-orientate their 
polarity during migration. As the metastatic process continues, integrin- 
mediated formation of microemboli - composed of tumour cells, platelets and 
leukocytes - is one route by which cell surface changes could affect the 
probability of docking of tumour cells to the endothelium and extravasation at a 
metastatic site (Guo and Giancotti, 2004). An important feature for cancer 
progression and the m etastasis process is the facilitation of cell migration and 
penetration through the ECM by proteolytic processing component of the ECM 
by cells (Wolf and Friedl, 2008). Conceptually, small cell lung cancer (SCLC) 
m etastasis would generally involve both tumour cell adhesion and proteolytic 
degradation of the extracellular matrix.
The present study shows no evidence that the variants have altered in 
vitro invasion potential although the limitations of the invasion assay  used are 
clear and does not necessary  determine in vivo behaviour. In a  collaborative 
study with ICT Bradford the suspension and early adherent variant showed 
similar in vivo growth (and retention of the in vitro PSA expression profiles) as 
subcutaneous xenografts. However, it is likely that subcutaneous sites are 
inappropriate for SCLC invasion modelling but critically dem onstrate that in vivo 
culture per se does not impose phenotypic reversion. Importantly, in vivo there 
is no ‘loss’ of cells from the system  by serial passage, a s  imposed in vitro, but 
there remain selective pressures for proliferative advantage. It is possible that
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the NCI-H69 AP3 state only com es into play at tumour regions experiencing 
microniche exploration and penetration through tissue barriers. This view is 
supported by the findings of an earlier study that attempted to reconcile the 
observation that the classic SCLC cell line NCI-H69, when grown in suspension 
expresses only negligible proteolytic activity. Salge et al. found that selection for 
adherent growth generated adherent cells with enhanced matrix 
metalloproteinases 2 and 9 expression (Salge et al., 2001).
NCI-H69 variants — implications on chemoresistance — The variant 
selection did not result in expansion of a  drug resistant clone, although a wider 
drug screen would be appropriate. However, in attempting to translate the clear 
demonstration of variation and plasticity in SCLC cell populations into an in vivo 
context the situation becom es more complex. Early tumours may harbour cells 
with innate non-phenotypic plasticity related drug resistance and the therapeutic 
intervention itself may act to modulate the dynamics of the metastatic process. 
The concept of phenotypic plasticity-targeting therapies may be of particular 
value in limiting responses of target populations to factors generated by a  given 
intervention such a s  surgery. Retsky et al. (1997) have used a  mathematical 
model of breast cancer m etastasis to investigate the observed double-peaked 
frequency of relapse distribution at 18 and 60 months. They attributed relapse 
to the stimulation of the m etastatic growth due to surgery with a proposed 
mechanism of stimulation via angiogenesis of distant dormant micrometastases 
(Retsky et al., 2004). Here the hypothesis is that a  burst of angiogenesis of 
distant dormant m icrom etastases after surgery provides for increased 
aggressiveness of the tumour and paradoxically a  recruitment into a more 
chemosensitive sta te  (Retsky et al., 2004).
The clonal expansion of the NCI-H69 AP78 variant with proliferative 
advantage could provide for sub-populations that could both acquire drug 
resistance according to the Goldie-Coldman model and rapidly repopulate 
tumours. The choice of TPT for the study w as also based on its known cell 
cycle specificity that would target rapidly growing tumour populations. The 
current results show that there is no firm connection between variant selection 
and a  natural acquisition of drug resistance.
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The Goldie-Coldman model (Goldie and Coldman, 1979) predicts the 
presence drug-resistant mutants even within the 109 neoplastic cells nominally 
present at diagnosis for treatment-naYve primary tumour sites. This has 
informed a chemotherapeutic approach of rapidly alternating the administration 
of equally effective drugs to prevent clonal resistance (Panetta, 1998). This 
‘clonal resistance’ problem can occur within a  background of phenotypic 
plasticity enhancing the probability of development of the metastatic phenotype. 
One of the early models that attem pted to describe effective adjuvant 
chemotherapy is that of Norton and Simon (Norton and Simon, 1986). They 
assumed that all tumour growth, tumour regression, and tumour regrowth is 
Gompertzian. The Norton-Simon hypothesis, at variance with the log-cell kill 
hypothesis (Skipper, 1964), suggested that tumours given less time to regrow 
between treatm ents are  more likely to be destroyed if therapeutic intent is to 
effect cell kill or de-population. According to Gompertzian kinetics, a s  the 
tumour becom es smaller its growth fraction increases and it regrows at a  faster 
rate. Thus a  cure will never be effected if regrowth rate is not matched or 
exceeded by the rate of cell kill. The implication for treatm ent is that the only 
way to overcome this ‘kinetic resistance’ barrier is the absolute eradication of 
every viable micrometastatic cell and that intervals between chemotherapy 
treatment are critical (Clare et al., 2000) -  a  process that would be enhanced by 
reducing any ongoing supply of micrometastatic cells. Again, limiting the 
potential for variant generation, for example through limiting phenotypic 
plasticity and hence a  driver for kinetic resistance. This view suggests that 
limitation, even without the accrual of drug resistance, of growth potential is as 
critical as  size of the target population. This view suggests that limitation, even 
without the accrual of drug resistance, of growth potential is a s  critical as size of 
the target population.
Phenotypic plasticity and origins of drug resistance — Most small cell 
lung cancer (SCLC) patients relapse within 12 months of starting combination 
chemotherapy plus radio-therapy, due to the development of acquired chemo- 
and radio-resistance. This phenom enon has been related to the induction of 
tumour differentiation, resulting in apoptosis-resistant, morphologically variant
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(v-SCLC) cells which lack the neuroendocrine expression of classic (c-) SCLC 
cells (Kraus et al., 2002).
A study of the isolation of spontaneously adherent SCLC sublines, as 
part of an attempt to generate an in vitro model of variant differentiation in 
SCLC, found down-regulation of neuroendocrine markers and up-regulation of 
epithelial differentiation markers cyclin D1, endothelin, the cell adhesion 
molecules CD 44 and integrin subunits a2, (33 and (34 (Kraus et al., 2002). 
Interestingly these workers also found that the sensitivity of the adherent SCLC 
sublines to etoposide, cyclophosphamide and gamma radiation was significantly 
diminished. This multi-agent resistance was attributed to the differentiation to v- 
SCLC and cell adhesion triggering an Akt-dependent inhibition of apoptosis with 
an un-tested prediction that v-SCLC could generate topotecan resistance 
(Kraus eta!., 2002).
Here it is suggested that resistance is likely to be multifactorial. Indeed, 
in the Kraus et al. study no connection was made between the discovered 
cyclophosphamide resistance and the possible contribution of the aldehyde 
dehydrogenase 1 (ALDH1A1) expression found to be present in the NCI-H69. 
The aldehyde dehydrogenase (ALDH) superfamily comprises genes encoding 
NAD(P)(+)-dependent enzym es that oxidize a wide range of reactive and toxic 
aldehydes to their corresponding carboxylic acids (Vasiliou et al., 2000). 
ALDH1A1 has previously been identified in a limited analysis of genes 
overexpressed in a classical multidrug resistance MDR P-glycoprotein 
expressing gastric carcinoma cell line (Ludwig et al., 2002). The anticancer 
agent, cyclophosphamide, is metabolized by cytochrome P450 (CYP), 
glutathione S-transferase (GST) and aldehyde dehydrogenase enzymes. 
Aldehyde-dehydrogenase levels have also been correlated with resistance to 
cyclophosphamide, while resistance induced by enforced overexpression of 
ALDH1A1 can be reversed by disulfiram, an ALDH1A1 inhibitor (Magni et al., 
1996). ALDH1A1 overexpression has been previously recognized a s  part of 
possible multidrug resistance patterns associated with drug-metabolizing 
capacity in cells resistant to cyclophosphamide (Bao et al., 2007) providing a 
rationale for CSC resistance. Moreover, ALDH1A1 is cancer stem  cell marker 
(Visvader and Lindeman, 2008). ALDH1A1 expression decreased in NCI-H69 
AP3 compared to the suspension parent and the NCI-H69 AP78 states. This
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observation of in variation ALDH1A1 expression in the variants indicates that 
variation, in the absence of drug selection, may lay the foundation of drug 
resistance to agents such a s  cyclophosphamide. However, on the basis of the 
lack of efflux-dependent changes in TPT and there being no apparent side 
population phenotype in the NCI-H69 we suggest that the recruitment of a  CSC- 
like population by adherence selection did not occur.
Tumour cell glycocalyx and the therapeutic challenge addressed in the 
PST inhibitor study — C hanges in cell surface decoration by complex 
carbohydrates (collectively forming a ‘glycocalyx’) are intimately involved in the 
shifts in cell-cell and cell-matrix adhesion properties that accompany cellular 
development, differentiation and m etastatic transition (Brooks and Leathern, 
1991; Kayser et al., 1998; Nakagoe et al., 2000; Nakagoe et al., 1998; 
Renkonen et al., 1997). Glycocalyx sugars are assem bled from simple 
m onosaccharides, notably A/-acetylneuraminic (sialic) acid, to form complex 
oligo- and polysaccharides (Yarema and Bertozzi, 2001) and present potential 
anti-cancer therapeutic targets (Christofori, 2003; Sell, 1990; Yarema and 
Bertozzi, 2001). An early step in m etastasis involves detachm ent and escape 
from the primary tumour (Couzin, 2003) with roles in this critical step for sialic 
acid metabolism (Brooks and Leathern, 1991; Nakagoe etal., 2000; Nakagoe et 
al., 1998; Renkonen et al., 1997). A refined model of primary tumour and 
metastatic growth dynamics, developed by (Koscielny et al., 1985) showed that 
metastatic initiation could occur at a  tumour volume of the primary lesion that 
w as only slightly smaller than that at the time of tumour diagnosis unlike the 
modelling outcome obtained by others that m etastatic initiation occurs very 
early in the development of the primary tumour if an exponential growth model 
is adopted (Koscielny et al., 1985). One implication is that m etastasis potential 
containment therapies may becom e increasingly important a s  screening 
programmes evolve and attempt to inform early intervention.
Phenotypic plasticity and tumour population dynamics- therapeutic 
implications — Phenotypic plasticity in tumour cell populations has the 
undesirable potential to maximise Darwinian fitness for the selection of 
m etastatic and drug-resistant variants. The operation of selection pressures
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during the expansion of a tumour cell population could operate on plastic 
characteristics such a s  the glycocalyx, affecting cell-cell contacts and increasing 
the probability of intravasation. Here critical factors would include the initiation 
time, population expansion kinetics and population size at diagnosis. The 
chemosensitivity of cells demonstrating neoplasia-favourable but reversible 
phenotypes, such a s  cell-adhesion mediated drug resistance (Sethi et al.,
1999), would also impact on the prognosis. These factors would act as 
stochastic drivers for the ongoing growth of variant lineages or cellular cohorts 
further facilitated by a  rachet-like and sequential accrual of non-reversible 
genetic changes - including those that impact upon genetic instability and 
apoptotic susceptibility. On the other hand, limiting the potential for variant 
generation, for exam ple through phenotype reversal or limiting phenotypic 
plasticity, is intuitively a  route for controlling neoplastic progression but would 
need to be integrated with active surgical or tumour eradication regimens.
Impact and future work:
Drug screening: The availability of cells with variant properties without 
apparent sub-populations of CSCs or innate differences in resistance to TPT 
provides a platform for drug screening against a wider panel of agents. The 
model allows for the impact of cell adhesion to be excluded or to be explored 
with respect to difference ECM influences. The availability of NCI-H69 AP78 
with an adherent phenotype but retention a  many critical NCI-H69 SP markers 
should allow for clonogenic assay s and other HTS-based screens (difficult to 
achieve with suspension cultures).
Novel methods of cellular analysis and sorting: The extensive 
characterisation for PSA expression and enzymatic removal allows basic 
studies on the impact of surface charge. Preliminary studies in collaboration 
with Bangor University have established methodologies for exploiting shifts in 
cell m em brane dielectric properties a s  a probeless method of cell separation. 
The current study has also laid the foundations for modulating the surface 
characteristics, through polysialyltransferases inhibition, and the possible use of 
dielectrophoretic properties for agent screening. A dielectrophoresis quadrapole
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system  has been used a s  a proof of principle study and has succeeded in 
identifying differences in permittivity characteristics for NCI-H69 SP and NCI- 
H69 AP3 cells. Further, a  sorting micro-technology device has been use  to sort 
phenotypic variations providing a novel (non-labelling) cytometric tool for 
analysis, identification and monitoring of tumour heterogeneity.
Glycocalyx targeting agents: Collaboration with Prof Patterson and Dr 
Falconer (Institute of Cancer Therapeutics, Bradford) will be pursued to develop 
new polysialyltransferases inhibitors. The primary focus will be the development 
an in vitro a ssay  for inhibition studies, before testing on a rat glioma 
overexpressing SIAT8SIA2 and the NCI-H69 model reflecting population 
heterogeneity. Further characterisation of the NCI-H69 model, in term of PSA- 
NCAM and NCAM kinetics upon polysialyltransferases inhibition will also be 
needed.
Modulation of SCLC behaviour in 3D ECM systems: In collaboration with 
Prof Peter Friedl (Department of Cell Biology, Nijmegen, The Netherlands) the 
variant SCLC system  is under study with a focus on the visualisation of cell- 
matrix interactions by using 3D extracellular-matrix-based cell-culture models 
and advanced imaging procedures. The preliminary studies are  aimed at 
observing the adherent form behaviour in the 3D Collagen Matrix Assay 
a sse ssed  by Time-Lapse videomicroscopy (Wolf and Friedl, 2008). The in situ 
drug responses for cells in this system  would be of particular interest with 
respect to polysialyltransferase inhibition.
In vitro/in vivo 3D microtumour systems: Our demonstration of the 
striking retention of cellular interaction and growth patterns of the NCI-H69 
AP78 variant when forced into 3-D growth on hydrophobic surfaces suggest that 
the NCI-H69 system  could be translated to a hollow fibre system  (Shnyder et 
al., 2006; Shnyder et al., 2005; Suggitt et al., 2006) to study the impact on drug 
sensitivity. Preliminary studies have established the cell loading requirements 
for NCI-H69 variants growth and recovery from fibres.
Cancer biomarkers from cell biology to clinic: The cancer biomarker 
problem in SCLC suggests a need for better cancer characterisation (Sawyers,
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2008), particularly in anticipation of new therapies that aim to target SCLC 
biology. In collaboration with Dr Allen Gibbs (Llandough Hospital, Department of 
Histopathology, Cardiff and Vale NHS Trust), we have identified 
histopathological specimens representing SCLC clinical presentation of primary 
tumour with no detectable metasases -  these primary samples showed very 
high levels of NCAM expression (figure VI.3). Here the future aim would be to 
survey using immunofluorescence for the ‘markers’ identified in our NCI-H69 
system to gauge co-expression and set the variant system into context. Here a 
priority is the expression of GPC3 protein.
Figure VI.3: SCLC. Localized small cell carcinoma of the lung vs. liver metastasis 
stained with haematoxylin-eosin or NCAM.
Primary tumour Liver metastasis
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Appendix I: Reagents and suppliers
Chloroform 
Coverslips
Ethanol, analytical grade 
Glass microscope slides 
Isopropanol
Methanol, analytical grade 
PBS (cell culture)
Cell culture dishes
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Fisher Scientific (Loughborough, UK) 
VWR international Ltd (Lutterworth, UK) 
Fisher Scientific (Loughborough, UK) 
Raymond A. Lamb (Eastbourne, UK). 
Fisher Scientific (Loughborough, UK) 
Fisher Scientific (Loughborough, UK) 
Gibco (Invitrogen, Carlsbad, CA, USA) 
Corning (Loughborough, UK)
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Appendix II: Western blotting solutions
Solutions for Western Blotting: 
Lysis buffer
Tris 50mM GE Healthcare (Little Chalfont, UK)
EGTA 5mM Sigma (St Louis, MO, USA)
NaCI 150mM Sigma (St Louis, MO, USA)
Triton 1% GE Healthcare (Little Chalfont, UK)
PMSF 1mM Sigma (St Louis, MO, USA)
Aprotinin 8pg/mL Sigma (St Louis, MO, USA)
Leupeptin 10pg/mL Sigma (St Louis, MO, USA)
H20
3x sample loading buffer
TRIS-CI pH 6.8 240mM
SDS 6%
Glycerol 30%
DTT 0.2M
Bromophenol blue 0.05%
H20
GE Healthcare (Little Chalfont, UK) 
GE Healthcare (Little Chalfont, UK) 
GE Healthcare (Little Chalfont, UK) 
Sigma (St Louis, MO, USA)
Sigma (St Louis, MO, USA)
Upper gel buffer
Tris 545mM GE Healthcare (Little Chalfont, UK)
SDS 0.4% GE Healthcare (Little Chalfont, UK)
H20
pH adjusted to 6.8
Lower gel buffer
Tris 1.2M GE Healthcare (Little Chalfont, UK)
SDS 0.4% GE Healthcare (Little Chalfont, UK)
h2o
pH adjusted to 8.8
Resolving gel 7.5% 10% 12.5%
Lower gel buffer 1.5mL 1.5mL 1.5mL
aciylamide/bisacrylamide* 40% l.lm L 1.5mL 1.9mL
ammonium persulfate** 10% 60pL 60pL 60pL
TEMED** 6|iL 6pL 6pL
h 2o 3.3mL 2.9mL 2.5mL
* Sigma (St Louis, MO, USA) **GE Healthcare (Little Chalfont, UK)
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Stacking gel 4% 5%
Upper gel buffer 600pL 600pL
acrylamide/bisacrylamide* 40% 250pL 300pL
ammonium persulfate** 10% 25 pL 25 pL
TEMED** 2.5pL 2.5pL
h 2o 1.6mL 1.5mL
‘Sigma (St Louis, MO, USA) **GE Healthcare (Little Chalfont, UK)
Running buffer
Glycine 192mM
Tris 25mM
SDS 0.1%
Transfer buffer
Glycine 192mM
Tris 25mM
Blocking solution
Blocking Reagent 3%
Tween-20 0.1%
PBS
Wash solution (PBS-T)
Tween-20 0.1%
PBS
GE Healthcare (Little Chalfont, UK) 
GE Healthcare (Little Chalfont, UK) 
GE Healthcare (Little Chalfont, UK)
GE Healthcare (Little Chalfont, UK) 
GE Healthcare (Little Chalfont, UK)
GE Healthcare (Little Chalfont, UK) 
GE Healthcare (Little Chalfont, UK) 
Sigma (St Louis, MO, USA)
GE Healthcare (Little Chalfont, UK) 
Sigma (St Louis, MO, USA)
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Appendix III: RT-PCR solutions
Solutions for RT-PCR:
50xTAE buffer
Tris base  2 M Fisher Scientific (Loughborough, uk)
Sodium acetate-3H20 1 M Fisher Scientific (Loughborough, uk)
EDTA Na2*2H20 50 mM Sigma (St Louis, MO, USA)
H20
pH adjusted to 7.2 with glacial acetic acid (Fisher Scientific, Loughborough, uk) 
5x non-denaturing sample loading buffer
Glycerol 50% GE Healthcare (Little Chalfont, UK)
Bromophenol blue 0.05% (w/v) Sigma (St Louis, MO, USA)
h 2o
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Appendix IV: SCLC cell lines panel PSA-NCAM expression.
NCAM
PSA-NCAM
NCI-H69
NCI-H69A
COR-L279
COR-279A
SHP-77
SHP-77A
COR-L88
COR-L88A
COR-L51B
COR-L47
COR-L23
1000 2000 
Norm alized flu orescen t in ten sity
3000
Figure 1: SCLC cell lines panel PSA-NCAM expression. Flow cytometry analysis of 
PSA-NCAM and NCAM expression.
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Appendix V: 2008 arrays quality assessment
Figure 1 shows the report from the simpleaffy package on the 5 metrics 
(http://www.affvmetrix.com/index.affx) commonly used to assess Affymetrix 
array quality. Metrics that do not follow the standard recommendations from 
Affymetrix are coloured red. Those Affymetrix accompanying guidelines are as 
follow: the scale factors need to be within 3-fold of each other (the blue shaded 
area represents the 3-fold), the background levels and the proportion of 
transcripts called present need to be similar to one another, the 5' / 3' ratio for 
GAPDH need to be around 1 and finally, the 5’ / 3' ratio for p-actin need to not 
be more than 3. Every array had satisfactory value for all metrics tested.
Scale factor
%  P 56 6%
B 68 54 
O/oP 55 89%
B 60.03 
% P  57.26%
B 61.78 
% P  57 04%
B 61 88
% P 57.33%
B 59 85 
% P 57.22%
B 55 41 
% P  55.5%
B 69 24 
%P 56.44%
B 65 99 
% P 57.11%
B 60.22 
A actin 3 ’ / actin 5 ’
- 3 - 2 - 1 0 1 2 3
°  GAPDH 3 ’ / GAPDH 5’
Figure 1: 2008 arrays — MAS5 computed quality control report. Simpleaffy package 
generated quality control showing 5 metrics (background (B), percent present (%P), 
scale factor, GAPDH 573’ ratio and Actin 573’ ration) commonly used to asses arrays 
quality.
A P 7 8 3
A P 7 8 2
A P 7 8 1
AP3_3
A P 3 2
A P 3 1
SP_3
SP_2
SP 1
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Figure 2 shows the report from the AffyPLM package. Every array 
showed a NUSE (normalised unsealed standard error) value around 1 and a 
RLE (relative log expression) value around 0, thus each array passed  the 
quality test. (RLE) and (NUSE) plots
NUSE
AP31  AP3 2  AP3_3 AP78_1 AP78_2 AP78_3 SP_1 SP_2 SP_3
RLE
AP3_1 AP3_2 AP3_3 AP78_1 AP78_2 AP78_3 SP_1 SP_2 SP_3
Figure 2: 2008 arrays — AffyPLM package for Bioconductor quality assessment — RLE 
and NUSE plots.
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Table 1: SCLC and NSCLC markers expression in the NCI-H69 variants (Kraus et al.,
2002). False-colour cluster view representing the expression o f each cell line (average
value o f the triplicates).
Affymetrix Gene 
name symbo
SCLC markers 
214347_s_at DDC  
20531 l_at DDC
20629 l_at NTS
206326_at GRP 
201313_at E N 02  
207466_at GAL  
20505 l_s_at KIT 
215551_at ESR1 
204697_s_at CHGA  
213200_at SYP  
211119_at ESR2
208138_at GAST  
205225_at ESR1 
212298_at NRP1 
214632_at NRP2 
217561_at CALCA  
210510_s_at NRP1 
214599_at IVL
NSCLC markers 
2 1 2 0 6 3 _ a t C D 44  
2 1 7 5 2 3 _ a t C D 44  
2 0 8 3 9 9 _ s_ a t  EDN3  
2 1 2 0 1 4 _ x _ a t C D 44  
2 1 0 9 1 6 _ s_ a t  C D 44  
2 0 9 8 3 5 _ x _ a t C D 44  
2 0 4 4 9 0 _ s_ a t  C D 44  
2 0 4 4 8 9 _ s_ a t  C D 44  
2 0 1 1 1 0 _ s_ a t  THBS1 
2 0 9 5 6 1_at T H B S3  
2 0 4 7 7 6 _ a t T H B S4  
2 1 6 0 6 2 _ a t C D 44  
2 0 8 7 1 2_ a t CCND1
2 1 5 7 7 5 _ a t  TH BS1  
2 0 6 7 5 8  at ED N 2
description SP AP3 AP78
dopa decarboxylase 
dopa decarboxylase 
neurotensin
gastrin-releasing peptide 
enolase 2 (gamma, neuronal) 
galanin
Proto-oncogene tyrosine-protein kinase Kit 
estrogen receptor 1
chromogranin A (parathyroid secretory protein 1) 
synaptophysin
estrogen receptor 2 (ER beta) 
gastrin
estrogen receptor 1 
neuropilin 1 
neuropil in 2
calcitonin/calcitonin-related polypeptide, alpha
neuropilin 1
involucrin
C D 44 antigen  
C D 44 antigen  
endothelin  3  
C D 44 antigen  
C D 44 an tigen  
C D 44 antigen  
C D 44 an tigen  
C D 44 antigen  
throm bospondin  1 
throm bospondin  3 
throm bospondin  4  
C D 44 an tigen  
cyclin  D1
T hrom bospondin  1 
en d oth elin  2
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Table 2: SCLC markers expression in the NCI-H69 variants (Pedersen et a l ,  2003). 
False-colour cluster view representing the expression of each cell line (average value of 
the triplicates).
Affymetrix
name
Gene
symbol description
213378_s_at DDX11 DEA D /H  (Asp-Glu-Ala-Asp/His) box polypeptide 11
209988_s_at ASCL1 achaete-scute complex-like 1 (Drosophila)
209987_s_at ASCL1 achaete-scute complex-like 1 (Drosophila)
213768_s_at ASCL1 achaete-scute complex-like 1 (Drosophila)
208149_x_at DDX11 D EAD/H  (Asp-Glu-Ala-Asp/His) box polypeptide 11
209985_s_at ASCL1 achaete-scute complex-like 1 (Drosophila)
20367 l_at TPMT thiopurine S-methyltransferase
217152_at NCOR1 Nuclear receptor co-repressor 1
214178_s_at SOX2 SRY (sex determining region Y)-box 2
206326_at GRP gastrin-releasing peptide
210206_s_at DDX11 D EA D /H  (Asp-Glu-Ala-Asp/His) box polypeptide 11
203453_at SCNN1A sodium channel, nonvoltage-gated 1 alpha
208159_x_at DDX11 D EA D /H  (Asp-Glu-Ala-Asp/His) box polypeptide 11
203415_at PDCD6 programmed cell death 6
213721_at SOX2 SRY (sex determining region Y)-box 2
209202_s_at EXTL3 exostoses (multiple)-like 3
211051_s_at EXTL3 exostoses (multiple)-like 3
201598_s_at INPPL1 inositol polyphosphate phosphatase-like 1
200856_x_at NCOR1 nuclear receptor co-repressor 1
213722_at SOX2 SRY (sex determining region Y)-box 2
216484_x_at HDGF Hepatoma-derived growth factor
200854_at NCOR1 nuclear receptor co-repressor 1
200896_x_at HDGF hepatoma-derived growth factor
200855_at NCOR1 nuclear receptor co-repressor 1
200857_s_at NCOR1 nuclear receptor co-repressor 1
203672_x_at TPMT thiopurine S-methyltransferase
209506_s_at NR2F1 nuclear receptor subfamily 2, group F, member 1
209505_at NR2F1 Nuclear receptor subfamily 2, group F, member 1
214848_at Y W H A Z 14-3-3 zeta
20064 l_s_at Y W H A Z 14-3-3 zeta
200639_s_at Y W H A Z 14-3-3 zeta
200638_s_at Y W H A Z 14-3-3 zeta
200640_at Y W H A Z 14-3-3 zeta
209030_s_at IGSF4 immunoglobulin superfamily, member 4
20903 l_at IGSF4 Immunoglobulin superfamily, member 4
209032_s_at IGSF4 immunoglobulin superfamily, member 4
SP AP3 AP78
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Table 1: Overlap between 1189 gene list and GO: 7049 cell cycle. False-colour cluster 
view representing the expression of each cell line (average value of the triplicates).
Affymetrix
name Gene symbol1 description SP AP3 AP78
200040_at KHDRBS1 K11 domain cunt. RNA hind, signal transduction assoc. 1 9E H g
40225_at GAK cyclin G associated kinase ^
218308_at TACC3 transforming, acidic coiled-coil containing protein 3 SHHB
203062_s_at MDC1 mediator o f DNA damage checkpoint 1 H E M
203725_at GADD45A growth arrest and DNA-damage-inducible, alpha H H B
219264_s_at PPP2R3B protein phosphatase 2, regulatory subunit B", beta H H j
202329_at CSK c-src tyrosine kinase 1 ",j
2 1 1928_at DNCH1 dynein, cytoplasmic, heavy polypeptide 1 ’ '^SBEB
209784_s_at JAG2 jagged 2 S B H |
213260_at FOXC1 Forkhead box C1 |j |N ||||
32137_at JAG2 jagged 2 f f j B f
202288_at FRAP1 FK506 binding protein 12-rapamycin associated protein 1
205289_at BMP2 bone morphogenetic protein 2
203132_at RBI retinoblastoma 1 (including osteosarcoma) B 9 H B
204827_s_at CCNF cyclin F J B B B
209361_s_at PCBP4 poly(rC) binding protein 4 ^ ^ ^ B
202934_at HK2 hexokinase 2 ^ ^ ^ B
205290_s_at BMP2 bone morphogenetic protein 2
216205_s_at MFN2 mitofusin 2
209260_at SFN stratifin
202336_s_at PAM peptidylglycine alpha-amidating monooxygenase H H f l
20273 l_at PDCD4 programmed cell death 4
212593_s_at PDCD4 programmed cell death 4
203786_s_at TPD52L1 tumor protein D52-like 1
210372_s_at TPD52L1 tumor protein D52-like 1 ". ■ ^
205848_at GAS2 growth arrest-specific 2
210512_s_at VEGF vascular endothelial growth factor , ’ .
213906_at MYBL1 v-myb myeloblastosis viral oncogene homolog-like 1
203588_s_at TFDP2 transcription factor Dp-2 (E2F dimerization partner 2)
218723_s_at RGC32 response gene to complement 32 jg^^Bj
208212_s_at ALK anaplastic lymphoma kinase (Ki-1) r.;; r ;
209035_at MDK midkine (neurite growth-promoting factor 2)
218718_at PDGFC platelet derived growth factor C
220407_s_at TGFB2 transforming growth factor, beta 2
209909 s at TGFB2 transforming growth factor, beta 2
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204890_s_at LCK lymphocyte-specific protein tyrosine kinase
20489 l_s_at LCK lymphocyte-specific protein tyrosine kinase
212414_s_at SEPT6 septin 6 ; cytokine-like nuclear factor n-pac
212413_at SEPT6 septin 6
205698_s_at MAP2K6 mitogen-activated protein kinase kinase 6
213666_at SEPT6 septin 6
2 1 1538_s_at HSPA2 heat shock 70kDa protein 2
212415_at SEPT6 septin 6
206939_at DCC deleted in colorectal carcinoma
31874_at GAS2L1 growth arrest-specific 2 like 1
201012_at ANXA1 annexin A 1
209590_at BMP7 Bone morphogenetic protein 7 (osteogenic protein 1)
212698_s_a SEPT10 septin 10
202388_at RGS2 regulator o f  G-protein signalling 2, 24kDa
206404_at FGF9 fibroblast growth factor 9 (glia-activating factor)
220386_s_at EML4 echinoderm microtubule associated protein like 4
20959l_s_at BMP7 bone morphogenetic protein 7 (osteogenic protein 1)
203037_s_at MTSS1 metastasis suppressor 1
214720_x_at SEPT10 septin 10
202409_at LOC492304 putative insulin-like growth factor II associated protein
207002_s_at PLAGL1 pleiomorphic adenoma gene-like 1
209318_x_at PLAGL1 pleiomorphic adenoma gene-like 1
205659_at HDAC9 histone deacetylase 9
212805_at KIAA0367 KIAA0367
207943_x_at PLAGL1 pleiomorphic adenoma gene-like 1
212806_at KIAA0367 KIAA0367
202859_x_at IL8 interleukin 8
209466_x_at PTN pleiotrophin
211506_s_at IL8 interleukin 8
2 1 1737_x_at PTN pleiotrophin (HBGF8, NEGF1)
209465_x_at PTN pleiotrophin (HGF8, NEGF1) sM hR
205899_at CCNA1 cyclin A 1
201307_at SEPT 11 septin 11
20554l_s_at GSPT2 G1 to S phase transition 2
206506_s_at SUPT3H suppressor o f Ty 3 homolog (S. cerevisiae)
213183_s_at CDKN1C Cyclin-dependent kinase inhibitor 1C (p57, Kip2)
213348_at CDKN1C Cyclin-dependent kinase inhibitor 1C (p57, Kip2)
219534_x_at CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2)
20402 l_s_at PURA purine-rich element binding protein A
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Table 2: Cell growth. Overlap between 1189 gene list and GO: 40007 growth. False- 
colour cluster view representing the expression of each cell line (average value of the 
triplicates).
Affymetrix
name
Gene
symbol description SP AP3 AP78
200920_s_at BTG1 B-cell translocation gene 1, anti-proliferative H | H B
20092 l_s_at BTG1 B-cell translocation gene 1. anti-proliferative -  ^ ,
20447 l_at GAP43 growth associated protein 43
201539_s_at FHL1 four and a half LIM domains 1 SSffl
210298_x_at FHL1 four and a half LIM domains 1 : .. ^
201540_at FHL1 four and a half LIM domains 1 JpBprel
215442_s_at TSHR thyroid stimulating hormone receptor
215443_at TSHR thyroid stimulating hormone receptor
220407_s_at TGFB2 transforming growth factor, beta 2
210055_at TSHR thyroid stimulating hormone receptor
210299_s_at FHL1 four and a half LIM domains 1
214505_s_at FHL1 four and a half LIM domains 1
221675_s_at CHPT1 choline phosphotransferase 1 '
201998_at ST6GAL1 S 16 beta-galactosamide alpha-2,6-sialyltranferase 1 H B
214321_at NOV nephroblastoma overexpressed gene
20450 l_at NOV nephroblastoma overexpressed gene
209220_at GPC3 glypican 3
203729_at EMP3 epithelial membrane protein 3 ,,'rC M  ■'
209909_s_at TGFB2 transforming growth factor, beta 2
202288_at FRAP1 1 K506 binding protein 12-rapamycin associated prot. 1 H M B
205289_at BMP2 bone morphogenetic protein 2 H B H K
203132_at RBI retinoblastoma 1 (including osteosarcoma) agSEpEai
205290_s_at BMP2 bone morphogenetic protein 2
205402_x_at PRSS2 protease, serine, 2 (trypsin 2) H jj^ H
216470_x_at PRSS protease, serine, 1, 2, 3; Trypsinogen C
208699_x_at TKT transketolase (W ernicke-Korsakoff syndrome) $1
208700_s_at TKT transketolase (W ernicke-Korsakoff syndrome) BHH
214602_at COL4A4 collagen, type IV, alpha 4 fi^ lllsil
204379_s_at FGFR3 fibroblast growth factor receptor 3 oSSSjxu
222006_at FGFR3 fibroblast growth factor receptor 3
203372_s_at SOCS2 suppressor o f cytokine signaling 2
203373_at SOCS2 suppressor o f cytokine signaling 2
219255_x_at IL17RB interleukin 17 receptor B ISBili
209590_at BMP7 Bone morphogenetic protein 7 (osteogenic protein 1) H H H K
20959 l_s_at BMP7 Bone morphogenetic protein 7 (osteogenic protein 1)
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Appendix VIII: Cell adhesion
Table 1: Overlap between 1189 gene list and GO: 7155: cell adhesion. False-colour 
cluster view representing the expression of each cell line (average value of the 
triplicates).
Aflymetri 
x name
Gene
symbol description
1007_s_at DDR1 discoidin domain receptor family, member 1
200635_s_at PTPRF protein tyrosine phosphatase, receptor type, F
200636_s_at PTPRF protein tyrosine phosphatase, receptor type, F
200637_s_at PTPRF protein tyrosine phosphatase, receptor type, F
200770_s_at LAMC1 laminin, gamma 1 (formerly LAMB2)
20077l_at LAMC1 laminin, gamma 1 (formerly LAMB2)
201015_s_at JUP junction plakoglobin
201028_s_at CD99 CD99 antigen
201029_s_at CD99 CD99 antigen
201579_at FAT FAT tumor suppressor homolog 1
201645_at TNC tenascin C (hexabrachion)
201842_s_at EFEMP1 EGF-containing fibulin-like ECM protein 1
202007_at NIDI nidogen 1
202008_s_at NIDI nidogen 1
202267_at LAMC2 laminin, gamma 2
203184_at FBN2 fibrillin 2 (congenital contractural arachnodactyly)
203394_s_at HES1 hairy and enhancer o f  split 1, (Drosophila)
203413_at NELL2 NEL-like 2 (chicken) ; NEL-like 2 (chicken)
203528_at SEMA4D semaphorin 4D
203562_at FEZ1 fasciculation and elongation protein zeta 1 (zygin I)
203726_s_at LAMA3 laminin, alpha 3
204359_at FLRT2 fibronectin leucine rich transmembrane protein 2
204489_s_at CD44 CD44 antigen
204490_sat CD44 CD44 antigen
205154_at LRRN5 leucine rich repeat neuronal 5
205206_at KALI Kallmann syndrome 1 sequence
205523_at HAPLN1 hyaluronan and proteoglycan link protein 1
205524_s_at HAPLN1 hyaluronan and proteoglycan link protein 1
205656_at PCDH17 protocadherin 17
206247_at MICB MHC class I polypeptide-related sequence B
206382_s_at BDNF brain-derived neurotrophic factor
206470_at PLXNC1 plexin C l
20647 l_s_at PLXNC1 plexin C 1
206935_at PCDH8 protocadherin 8
207169_x_at DDR1 discoidin domain receptor family, member 1
208779_x_at DDR1 discoidin domain receptor family, member 1
SP AP3 AP78
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209436_at SPON1 spondin 1, extracellular matrix protein
209437_s_at SPON1 spondin 1, extracellular matrix protein
209835_x_at CD44 CD44 antigen
209847_at CDH17 cadherin 17, LI cadherin (liver-intestine)
209897_s_at SLIT2 slit homolog 2 (Drosophila)
210749_x_at DDR1 discoidin domain receptor family, member 1
210916_s_at CD44 CD44
212014_x_at CD44 CD44 antigen
212063_at CD44 CD44 antigen
212298_at NRP1 neuropilin 1
212713_at MFAP4 microfibrillar-associated protein 4
213241_at PLXNC1 plexin C l
213438_at NFASC neurofascin
213808_at ADAM23 ADAM  metallopeptidase domain 23
213993_at SPON1 spondin 1, extracellular matrix protein
213994_s_at SPON1 spondin 1, extracellular matrix protein
215020_at NRXN3 neurexin 3
216167_at LRRN5 leucine rich repeat neuronal 5
217523_at CD44 CD44 antigen
217901 at DSG2 Desmoglein 2
219414_at CLSTN2 calsyntenin 2
219737_s_at PCDH9 protocadherin 9
219738_s_at PCDH9 protocadherin 9
221933_at NLGN4X neuroligin 4, X-linked
36499_at CELSR2 cadherin, EGF LAG seven-pass G-type receptor 2
20093 l_s_at VCL vinculin
201976_s_at MYO10 myosin X
205402_x_at PRSS2 protease, serine, 2 (trypsin 2)
208636_at ACTN1 Actinin, alpha 1
208637_x_at ACTN1 actinin, alpha 1
209209_s_at FERMT2 fermitin family homolog (Drosophila)
209210_s_at FERMT2 fermitin family homolog (Drosophila)
2 1 1340_s_at MCAM melanoma cell adhesion molecule
212724_at RND3 Rho family GTPase 3
214198_s_at DGCR2 DiGeorge syndrome critical region gene 2
214212_x_at FERMT2 fermitin family homolog (Drosophila)
216470_x_at PRSS 1,2,3 protease, serine, 1, 2, 3 (trypsin 1, 2, 3)
221408_x_at PCDHB12 protocadherin beta 12
203780_at EVA1 epithelial V-like antigen 1
204114_at NID2 nidogen 2 (osteonidogen)
204619_s_at CSPG2 chondroitin sulfate proteoglycan 2 (versican)
204620_s_at CSPG2 chondroitin sulfate proteoglycan 2 (versican)
206394_at MYBPC2 myosin binding protein C, fast type
207717_s_at PKP2 plakophilin 2
210945_at COL4A6 collagen, type IV, alpha 6
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211473_s_at COL4A6 collagen, type IV, alpha 6
211571_s_at CSPG2 chondroitin sulfate proteoglycan 2 (versican)
212070_at GPR56 G protein-coupled receptor 56
213992_at COL4A6 collagen, type IV, alpha 6
215646_s_at CSPG2 chondroitin sulfate proteoglycan 2 (versican) ^
215785_s_at CYFIP2 cytoplasmic FMR1 interacting protein 2
219302_s_at CNTNAP2 contactin associated protein-like 2 \
221731_x_at CSPG2 chondroitin sulfate proteoglycan 2 (versican) 3 3 ® ^ ’
222020_s_at HNT neurotrimin
201005_at CD9 CD9 antigen (p24)
202363_at SPOCK testican ■ H J
202859_x_at IL8 interleukin 8
203037_s_at MTSS1 metastasis suppressor 1
203953_s_at CLDN3 claudin
203954_x_at CLDN3 claudin 3 ’■ W S S
204482_at CLDN5
204955_at SRPX sushi-repeat-containing protein, X-linked
205042_at GNE glucosamine-2-epimerasc/N-acetylmannosaminekinase
205185_at SPINK5 serine peptidase inhibitor, Kazal type 5
205669_at NCAM2 neural cell adhesion molecule 2
207149_at CDH12 cadherin 12, type 2 (N-cadherin 2)
209114_at TSPAN1 tetraspanin 1
211506_s_at IL8 interleukin 8
213620_s_at I CANO intercellular adhesion molecule 2 I B B
215571_at NCAM2 Neural cell adhesion molecule 2
218087_s_at SORBS 1 sorbin and SH3 domain containing 1 H H I
220999_s_at CYFIP2 cytoplasmic FMR1 interacting protein 2 S H B
37965_at PARVB parvin, beta V " j
37966_at PARVB parvin, beta
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Table 2: Overlap between 1189 gene list and GO: 5856: cytoskeleton and GO: 7010: 
cytoskeleton organisation and biogenesis. False-colour cluster view representing the 
expression of each cell line (average value of the triplicates).
Affymetrix
name
Gene
symbol description
200609_s_at WDR1 WD repeat domain 1
208636 at ACTN1 Actinin, alpha 1
20061 l_s_at WDR1 WD repeat domain 1
X00351_5_at ACTB actin, beta
201976_s_at MYO10 myosin X
2 1 1928_at DNCH1 dynein, cytoplasmic, heavy polypeptide 1
200859_x_at FLNA filamin A, alpha (actin binding protein 280)
208637_x_at ACTN1 actinin, alpha 1
213746_s_at FLNA filamin A, alpha (actin binding protein 280)
202389_s_at HD huntingtin (Huntington disease)
210935_s_at WDR1 WD repeat domain 1
214752_x_at FLNA filamin A, alpha (actin binding protein 280)
201564_s_at FSCN1 fascin homolog 1, actin-bundling protein
209209_s_at FERMT2 fermitin family homolog (Drosophila)
20862l_s_at VIL2 villin 2 (ezrin)
209210_s_at FERMT2 fermitin family homolog (Drosophila)
212338_at M YOID myosin ID
201015_s_at JUP junction plakoglobin
209008_x_at KRT8 keratin 8 ; keratin 8
221047_s_at MARK1 MAP/microtubule affinity-regulating kinase 1
201596_x_at KRT18 keratin 18
214721_x_at CDC42EP4 CDC42 effector protein (Rho GTPase binding) 4
201648_at JAK1 Janus kinase 1 (a protein tyrosine kinase)
212566_at MAP4 microtubule-associated protein 4
202274_at ACTG2 actin, gamma 2, smooth muscle, enteric
214736_s_at ADD1 adducin 1 (alpha)
218966_at M Y 05C myosin VC
208030_s_at ADD1 adducin 1 (alpha)
20093 l_s_at VCL vinculin
210933_s_at FSCN1 fascin homolog 1, actin-bundling protein
209234_at KIF1B kinesin family member IB
214212_x_at FERMT2 fermitin family homolog (Drosophila)
201349_at SLC9A3R1 solute carrier family 9, member 3 regulator 1
216205_s_at MFN2 mitofusin 2
212724_at RND3 Rho family GTPase 3
214771_x_at M-RIP myosin phosphatase-Rho interacting protein
203780_at EVA1 epithelial V-like antigen 1
220773_s_at GPHN gephyrin
207717_s_at PKP2 plakophilin 2
200696_s_at GSN gelsolin (amyloidosis, Finnish type)
SP AP3 AP78
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212551_at CAP2 CAP, adenylate cyclase-associated protein, 2
212554_at CAP2 CAP, adenylate cyclase-associated protein, 2
203562_at FEZ1 fasciculation and elongation protein zeta 1 (zygin I)
203662_s_at TMOD1 tropomodulin 1
20366l_s_at TMOD1 tropomodulin 1
220119_at EPB41L4A erythrocyte membrane protein band 4.1 like 4A
208212_s_at ALK anaplastic lymphoma kinase (Ki-1)
209789_at C 0R 02B coronin, actin binding protein, 2B
220120_s_at EPB41L4A erythrocyte membrane protein band 4.1 like 4A
59375_at M Y 015B myosin XVB pseudogene
217901 at DSG2 Desmoglein 2
219173_at M Y 015B myosin XVB pseudogene
31874_at GAS2L1 growth arrest-specific 2 like 1
202039_at TIAF1 TGFB1 -induced anti-apoptotic factor 1
203333_at KIFAP3 kinesin-associated protein 3
20489l_s_at LCK lymphocyte-specific protein tyrosine kinase
204890_s_at LCK lymphocyte-specific protein tyrosine kinase
202052_s_at RAI14 retinoic acid induced 14
209191_at TUBB6 tubulin, beta 6
209850_s_at CDC42EP2 CDC42 effector protein (Rho GTPase binding) 2
209615_s_at PAK1 p21/Cdc42/Racl -activated kinase 1
201034_at ADD3 adducin 3 (gamma)
212390_at PDE4DIP phosphodiesterase 4D interacting protein
213388_at PDE4DIP phosphodiesterase 4D interacting protein
214099_s_at PDE4DIP phosphodiesterase 4D interacting protein
201752_s_at ADD3 adducin 3 (gamma)
205882_x_at ADD3 adducin 3 (gamma)
207705_s_at KIAA0980 KIAA0980 protein
20388 l_s_at DMD dystrophin
204042_at WASF3 WAS protein family, member 3
204513_s_at ELMOl engulfment and cell motility 1
214130_s_at PDE4DIP phosphodiesterase 4D interacting protein
205872_x_at PDE4DIP phosphodiesterase 4D interacting protein
212392_s_at PDE4DIP phosphodiesterase 4D interacting protein
214129_at PDE4DIP Phosphodiesterase 4D interacting protein
210305_at PDE4DIP phosphodiesterase 4D interacting protein
20420 l_s_at PTPN13 protein tyrosine phosphatase, non-receptor type 13
205848_at GAS2 growth arrest-specific 2
204797_s_at EML1 echinoderm microtubule associated protein like 1
205347 s at TMSL8 thymosin-like 8
216060_s_at DAAM1 dishevelled associated activator o f  morphogenesis 1
206710_s_at EPB41L3 erythrocyte membrane protein band 4.1 -like 3
211776_s_at EPB41L3 erythrocyte membrane protein band 4.1-like 3
212681 at EPB41L3 erythrocyte membrane protein band 4.1-like 3
201012 at ANXA1 annexin A 1
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20292l_s_at ANK2 ankyrin 2, neuronal
216195_at ANK2 Ankyrin 2, neuronal
202920_at ANK2 ankyrin 2, neuronal
203037_s_at MTSS1 metastasis suppressor 1
20396 l_at NEBL nebulette
204734_at KRT15 keratin 15
214156_at MYRIP myosin VIIA and Rab interacting protein
220386_s_at EML4 echinoderm microtubule associated protein like 4
214051 at MGC39900 hypothetical protein MGC39900
201307_at SEPT 11 septin 11
203928_x_at MAPT microtubule-associated protein tau
219106_s_at KBTBD10 kelch repeat and BTB (POZ) domain containing 10
20640l_s_at MAPT microtubule-associated protein tau
216526_x_at HLA-C major histocompatibility complex, class I, C
208812_x_at HLA-C major histocompatibility complex, class I, C
208885_at LCP1 lymphocyte cytosolic protein 1 (L-plastin)
214459_x_at HLA-C major histocompatibility complex, class I, C
202391_at BASP1 brain abundant, membrane attached signal protein 1
212365_at M YOIB myosin IB
218980_at FHOD3 formin homology 2 domain containing 3
37965_at PARVB parvin, beta
203139_at DAPK1 death-associated protein kinase 1
203636_at MIDI midline 1 (Opite/BBB syndrome)
21821l_s_at MLPH melanophilin
212364_at M YOIB myosin IB
203637_s_at MIDI midline 1 (Opitz/BBB syndrome)
37966_at PARVB parvin, beta
205899_at CCNA1 cyclin A 1
208188_at KRT9 keratin 9 (epidermolytic palmoplantar keratoderma)
215575_at PDE4DIP phosphodiesterase 4D interacting protein
218087_s_at SORBS 1 sorbin and SH3 domain containing 1
208690_s_at PDLIM1 PDZ and LIM domain 1 (elfin)
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Table 3: Overlap between 1189 gene list and GO: 30054: cell junction. False-colour 
cluster view representing the expression of each cell line (average value of the 
triplicates).
Affymetrix
name
Gene
symbol description SP AP3 AP78
20093l_s_at VCL vinculin
207717_s_at PKP2 plakophilin 2
219321_at MPP5 membrane protein, palmitoylated 5
201015_s_at JUP junction plakoglobin
202329_at CSK c-src tyrosine kinase
208636_at ACTN1 Actinin, alpha 1
208637_x_at ACTN1 actinin, alpha 1
203726_s_at LAMA3 laminin, alpha 3
206710_s_at EPB41L3 erythrocyte membrane protein band 4.1-like 3
211776_s_at EPB41L3 erythrocyte membrane protein band 4.1-like 3
212681_at EPB41L3 erythrocyte membrane protein band 4.1-like 3
217901_at DSG2 Desmoglein 2
203953_s_at CLDN3 claudin 3
203954_x_at CLDN3 claudin 3
218087_s_at SORBS 1 sorbin and SH3 domain containing 1
204482_at CLDN5 claudin 5
205079_s_at MPDZ multiple PDZ domain protein
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Table 4: Integrins expression. False-colour cluster view representing the expression of 
each cell line (average value of the triplicates).
Affymetrix name Gene symbol description SP AP3 AP78
206766_at ITGA10 integrin, alpha 10
204627_s_at ITGB3 integrin, beta 3
216261 at ITGB3 integrin, beta 3
201656_at ITG A6 integrin, alpha 6
205816_at 1TGB8 integrin, beta 8
215240_at ITGB3 integrin, beta 3
2 1 1488_s_at ITGB8 integrin, beta 8
211905_s_at ITGB4 integrin, beta 4
215177_s_at ITGA6 integrin, alpha 6
213475_s_at ITG A L integrin, alpha L
216190_x_at ITGB1 integrin, beta 1
201124_at ITGB5 integrin, beta 5
204628_sat ITGB3 integrin, beta 3
20235 l_at IT G A V integrin, alpha V
211945_s_at ITGB1 integrin, beta 1
216178_x_at ITGB1 integrin, beta 1
215878_at ITGB1 integrin, beta 1
206493_at ITGA2B integrin, alpha 2b
214927_at ITGBL1 Integrin, beta-like 1
206009_at ITGA9 integrin, alpha 9
205884_at ITGA4 integrin, alpha 4
205885_s_at ITGA4 integrin, alpha 4
213416_at ITGA4 integrin, alpha 4
205055_at ITG AE integrin, alpha E
214020_x_at ITGB5 Integrin, beta 5
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Appendix IX: MSA
■  NCI-H69 SP
■  NCI-H69 AP3 
□ NCI-H69 AP78
N C I-H 69 N C I-H 69 NC I-H 69
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Figure 1: MSA adhesion profile after PSA digestion. Cells were treated overnight (15H) 
with 0.7 U of endoN or heat inactivated endoN (80°C for 15min). a. MSA adhesion 
profile, b. Western blotting confirmation of endoN digestion of PSA.
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Figure 2: Cell morphology on MSA ECM proteins spot after endoN digestion
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Figure 3: Reassembled fu ll MSA array — NCI-H69 SP.
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Appendix X: Cell motility
Table 1: Cell motility. Overlap between GO 6928 cell motility and 1189 gene list. False- 
colour cluster view representing the expression o f each cell line (average value of the
triplicates).
Affymetrix name Genesymbol description
200770_s_at LAMC1 laminin, gamma 1
20077 l_at LAMC1 laminin, gamma 1
212048_s_at YARS tyrosyl-tRNA synthetase
200859_x_at FLNA filamin A, alpha
208637_x_at ACTN1 actinin, alpha 1
213746_s_at FLNA filamin A, alpha
214752_x_at FLNA filamin A, alpha
213260_at FOXC1 Forkhead box C 1
32137_at JAG2 jagged 2
209784_s_at JAG2 jagged 2
208636_at ACTN1 Actinin, alpha 1
HSAC07/X0035 l_5_at ACTB actin, beta
20093 l_s_at VCL vinculin
200920_s_at BTG1 B-cell translocation gene 1
20092 l_s_at BTG1 B-cell translocation gene 1
204035_at SCG2 secretogranin 11 (chromogranin C)
212190_at SERPINE2 serpin peptidase inhibitor, clade E
204513_s_at ELMOl engulfment and cell motility 1
209108_at TSPAN6 tetraspanin 6
209109_s_at TSPAN6 tetraspanin 6
201005_at CD9 CD9 antigen (p24)
211506_s_at IL8 interleukin 8
202859_x_at IL8 interleukin 8
209114_at TSPAN1 tetraspanin 1
202363_at SPOCK testican
203562_at FEZ1 zygin I
205206_at KALI Kallmann syndrome 1 sequence
20600 l_at NPY neuropeptide Y
206382_s_at BDNF brain-derived neurotrophic factor
20954 l_at IGF1 insulin-like growth factor 1
220407_s_at TGFB2 transforming growth factor, beta 2
212298_at NRP1 neuropilin 1
SP AP3 AP78
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215020_at NRXN3 neurexin 3
209909_s_at TGFB2 transforming growth factor, beta 2
203726_s_at LAMA3 laminin, alpha 3
210839_s_at ENPP2 autotax in
209147_s_at PPAP2A phosphatidic acid phosphatase type 2A
209392_at ENPP2 autotaxin
210946_at PPAP2A phosphatidic acid phosphatase type 2A
210512_s_at VEGF vascular endothelial growth factor
206939_at DCC deleted in colorectal carcinoma
216268_s_at JAG1 jagged 1 (Alagille syndrome)
209099_x_at JAG1 jagged 1 (Alagille syndrome)
209897_s_at SLIT2 slit homolog 2 (Drosophila)
201012_at ANXA1 annexin A 1
209590_at BMP7 Bone morphogenetic protein 7
20959 l_s_at BMP7 bone morphogenetic protein 7
203037_s_at MTSS1 metastasis suppressor 1
203928_x_at MAPT microtubule-associated protein tau
209985_s_at ASCL1 achaete-scute complex-like 1
213768_s_at ASCL1 achaete-scute complex-like 1
209987_s_at ASCL1 achaete-scute complex-like 1
209988_s_at ASCL1 achaete-scute complex-like 1
20640 l_s_at MAPT microtubule-associated protein tau
216526_x_at HLA-C major histocompatibility complex classic
208812_x_at HLA-C major histocompatibility complex classic
214459_x_at HLA-C major histocompatibility complex classic
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A ppendix XI: Glycosylation
Table 1: Glycans structure and biosynthesis (KEGG 1.7). False-colour cluster view 
representing the expression o f each cell line (average value o f the triplicates).
Affymetrix
name gene sym bol description
54037_at HPS4 Hermansky-Pudlak syndrome 4
218402_s_at HPS4 Hermansky-Pudlak syndrome 4
218854_at SART2 squamous cell carcinoma antigen recognized by T cells 2
201998_at ST6GAL1 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1
220979_s_at ST6GALNAC5 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyI-l,3)-N- 
acetylgalactosaminide alpha-2,6-sialyltransferase 5
203066_at GALNAC4S-6ST N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase
209892_at FUT4 fucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid- 
specific)
210073_at ST8SIA1 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 
1
213552_at GLCE glucuronyl C5-epimerase
20392 l_at CHST2 carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2
219403_s_at HPSE heparanase
217788_s_at GALNT2 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N - 
acetylgalactosaminyltransferase 2
217452_s_at B3GALT2 UDP-Gal:betaGlcNAc beta 1,3-galactosyItransferase, 
polypeptide 2
210121_at B3GALT2 UDP-Gal :betaGlcNAc beta 1,3-galactosy Itransferase, 
polypeptide 2
202673_at DPMI dolichyl-phosphate mannosyItransferase polypeptide 1, 
catalytic subunit
21 1812_s_at B3GALT3 UDP-Gal :betaGlcN A c beta 1,3-galactosy Itransferase, 
polypeptide 3
205505_at GCNT1 glucosaminyl (N-acetyl) transferase 1, core 2 (beta-l,6-N- 
acetylglucosaminy Itransferase)
203988_s_at FTJT8 fucosyltransferase 8 (alpha (1,6) fucosyltransferase)
SP AP3 AP78
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Appendix XII: 2005 arrays quality assessment
Scale factor
%P 44.79%
B 92.43 
o/oP 48.08%
B 94 
%p 41.61%
B 282.58 
o/oP 47.49%
B 100.61 
%p 49.68%
B 101.01 
o/oP 48.36%
B 101.67 
%p 49.64%
B 97.77 
%p 46.34%
B 120.1 
%P 48.71%
B 115.55 
%P 48.43%
B 112.56 
%P 48.76%
B 102.1 
%P 48.8%
B 97.02
A actin 3’ / actin 5’ - 3 - 2 - 1 0 1 2 3
o GAPDH 3’ / GAPDH 5’
Figure 1: 2005 arrays — MAS5 computed quality control report. Simpleaffy package 
generated quality control showing 5 metrics (background (B), percent present (%P), 
scale factor, GAPDH 5 73’ ratio and Actin 573’ ration) commonly used to asses arrays 
quality.
o, SPR1108_1
A1 S P R 1 1 0 8 2
o k SP_R1108_3
A ) SP_3
C A SP _2
X SP_1
a v A P 5 5 R 1 1083
o A P 5 5 R 1 1082
o \ A P 5 5 R 1 1081
0 AP553
t AP55_2
6 AP55_1
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Figure 2: 2008 arrays. AffyPLMpackage for Bioconductor quality assessment — RLE 
and NUSE plots.
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com plete
analysis
analysis without 
S P R 1 1 0 8 1
12946flags call
T-test
T-test and 
> 2-fc filtering
Figure 3: Microarray analysis accounting fo r  fa iled  quality control array.
Table 1: Microarray analysis accounting fo r fa iled  quality control array. The table lists 
the results o f analyses including (a) or excluding (b) the high background array.
Affymetrix
name
gene
symbol descritpion
fold change 
(a) (b)
T-test p-value
(a) (b)
203665_at HMOX1 hem e oxygenase (decycling) 1 16.95 13.43 0.0154 0.146
212859_x_at MT1E m etallothionein IE 3.563 3.604 0.0294 0.193
221577_x_at GDF15 growth differentiation factor 15 2.524 2.506 0.00244 0.0822
221258_s_at KIF18A kinesin family member 18A 0.447 0.531 0.0452 0.163
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